OPTIMIZATION AND USE OF TALC IN DIRECT COMPRESSION TABLET FORMULATIONS by Dawoodbhai, Shabbir S.
University of Rhode Island 
DigitalCommons@URI 
Open Access Dissertations 
1989 
OPTIMIZATION AND USE OF TALC IN DIRECT COMPRESSION 
TABLET FORMULATIONS 
Shabbir S. Dawoodbhai 
University of Rhode Island 
Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss 
Recommended Citation 
Dawoodbhai, Shabbir S., "OPTIMIZATION AND USE OF TALC IN DIRECT COMPRESSION TABLET 
FORMULATIONS" (1989). Open Access Dissertations. Paper 341. 
https://digitalcommons.uri.edu/oa_diss/341 
This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for 
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more 
information, please contact digitalcommons@etal.uri.edu. 
OPTIMIZATION AND USE OF TALC IN 
DIRECT COMPRESSION TABLET 
FORMULATIONS 
BY 
SHABBIR S. DAWOODBHAI 
A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMNTS FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
IN 
PHARMACEUTICAL SCIENQES 
UNIVERSITY OF RHODE ISLAND 
1989 
DOCTOR OF PHILOSOPHY DISSERTATION 
OF 
SHABBIR S. DAWOODBHAI 
APPROVED: 
DISSERTATION COMMITTEE 
MAJOR PROFESSOR C....J"' (L~ 
( 
,,\'IA. h.,f,O\_ !A__l>Jl__ ~tAVl___ 
('. v. t:J,~ v 
DEAN OF THE GRADUATE SCHOOL 
UNIVERSITY OF RHODE ISLAND 
1989 
ABSTRACT 
Talc is extensively used in a wide vaFiety of cosmetic 
products , particularly in powder products . Talc keeps the 
skin feeling smooth and dry. Talc in the pharmaceutical 
industry is used as a glidant and lubricant. Glidants such 
as talc improve flow properties of powder by decreasing 
interparticulate friction, by decreasing van der Waals 
forces and electrostatic charges, by changing particle size 
distribution, and by decreasing the effect of humidity on 
surfaces of host particles by forming a mechanical barrier. 
The loosely bound lattice layers slide over each other and 
form roller structures which explains its lubr ication 
characteristics. Talc has less deleterious effect compared 
to magnesium stearate on tablet in vitro properties. 
Talcs from different size grades were evaluated for 
their use in direct compression tablet formulations. 
Lubricant efficiencies of talcs were measured using ejection 
force values. The Supra grade of the Cyprus Industrial 
Mineral company talc was found to be most efficient of the 
grades tested as lubricant and also gave tablets of more 
acceptable in vitro properties than t ablets lubricated with 
magnesium stearate only. 
Additionally talcs in substantial percentages were 
evaluated for their potential as a direct compression matrix 
material. With commonly used excipients such as 
microcrystalline cellulose and lactose, the formulations 
were self lubricating and the tablets ejected easily. 
Tablets with very low friability, high crushing strength, 
rapid dissolution rates, good weight uniformity, content 
uniformity and potency of drugs were obtained. At similar 
compression forces, tablet hardness with the 300 grade of 
Alabama, Altalc, and Beaverwhite talcs was significantly 
greater than corresponding 400 and 500 grades. 
An optimum direct compression tablet formulation of a 
conventional theophylline tablet was achieved using the 
technique of response surface methodology and successive 
quadratic programming (SQP) . The response surfaces were 
obtained from a second order uniform precision hexagonal 
design. The tablet formulation was optimized for mean 1.n 
vitro dissolution time using friability, hardness, ejection 
force and disintegration time as constraints within the 
experimental region by the SQP algorithm. The response 
surface model was validated by preparing and evaluating the 
predicted formulation. The characteristics of the tablet 
formulation were analyzed by principal component analysis. 
Sensitivity analysis of optimal solution was performed for 
each constraint, while all remaining constraints were held 
constant. The robustness of the response surface model was 
evaluated by simulation for error in the compression force 
values due to its inherent variation. Although 
pharmaceutical scientists have previously reported 
optimization studies, the approach used in this thesis has 
signifi cant advantages and has not apparently been 
previously used for the optimization of pharmaceutical 
formulation. 
A completely novel use for talc as a major matrix 
component in direct compression tablet formulation, has been 
proposed and examined . A robust and efficient response 
surface experimental design and mathematical optimization 
technique has been evaluated for application to the 
pharmaceutical sciences . The computer search method has the 
disadvantage of frequently giving a plural solution for 
suitable formulations. With the classical Lagrangian 
method , it can become difficult to solve the resultant set 
of simultaneous equations especially for nonlinear problems. 
The SQP method is more efficient and robust compared to 
previously published optimization techniques including SUMT 
(Successive Unconstrained Minimization Technique) . The SQP 
method can also be used to obtain solution to the problems 
solved by the previously mentioned optimization methods. 
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PREFACE 
This dissertation is written in the MANUSCRIPT 
plan option. It is divided into three sections. Section I 
is introduction and literature review of optimization. 
Section II, the main body of dissertation comprises four 
manuscripts, which have been written in the format required 
by specific journals for publications. Section III, the 
appendices consists of additional analytical data, computer 
programs, additional manuscript and patent information. An 
alphabetical bibliography of the entire dissertation is at 
the end of the thesis. 
Manuscr i pt I will be submitted for publication in the 
journal of Drug Dev . Indus. Pharmacy. 
Manuscript II has been published in the journal of Drug 
Dev. Indus. Pharmacy 13, 2441 (1987). 
Manuscript III will be submitted for publication in the 
journal of Pharmaceutical Technology. This manuscript has a 
US patent claim. 
Manuscript IV will be submitted for publication in the 
Journal of Phamaceutical Sciences. 
Manuscript V has been accepted for publication in the 
journal Drug Dev. Indus. Pharmacy (1989). 
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Section I 
INTRODUCTION 
Formulation of new drugs and reformulation of 
established drugs into tablet dosage forms with different 
excipients is an ongoing process in the pharmaceutical 
industry . By combining the method of direct compression for 
manufacturing of tablets and an optimization technique , it 
is possible to save expenses in terms of time, labor and 
material costs . 
Talc in the pharmaceutical industry has mainly been 
used as a glidant (1-10). Its use as a lubricant with anti-
adherent properties has been studied ( 11-20). Its mechanism 
of lubrication has been attributed to loosely bound lattice 
layers sliding over each other in the direction of motion to 
form roller like structures (21). When the sliding surfaces 
have alternating direction of motion the rollers would need 
to unravel and reform in the opposite direction (21) . This 
can occur efficiently only when sufficient space is 
available between sliding surfaces . At high compaction 
forces the relative density of the tablet and the radial die 
wall force increases . Consequently, less space becomes 
available between the tablet and the die wall, and therefore 
talc efficiency as lubricant may decrease with increase in 
compaction force (22). Therefore , an additional more 
efficient lubricant on equal weight basis, such as magnesium 
stearate, is combined with talc. There have been 
conflicting reports regarding the combined use of talc with 
2 
magnesium stearate, (15) . However , talc has much less 
deleterious effect on tablet properties compared to 
magnesium stearate (16 - 20). For example, talc gives harder 
tablets ( 16 , 17) and does not delay dissolution rate of drugs 
(19-20). 
The use of talc as a matrix component in · a direct 
compression formulation is completely novel. The use of talc 
as a matrix component confers the following possible 
advantages . Combination of talc with other material will 
help to reduce the cost of direct compression matrix in a 
formulation. Talc has an adsorbent property (22 - 23). 
This adsorbent property may possibly explain why talc has 
less deleterious effect on the dissolution rate of the drug 
compared to the other hydrophobic lubricants such as 
magnesium stearate. There is some experimental evidence to 
suggest that presence of an adsorbent at the dissolution 
site will increase the saturation solubility of the drug and 
thereby enhance the dissolution rate of the drug (24) . 
Furthermore, talc as a matrix component may in some cases 
completely eliminate the need for using magnesium stearate 
as a lubricant in that formulation. 
Objectives of this Study 
1 . To evaluate relative lubricant efficiency and the tablet 
in vitro properties of a number of different types of 
3 
talcs in combination with magnesium stearate. The talc 
containing tablets in vitro properties will be compared 
with those of tablets not containing any talc, but just 
magnesium stearate only as the lubricant. 
2. To examine the potential uses of a number of talcs as a 
major matrix component for commonly used drugs in direct 
compression tablet formulations. A number of different 
talcs will be examined for their in vitro properties to 
asses potential usefulness of these talcs, as a direct 
compression formulation matrix component. Furthermore, 
properties of tablets from formulations not containing 
talc in the matrix will be prepared and their properties 
compared with those containing talc. 
3. To apply an optimization technique to the study of the 
processing and formulation variables using talc as a 
major matrix component in direct compression tablet 
formulation for a drug. In addition, an optimum 
formulation for tablets containing talc as a major 
matrix component of direct compression formulation will 
be prepared, as predicted by the optimization technique 
and the properties compared with actual values obtained 
experimentally. 
4 
4 . To perform sensitivity analysis of the optimal solution 
In addition errors in the ' X' (d'U.e to variation in 
the compression force values) will be examined by 
s i mulation . 
5 . To identfy the important tablet properties that 
characterize the tablet formulation using principal 
component analysis , in the optimization study . 
5 
* Literature review 
Computer Optimization 
Schwartz and coworkers ( 25 ), used a half fractional 
factorial based orthogonal , non- rotatable central composite 
design , for five independent variables. Although nine 
tablet properties were measured , the optimization procedure 
involved locating a set of constraints based on three tablet 
properties namely disintegration time, hardness , and percent 
drug dissolved at 50 minutes such that a feasible solution 
existed , but further tightening of constraints would produce 
no feasible solution . The grid search program then printed 
out all the formulations possible that satisfied the 
feasibility region requirements. The optimal solution was 
then selected from the multiple suitable solutions 
suggested by the grid search . 
Schwartz and coworkers (26) also showed how the 
trend in optimal solution can be used as an effective guide 
for efficient trouble shooting during production while 
working within the NDA (New Drug Application) limits for the 
product . Principal component analysis can be used for 
identifying the important tablet properties that 
characterize the tablet formulation (27) . Of the nine 
* More detailed consideration of pertinent literature is 
contained in the various manuscripts. 
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tablet formulation characteristics examined , it was found 
that the most important property of the tablet was the 
percent drug dissolved at 50 minutes since it explained 
95 . 4% , while the second most important tablet property was 
the tablet disintegration time since it explained an 
additional 3.9% , of the tablet formulation characteristics 
(26). The contributions of the remaining tablet properties 
were negligible in explaining the tablet formulation 
characteristics (27) . Similarly selected main properties of 
any drug delivery system could be used for evaluation during 
routinely performed quality control and quality assurance 
programs as a more economical approach. Only if one or more 
of these main properties were not acceptable or deviated 
from their limits, would it become necessary to evaluate the 
complete set of properties of that drug delivery system to 
identify the possible problems and their corresponding 
solutions. 
Down et al (28) used an orthogonal but non-
rotatable central composite design , for two formulation 
variables and one processing variable. Optimization of 
tablet property was carried out similarly to Schwartz and 
coworkers method , with a constraints set consisting of 
tablet thickness , hardness , friability, and ejection force . 
They were apparently the first to report that the 
compression force values were difficult to achieve exactly 
because of compression variations of the tablet press and 
7 
the die fill variations (28) . Therefore the mean 
compression force values were used for multiple regression 
analysis. 
Keeping the tablet weight constant Bohidar et al 
( 29) varied the ratio of drug to the excipient , by using 
drug potency as one of the formulation variables. · A half 
fractional factorial based orthogonal , non- rotatable central 
composite design, for five independent variables was used 
(29). Sequential prediction analysis was carried out as 
follows (29). For a range of acceptable tablet properties , 
the values of corresponding independent variable were 
obtained. All the independent variables were kept at a 
constant optimal value , except for drug potency variable and 
the most influential variable . For each drug potency , the 
most influential factor was varied within the optimal range 
previously obtained , and the tablet properties were 
predicted using the second order response surface equations . 
Then the values for the most influential variable were 
selected to give the most suitable compromise for the tablet 
properties for each of the potencies. Then the tablets at 
each of the potencies were prepared , using individualized 
value of the most influential variable and the remaining 
independent variables at their accepted optimal value (29). 
Nagai and co-workers used a composite design based 
on full factorials to study the dissolution properties for 
the solid dispersions of flufenamic acid (30) and 
8 
griseofulvin (31) using two and three formulation factors 
respectively. The former experimental design ·had 
rotatability property . The optimization in both cases was 
concerned with obtaining formulation with high dissolution 
rate and good stability of dissolution properties . The 
computer optimization technique similar to Schwartz and 
coworkers was used. 
Mathematical Optimization 
Fonner et al (32) studied the levels of binder (stearic 
acid) and disintegrant (corn starch) for optimization of the 
time for 50% drug release in vitro (T50%) using response 
surface equations for friability and tablet volume as 
constraints. The two formulation factors were studied using 
an orthogonal but non-rotatable central composite design 
(32). The optimal solution was more sensitive to changes in 
tablet volume compared to percent friability (32). In 
addition, tablet friability was minimized using time for 50% 
of the drug to be eliminated in urine and tablet volume , as 
the constraints (32). Fonner et al also applied the 
Lagrangian method to the data obtained by Reier et al to 
minimize capsule weight variation (32). The machine speed 
and flowability of powder were the two independent variables 
to be optimized subject to constraint of mean gross capsule 
weight. 
9 
The Lagrangian method is a mathematical nonlinear 
programming method that locates the opt~mum directly and 
does not search for infeasible solution points (32,33). It 
generates only feasible solutions. It efficiently handles 
inequality as well as equality c9nstraints . The objective 
function always has the equality form. The inequality 
constraints are converted to equality by slack variables. 
Each constraint has its Lagrange multiplier. The Lagrange 
multiplier is a penalty that must be paid for violating a 
given constraint. The Lagrangian is the resultant lagrange 
function that is to be optimized. The optimum solution 1s a 
stationary point; that is, at this point the partial 
derivative of the Lagrangian is zero with respect to each of 
the independent variable, the slack variables and the 
Lagrange multipliers. So, the partial derivatives are 
calculated with respect to each of these variables and set 
equal to zero. The optimal solution is obtained by solving 
a set of simultaneous equations (32,33). 
In another study Nagai and coworker (34) used half 
fractional factorials and axial spacing of 1.713 to obtain a 
non-rotatable _ spherical composite design. The formulation 
factors were studied for their effects on dissolution and 
chemical stability of indomethacin solid dispersion (34). A 
mathematical optimization for high dissolution rate as 
measured by T50% value using good stability of dissolution 
properties and chemical stability as constraints was 
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achieved by the use of sequential unconstrained minimization 
technique (SUMT) (34). This mathematical optimization 
technique transforms a constrained optimization problem to 
unconstrained optimization problem (Eq. 1) by adding penalty 
P(x,r) m p 2 F(x) - r [. 1ln[g.(x)] + (l / r) [. 1 [h.(x)] 1= 1 J= J 
terms for inequality constraints Cgi) (Eq. 2), equality 
constraints (hj) (Eq. 3), to the objective function F(x) 
1,2, .... m 
0 j 1,2, .... p. 
(1) 
(2) 
(3) 
The penalty parameter (r) has a relatively large value when 
the search is first initiated. The minimization of the 
unconstrained penalty function P(x,r) is carried out by a 
general unconstrained non-linear optimization method. The 
optimum (miminimum solution) at point x(r) is obtained when 
r is sufficiently close to zero, that is l/r approaches 
infinity value, which means that the value of x has to be 
minimized greatly to keep the penalty term as minimal as 
possible. The SUMT like Lagrangian and unlike Schwartz 
search method gives a single solution strictly obtainable as 
best formulation. 
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The simplex search method was used for optimization 
of a capsule formulation with respect to its dissolution and 
compaction rate (35 ). Four independent formulation 
variables were studied (35) . Fitting of this experimental 
data to second order response surface equation is not 
warranted , since this is a first order optimization 
technique. In addition, to overcome the unconstrained 
nature of this optimization technique, an overall response 
was created and optimized . This overall response consisted 
of two dissolution rate and one compaction rate dependent 
variables , which were arbitarily weighed and linearly 
combined (35). 
Two formulation and two processing variables were 
studied by half fractional factorial design (36). First 
order response surfaces were found to be adequate for the 
two properties to be optimized for enteric coated tablets 
(36). The steepest descent gradient method searches for 
independent variables values for which the gradient vector 
equals to zero. Therefore the steepest descent method can 
terminate at any type of stationary point , for example , 
minimum or saddle point , to give approximate optimal 
solution (34) . If it is a saddle point , then indirect 
second order method should be used to move away from the 
saddle point. Since the method of steepest descent is an 
unconstrained optimization technique, only the response 
regarding the disintegration time in the intestinal fluid 
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was minimized and the optimal solution obtained also 
satisfied the additional restriction of resistance to 
disintegration in gastric fluid (36). 
The computer search method has the disadvantage of 
frequently giving a plural solution for suitable 
formulations (34) . With the classical Lagrangian method, it 
can become difficult to solve the resultant set of 
simultaneous equations especially for nonlinear problems . 
Therefore a numerical method such as SUMT or SQP must be 
used to locate the optimal solution point. The SQP method 
is more efficient and robust compared to previously 
published optimization techniques including SUMT (33). The 
SQP method can also be used to obtain solution to the 
problems solved by the previously mentioned optimization 
methods. 
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1. Introduction. 
Talc is a mineral with the composition of 
3Mg0.4Si02 .H2o, and referred to as hydrous magnesium 
silicate (1). The structure consists of MgO sheet 
sandwiched between two silica sheets. Each layer is 
electrically neutral, and the adjacent layers are held 
together by only weak van der Waals forces (1). The 
mineral composition of talc may vary depending on the 
geographical source of the deposit (1,2). Impurities in the 
form of calcium silicate and calcium carbonate makes the 
powder abrasive, while iron oxide or magnesium ferric 
silicate makes talc greyish in appearance (1,2). Very 
finely powdered talc is boiled in 2% hydrochloric acid and 
subsequently in weaker hydrochloric acid solution to remove 
iron and other soluble impurities. Finally the talc is 
thoroughly washed with water and dried at l00°c (2). (For 
the variety of cosmetics products in which talc is a major 
component , see Table 1.) 
2. Cosmetic Uses of Talc 
Talc is used as face, body and foot powder to keep 
skin smooth, cool and dry (3). The smoothness of talc felt 
by human hands is dependent on its slip characteristic. The 
slip characteristic is dependent on particle size and shape. 
Talc has lamellar particle shape and this produces the 
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Table 1. Utilization of Talc in Cosmetic Products. 
Product Percent Talc Purpose of Talc Ref it 
Face powder 10-75 Keeps skin smooth and dry 3 
Foot powder 70-85 Keeps skin smooth and cool 3 
Baby powder 45-97 Keeps skin smooth and dry 3 , 4 
Pressed powder 40 Easy spread of rougher color 3 
Bleaching mask 52 Absorbs sebaceous secretions 3 
Dry shampoos 60 Absorbs sebaceous secretions 3 
Pre-electric 5 Absorbs sebaceous secretions 
Talc sticks and provides slip for shaver 3,6 
Foot spray 10-15 Cooling and refreshing 3 
Dusting powder 90 Keeps skin cool, smooth, dry 7 
and fragmented 
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slippery feel (1) . The larger the individual plate the 
better the slip. Italian talcs have excellent slip 
characteristics (1) . More than 98% of the talc particle 
size, especially in baby powders, should be less than 74 um 
(1 ) . Apparent bulk and tap density of talc is proportional 
to particle size distribution. The finer the distribution 
the lower the apparent density .(1). Baby powders are like 
talcum dusting powders, but contain an antiseptic, with less 
perfume and more absorbent for example 20% rice starch and 
15% zinc oxide to increase the covering power of talc (4). 
Talc has low water wettability (5), absorption (3) 
and adsorption capacity (5), so it is common to include 
starch, kaolin, precipitated calcium carbonate or magnesium 
carbonate to increase absorbancy for products such as face 
powders (1,3,6,7) . These carbonates also serve as the 
carrier for perfume (6). To enhance powder adherance and 
thereby improve powder feel on the skin, the metallic 
stearates for example magnesium stearate or zinc stearate 
are added (3). Magnesium stearate is prefered over zinc 
stearate because it is less toxic if powder is accidentally 
ingested (3) . Substances such as kaolin, titanium dioxide , 
magnesium oxide, zinc oxide may be included in formulation 
to improve the covering power of talc (3). Currently 
available alternatives to talc include rice starch (3) and 
Pullulan (3), however, they are expensive. Since talc 
absorbs sebaceous secretions it is used in dry shampoos (3), 
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and in pre-electric shave talc sticks (3,6) . Veegum or 
colloidal magnesium aluminum silicate is used as a binder 
for pre-electric shave talc sticks (3 , 6). Skin exhibits 
higher friction when rubbed on smooth surface as compared to 
relatively rough surface because of skins flexibility (8) . 
A decrease averaging 50% in frictional force was observed 
with a polished or rough metal probe after application of 
talc to the skin (8). This effect of talc is attributed to 
its low shearing strength per unit area and the talcs 
ability to adhere to stainless steel surface of metal probe 
(8). 
Pressure packaging of talc formulated powder for 
use as a foot spray is not necessary because of reasonably 
good delivery to skin using conventional packaging (3). 
Talc containing foot sprays are mainly used for their 
refreshing fragrance and cooling effect (3). They are not 
used as antiperspirant sprays because talc has poor 
adherance to the skin and its antiperspirant effect is small 
(3). As a fragrance carrier, cosmetic talc must hold the 
fragrance oil on its surface and release it unchanged (1). 
Total powder in an aerosol formulation should be 
less than 15% to avoid blockage of valve activator, and the 
powder size of all particles should be fine enough to pass 
through the mesh size 200 (6). Some of the ingredients that 
are often combined with talc in a formulation for example 
zinc oxide, zinc stearate, kaolin, and calcium carbonate 
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cannot be used because they all agglomerate in presence of 
propellant (6). However , talc presents no great problem in 
getting satisfactory valve function, because of the 
lubricating characteristics of talc (9). 
Talc particle size in aerosol formulations should 
be 50m or less to aid in dispersion (1 , 6,9,10). The 
dispersibility of talc becomes better as zeta potential 
increases above 70 mV (11) . In propellant mixtures , 
propylene glycol monoisostearate was the most effective 
suspending agent and dispersing agent . Other dispersing 
agents showed little differences among themselves and were 
less effective (10) . Talc sprays have to be shaken 
vigorously (3) since talc has a high density and therefore 
it settles faster than starch or a.luminum chlorhydrate ( 10 
) . Talc settling velocity can be reduced and final 
sedimentation volume can be increased by using long 
hydrocarbon chain alcohols, glycerol and sorbitol , any type 
of surfactant in low concentration of 0.005 to 0.1%, or 
small quantities of water immiscible liquids e.g. 0.2% to 
5.0% of caprylic acid, capronic acid, or oleic acid (12) . 
3 . Talc As Glidant 
Free and uniform flow rate of powder mixtures is an 
important formulation consideration for the manufacture of 
solid dosage forms. Gold et al . (13) has shown the 
importance of uniformity of powder flow using two 
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formulations both of which had similar flow rates. The 
tablets made on single punch press from the formulation 
which did not flow uniformly had a higher coefficient of 
weight variation compared to formulation which did flow 
uniformly. Presence of talc decreased the capsule weight 
variation by making the powder flow more uniform(l4). 
However , talc had no effect on mean capsule weight (14). 
Optimal talc concentration for improving flow has 
been reported to be about 0 . 5% (15) and 2% (16,17,18) using 
powder flow and shear cell studies. The percent of fines 
(particle sizes smaller than 40 to 200 mesh) can be a major 
factor that influences the percent of glidant required for 
improving the powder flow rate (15,18). Therefore, glidants 
should mainly consists of very fine particles. To a certain 
extent talc in concentration of 2 to 3% can increase the 
flow rate of powder lacking in percent fines (18). Gold et 
al. (19) has shown that addition of talc does not always 
result in an increase in flow rate. This stresses the 
importance of powder particle size distribution on flow. 
Magnesium stearate was able to increase flow factor 
(16) and flow rate (15,19) of tablet excipients such as 
lactose to a greater extent compared to talc. However, 
magnesium stearate causes a much sharper decrease in flow 
rate when used above its optimum concentration compared to 
talc (15,19). 
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3.1 Mechanism for Improved Powder Flow 
It has been suggested that cor"D.starch (15), talc of 
fine particle size (15,16) and also siliconized talc (21) 
form a mono particulate layer onto host powder particles. 
The smoothing out of the host particle surface that takes 
place, helps to decrease both the friction and mechanical 
interlocking of host particles (15,16,21). In addition, the 
host-host interactions at particles contact points would be 
replaced by weaker glidant-glidant forces (15,16 , 21). 
Glidants such as magnesium stearate and talc tend to reduce 
van der Waals interparticulate cohesive forces among host 
particles (15) . The interparticulate van der Waals forces 
increase as particle size decreases. Talc and cornstarch 
also tend to fill the void spaces between particles (15) . 
Talc has a laminar crystalline structure, which 
rolls up into a spherical or roller structure when subjected 
to low shearing forces as generated by flow. These spheres 
of talc improve flowability of powders (16 , 20) . Siliconized 
talc was able to improve flow rate of powder (as measured 
using a flowometer) to a greater extent compared to 
non-siliconized talc. The latter produced higher flow rates 
compared to unlubricated powder (21). In addition talc is 
also able reduces the static charges on powder particles 
surfaces (22 , 23). 
Static charges on particles surfaces is one of the 
reasons for poor powder flow . Static charges on particles 
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can be reduced by decreasing the percent of fines (22) and 
by increasing the percent of humidity (22) . However , 
i ncrease in humidity may decrease the chemical stability of 
some drugs and physical stability of the dosage form . 
Furthermore , increase in humidity and / or change in particle 
size distribution may have detrimental effects on mixing , 
flow and tablet compaction of powders . 
Tablet lubricants in relatively low concentrations 
can significantly lower static charges on powders (22,23) . 
Talc and magnesium stearate were equally effective in 
concentration ranging from 0 . 1% to 5%, in progressively 
decreasing electrostatic charges on materials (23). It is 
interesting to note that stearic acid was found to be 
ineffective for reducing electrostatic charges on powder 
materials evaluated (23) . 
These substances may be decreasing static charges 
by decreasing friction and forming a protective coat on 
surf ace of particles thereby minimizing contact between host 
particles. Since magnesium stearate has a more deleterious 
effect on tablet hardness and dissolution, it appears that 
talc is the better choice for reducing electrostatic charges 
on powder material flowing through hopper . 
3. Talc As A Lubricant 
In tableting, lubricants are required for reducing 
friction and preventing the binding between the tableting 
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mass and die wall during compression and ejection. 
Lubricants also prevent picking and sticking of tableting 
mass to upper and lower punches respectively . Lubricants 
can help to reduce capping and laminating. Properly 
lubricated formulation will provide unblemished tablets of 
good appearance and uniform weight. In addition the tablet 
press tooling can operate with minimal wear and stress. 
Lubricant efficiency of tablet lubricants have been 
evaluated mainly using single punch press (24- 27) and rotary 
press (28) and more specialized equipment (29 , 30) . It has 
been observed that after addition of lubricant , values of 
compression force decreased and the difference between 
compression and transmitted force became significantly 
reduced (24). The majority of studies have measured R 
values and / or ejection force for evaluation of lubricant 
efficiency . 
Magnesium stearate in concentration of about 1 or 
2% provides maximal lubricant efficiency as evaluated by R 
values (25 , 30). Magnesium stearate is a more efficient 
lubricant compared to talc on equal weight basis. However, 
increasing the concentration of talc decreases ejection 
force and increases R values (24-27). Talc should 
preferably be used in concentration greater than 0.5% (30). 
Compared to incorporation method the mixing of lubricants 
with formulation prior to compaction yielded better 
lubrication (30). 
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r There are conflicting reports about the use of talc 
in combination with magnesium stearate (28). The 
Mechtersheimer et al . (28) study offers the following 
observations on interactions between talc and magnesium 
stearate with the flat face punch tooling. Talc used alone 
or mixed simultaneously in combination with 0.3% magnesium 
stearate led to an increase in ejection forces. Further 
increase in talc concentration progressively lowered values 
of ejection force close to that obtained with 0.3% magnesium 
stearate alone. Talc added before or after magnesium 
stearate did not lower the ejection force values below those 
obtained with 0.3% of magnesium stearate alone (28). The 
residual die wall forces behaved similarly to ejection force 
values. However, increasing concentration of talc beyond 2% 
reduced the residual die wall forces below that obtained 
with 0.3% magnesium stearate (28). Talc used alone or mixed 
simultaneously with magnesium stearate led to an increase in 
the die wall force. However, by increasing talc 
concentration beyond 1% or by adding talc before or after 
magnesium stearate, the die wall forces decreased below that 
obtained with 0.3% magnesium stearate used alone (28). It 
is not clear whether these observations were due to the 
sequence of mixing or partially different mixing times for 
magnesium stearate and talc. The recommendation that talc 
should be added before magnesium stearate needs to be 
further validated. 
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Additional observations of interest reported by 
Mechtersheimer et al. were that with addition of increasing 
concentration of talc, the residual die wall force increase 
were not as pronounced with curved face punches as compared 
to flat face punches (28). With curved face punches, 
therefore, one can decrease residual die wall force, by 
compensating the reduced amount of magnesium stearate used 
with an increase in the concentration of talc. The die wall 
pressure and the residual die wall pressure generated in 
response to increase in compression force is greater for 
curved face punches than that for flat face punch tooling 
and are not significantly altered by increasing the talc 
concentrations (28) . 
3.1 Mechanism of Lubrication 
Talc is classified as boundary type lubricant whose 
main action is to promote anti-adherance during compression 
(26). More precisely talc is a laminar type boundary 
lubricant (20). In tableting sufficient lubricant should be 
used to maintain a film on the surface of the die, so that 
the friction observed would be mainly due to shearing of 
lubricant - lubricant film. Therefore, the effectiveness of 
a lubricant coat will depend on its shear strength, the 
force with which it adheres to the metal of the die, its 
resistance to penetration by material of the compact and its 
resistance to wear (29). 
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The shear strength of stearic acid and its salts 
was reported to be almost constant with cincrease in 
compaction pressure (29). The shear strength of talc was 
higher compared to that of stearic acid and its salts when 
subjected to constraining loads ( 20) . 
The mechanism of lubrication by talc is attributed 
to loosely bound lattice layers sliding over each other when 
placed between moving surfaces (20). The laminar layers 
roll up in the direction of motion , to form a roller like 
structures . The roller mechanism explains the high 
coefficient obtained on alternating the direction of motion 
of sliding surfaces , since the roller would have to be 
unravelled and be reformed in opposite direction (20) . For 
roller mechanism to act efficiently , sufficient space for 
roller to form must be available between sliding surfaces . 
This space becomes less available at high compaction forces 
because the relative density of tablet becomes high. This 
consequently results in greater radial die wall force and 
friction (20). 
4 . 2 Effect of Talc on Tablet In Vitro Properties 
4.2.1 . Mechanical Stren~th 
Mixing of lubricants with a formulation prior to 
compaction yielded harder tablets compared to the 
incorporation method (30). For brittle materials the axial 
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and radial tensile strengths for dibasic calcium phosphate 
tablets (31) and the crushing strength of sucrose tablets 
( 32) were not greatly affected by lubricants because of new 
surfaces generated by fracture of particles during 
compression . 
For plastically deforming materials the axial and 
radial tensile and crushing strength of tablets were reduced 
by lubricants (31 , 32) . This is because the coating of the 
particle surface by lubricants reduces the extent of bonding 
between particles during compression (25 , 31,32). Magnesium 
stearate markedly decreased the axial tensile strength 
relative to radial tensile strength for microcrystalline 
cellulose tablets even at 0.25% concentration , and 
progressively for aspirin and anhydrous lactose with 
increasing magnesium stearate concentration (31). While the 
effects with talc up to 6 to 8% on the axial to radial ratio 
of tensile strength was a moderate decrease for 
microcrystalline cellulose tablets and only a slight 
decrease for aspirin tablets (31) . Jarosz and Parrott (31) 
concluded that for microcrystalline cellulose tablets the 
capping potential was greater with magnesium stearate 
compared to talc. However , with anhydrous lactose tablets a 
slight increase in ratio of axial to radial tensile strength 
was observed (31) . Using microcrystalline cellulose as a . 
direct compression excipient in formulation, it was shown 
that tablets lubricated with 1% of various talcs in 
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combination with 0.25% magnesium stearate gave tablets of 
higher crushing strength compared to tablets lubricated with 
0 . 5% magnesium stearate lubricated tablets (33) . 
4.2 . 2 . Dissolution 
Excipients used in a formulation can affect a 
products in vitro properties, such as the drugs dissolution 
rate and may also affect its bioavailability . Talc, 
although a hydrophobic lubricant , does not seem to have as 
deleterious effect on dissolution of drugs as does magnesium 
stearate (33,34,35). Levy et al . (34) reported that initial 
dissolution rate of salicylic acid from a rotating disk was 
faster with talc as a lubricant compared to magnesium 
stearate . Levy et al. (34) also concluded that hydrophobic 
lubricants retard dissolution rate of drugs contained in 
compressed tablets by prolonging disintegration time and by 
reducing the area of interface between drug particle and 
solvent. Using compressed disk of aspirin , salicylic acid 
and equimolar mixture of aspirin and salicylic acid an 
increase in concentration of magnesium stearate from 0 . 1 to 
5% progressively slowed dissolution rate (35), while 0.1 to 
5% of talc did not affect the dissolution rates of these 
drugs (35) . It has been postulated that the stearates 
soften and spread under compression to provide a more 
coherent coverage of matrix than talc (34,35,36). 
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Another possible reason as to why talc has less 
deleterious effects than magnesium stearate is that due to 
its adsorption ability talc may not retard water penetration 
to the extent suggested by its hydrophobicity. Also an 
adsorbent like talc would provide a large surf ace area for 
adsorption of drugs from solution , thereby maintaining a 
high concentration gradient for the precipitated drug to 
redissolve. Wuster et al. (37) has shown that presence of 
an adsorbent increases dissolution by increasing the 
apparent saturation concentration for a drug. 
For a given adsorbent the affinity and extent of 
adsorption will depend on nature of drug (molecular weight, 
pKa , lipophillicity) and its environmental conditions (pH, 
ionic strength and temperature). Adsorption studies of 
drugs by talc have shown that talc has a much lower 
adsorption affinity and capacity compared to adsorbents like 
kaolin (38) and activated charcoal (39 , 40) . Using activated 
attapulgite (41) , which is a similar mineral to talc, it was 
shown that the rate of drug absorption was less rapid 
compared to an aqueous solution but much faster compared to 
formulation containing activated charcoal . In addition , the 
drug bioavailability in presence of attapulgite was complete 
as with aqueous solution , but incomplete in presence of 
activated charcoal. Monkhouse et al . (42,43) have reported 
that rapid dissolution of drugs by rapid desorption from an 
adsorbent surface of silica type compounds occurred and that 
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H-bonding and van der Waals forces accounted for this rapid 
desorption. So the adsorption by talc of a drug with poor 
aqueous solubility would facilitate the drugs dissolution 
rate and the desorption will allow full availability of 
drug. The desorption of drug and adsorption of solvent 
molecules onto adsorbent surface will occur as the contents 
at adsorption site becomes diluted. 
4 . 3 . Effect of Talc on Chemical and Physical Stability of 
Tablets. 
Aspirin in presence of talc showed 1% decomposition 
compared to 15% decomposition in presence of magnesium 
stearate, when tablets containing aspirin , phenacetin, and 
caffeine were stored at 45°c for 5 weeks (44). Of the four 
USP talcs that were studied only one of the talc induced 
aspirin instability to the maximum extent of producing about 
1% salicylic acid when the tablets were stored for 4 weeks 
at 40°c and at relative humidity of 90% (2). The pH of the 
talcs did not appear to be related to aspirin stability, and 
washing talcs with hydrochloric acid greatly reduced the 
influence of talcs on aspirin stability (2). It was 
concluded that impurities in talc responsible for reducing 
aspirin stability were calcium carbonate , calcium silicate , 
but not aluminum silicate or ferric oxide (2). Nazareth et 
al. (45) reported that formulations containing calcium 
succinate alone or in combination with calcium carbonate, 
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but not calcium carbonate alone accelerated decomposition of 
aspirin into salicylic acid in tablets Stored at room 
temper ature or 45°c at unspecified humidity conditions . 
Physical stability of tablets , containing acetaminophen , 
stored at 40°c in dry condition for ten weeks , showed that 
those tablets lubricated with 1% talc plus 0.25% magnesium 
stearate had better appearance compared to tablets 
lubricated with 0 . 5% magnesium stearates only . In addition 
the hardness and rapid disintegration times of these tablets 
did not change (34) . 
5 . Miscellaneous Uses of Talc 
Polymer films use dispersed insoluble solid filler 
materials such as talc to accelarate the build up of film 
coat structures on particles or tablets , thereby reducing 
coating time and costs (46). Talc gave a more varied and 
complex surface than titanium dioxide (46), and it was 
suggested that this may be due to variation in elemental 
content of talcs as determined by their source of deposit 
(46). 
Talc in the range of O to 50% was included as an 
additive in the formulation of an enteric- coated 
microcapsules prepared by spray drying . Presence of talc 
greatly improved the microcapsules flow properties and 
compressibility for tableting . In addition, the greater the 
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percentage of talc used the greater was the increase in 
tablets crushing strength (47). 
6 . Conclusions 
Talc is extensively used in a wide variety of 
cosmetic products , particularly in powder products . Talc 
keeps the skin feeling smooth and dry . Talc in the 
pharmaceutical industry is used as a glidant and lubricant . 
The glidants such as talc improve flow properties of powder 
by decreasing interparticulate friction, by decreasing van 
der Waals forces and electrostatic charges, by changing 
particle size distribution, and probably by decreasing the 
effect of humidity on surfaces of host particles by forming 
a mechanical barrier. The loosely bound lattice layers 
slide over each other and form roller structures which 
explains its lubrication characteristics . Talc has less 
deleterious effect compared to magnesium stearate on tablet 
in vitro properties . 
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Glidants and Lubricant Properties 
of Several Types of Talcs 
Shabbir Dawoodbhai , Hann- Rong Chueh , 
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ABSTRACT 
Glidant and lubricant efficiencies of a number of 
different types of talcs were evaluated. The in vitro 
properties of tablets lubricated with talcs were compared to 
those lubricated with magnesium stearate. Talc lubricated 
tablets showed superior in vitro properties compared to 
magnesium stearate lubricated tablets. Different sources of 
talcs showed significant differences in glidant and 
lubricant efficiencies. 
INTRODUCTION 
A number of different types of talcs were obtained 
from Cyprus Industrial Mineral Company. The objective of 
this study was to determine the potential glidant and 
lubricant efficiencies of these talcs . Also to determine 
the effects of these talcs on tablets in vitro properties 
40 
( and to test the physical stability of some of these tablets. 
METHODS 
Glidant Properties of Talcs 
The physical properties of the talcs available from 
the Cyprus Industrial Mineral Company are shown in Table 1. 
A recording powder f lowmeter was used for evaluating the 
glidant efficiencies of these talcs. The recording powder 
flowmeter equipment consisted of a Mettler PR-1200 top 
loading electronic balance connected to a strip chart 
recorder with a linear potentiometer. The linear 
potentiometer reduced the analog signal output from the 
balance to a level suitable for input into the strip chart 
recorder . The glass funnel used as the hopper had 12 cm top 
diameter , 11 cm length and 1 . 2 cm orifice diameter. 100 g 
of powder was poured into the funnel with the orifice 
closed . When the orifice was opened the powder flowed into 
the beaker and a trace was obtained on the strip chart 
recorder. The chart speed was set at 30 cm / min . 
The formulation used for the powder flow study 
consisted of 55% Emcompress and 45% acetaminophen which had 
been mixed for 5 minutes on a turbula mixer. The talc was 
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TABLE l 
Properties and Sources of Talcs Used in This Study 
Geographic Density (lbs / ft) Percent Undersize 
Source Loose Tapped Median(um) <lOum <20um 
Al talc 300* Montana 20 48 6 75 95 
Al talc 400* Montana 16 41 4 90 98 
Al talc 500* Montana 14 37 3 95 99 
Alabama 300* Alabama 19 51 6 68 86 
Alabama 400* Alabama 16 45 4 80 97 
Beaverwhite Montana 21 40 6 66 88 
325* 
Supra Italian 26 58 15 39 64 
Supraf ino Italian 16 44 5 85 99 
Alpha Glide 
200* Italian 26 59 13 41 
Alpha Glide 
325* Italian 16 40 5 88 
aAll Products and Information Supplied By Cyprus Industrial 
Minerals Company. 
*USP Grade 
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then added in concentration of 0.0% to 0 . 5% and mixed for 
further 3 minutes . The flow of each of the lOOg of 
formulation was done in triplicate . The mass flow rate and 
the linearity were determined . 
Lubricant Properties of Talcs 
An instrumented stokes B-2 rotary press was used 
for evaluating the lubricant efficiencies of talcs . The 
compression and ejection forces were measured by the piezo 
electric transducers located in the eyebolt and the ejection 
cam respectively . The analog data from the piezo 
electric transducers were converted to the digital form by 
the analog to the digital converter . The digital output was 
then collected and analyzed on Apple II computer. 
250g of the formulation as shown in Table 2 was 
prepared and mixed for 6 minutes on the turbula mixer . The 
tablets were compressed at fixed press settings and the 
press speed was set at 24 revolutions per minute. The 
output of force against time data was collected for 10 
tablets per minute in triplicate. 
The tests done to determine the in vitro properties 
of the tablets prepared included USP weight variation test , 
crushing strength, friability , USP disintegration test and 
USP dissolution test. In addition the physical stability 
test was done on tablets made with model acetaminophen 
formulations as shown in which Table 2 which additionally 
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also contained 0.5% of primogel . The physical stability 
test involved storing the tablets in an oven at 40°c in 
closed and open containers, in dry environmental conditions , 
for 10 weeks. The properties of these tablets were compared 
to their initial properties prior to start of the physical 
stability study . The data were evaluated using one way 
fixed effects ANOVA and least significant difference test , 
at significance level of 0.05 . 
RESULTS AND DISCUSSION 
Powder Flow Studies 
The literature suggests that the 3 major factors 
that influence the flowability of powders are the particle 
properties, the environmental conditions and the testing 
methods . The particle properties includes the particle 
shape (1). The spherical and the oblong shaped particles 
flow easily while the sharp edged particles flow less 
readily . The flow becomes poorer with irregularly shaped 
particles and the flow is even more adversely affected by 
the formation of bridges which tends to occur particularly 
with plate shaped and the fibrous type particles . Glidants 
are postulated to improve the flowability of powders by 
decreasing the surface rugosity of the irregularly shaped 
particles (1,2) and also by reducing van der Waals 
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( TABLE 2 
Formulations Used For Evaluating Lubricrant 
Efficiencies of Talcs 
Lubricant Drug Matrix 
Talc(s) 1%a Acetaminophen 5% Avicel PH102 93.75% 
Magnesium stearate Acetaminophen 5% Avicel PH102 94 . 50% 
0.5% 
Talc(s) 1%b Hydrochlorothiazide Avicel PH102 88 . 8% 
10% 
Magnesium stearate Hydrochlorothiazide Avicel PH102 88.0% 
2 . 0% 10% 
aPlus magnesium stearate 0 . 25% 
bPlus magnesium stearate 0.2% 
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attractions (2,3) among particles, thereby preventing 
formation of bridges. 
The particle size is another easily evident factor 
that differs between the free flowing and the poor flowing 
or cohesive powders . The cohesive powders poor flow is due 
to their large surface area available for interparticulate 
friction resulting in development of electrostatic charges 
and the adsorption of moisture and gases. It is postulated 
that glidants tend to minimize these tendencies and collect 
very fine host particles on glidant surfaces (1,2). 
Another particle property that influences the powder flow is 
the particle size distribution. Several studies have shown 
that the powder flow is greatly influenced by the proportion 
of the fines present in the powder. The flow rate of a 
ternary mixture of magnesium oxide was shown to increase as 
proportion of fines in the mixture was increased (4). 
However, an excess of fines usually adversely affects the 
powder flow (3). Other particle properties that tend to 
affect the flow are the particle density, the particles 
elastic and plastic deformation properties (5). 
The second major factor that influences the flow of 
the particles is the environment. The humidity affects the 
particle moisture content. In addition to adsorbing 
moisture, the particles adsorb gases and impurities present 
in the environment (5). 
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The third major factor that affects the flowability 
of the powders is the testing methods. Some of the factors 
that can control the rate at which the powder emerges from 
the circular orifice are the shape of the hopper (6,7). The 
flow contours of powder in a flat bottom hopper have been 
studied. The particles in the center of the hopper flow 
faster, and the particles next to the wall flow the slowest. 
The stationary region of powder next to the wall of the 
hopper slows the flow rate of the powder adjacent to the 
wall. This wall effect is minimal when the difference 
between diameter of container and the diameter of hopper 
~ 
orifice is greater than 30 times the diameter of the 
particle and also when the ratio of the diameter of the 
container to that of the orifice is greater than the value 
2.5 (8). The height of the powder column in the hopper does 
not affect the flow rate, unless the head of the powder 
column falls below the height of 2.5 times the diameter of 
the container at which point the flow rate will increase 
(8). Another factor that affects the flow of powder from 
the hopper is the bulk density. One of the reasons why 
addition of fines to regular size particles increases the 
flow rate is that, the fines tend to fill the voids between 
the larger particles and thereby increase the bulk density. 
Consequently a greater mass per unit volume is discharged 
and therefore the flow rate is increased. However, the use 
of very high percentage of fines will fully fill the voids 
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between the larger particles and therefore increase the 
interparticulate friction (8). 
The single most important factor that influences the 
flow rate is hopper orifice diameter (4,8). The flow rate 
in grams per second is proportional to the orifice diameter 
raised to the power n, for many materials the value of n is 
between 2.5 and 3.2 (6). 
Jones and Pipel (4), and Danish and Parrot (8) have 
developed more precise relationships between the diameter of 
hopper orifice and the flow rate. These equations take into 
consideration the factors that are functions of particle 
size, particle shape, particle surface roughness, the 
density of the powder material and the hopper geometry. 
Most of the studies in the literature have expressed results 
in terms of flow rate. Another function that is important 
in addition to flow rate is the uniformity or the linearity 
of flow. This was evaluated qualitatively by Gold et al. 
(9) and quantitated by Hegde et al (7) using the linearity 
powder flow index. The linearity powder flow index is the 
difference between the square of the least square 
correlation coefficient and the minimal value of 0.8 
multiplied by 100. The linearity combined with flow rate 
can be of great help in formulation development, quality 
control and scale up trouble shooting. 
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Glidant Properties of Talcs 
The basic avenues available for improving the flow 
rate of powders are precompression, wet granulation, and 
addition of glidants. The selection of glidants and their 
concentration is empirical since there is no generally 
acceptable method for evaluating the glidant effectiveness. 
Gold et al. (3) highlighted some of the ways in which the 
glidants affect the powder flow. They obtained f-values 
which is the ratio of the powder flow rate in the presence 
of the glidant compared to the flow rate in the absence of 
the glidant . F-values greater than one indicated increased 
flow rate, while f-values less than one indicated decreased 
flow rate upon addition of glidant. Using lactose powder 
they showed that addition of up to 20% of fines increased 
f-values. However, addition of talc or magnesium stearate 
produced even higher f-values compared to addition of fines. 
Therefore glidants increased the flow rate by an additional 
mechanism other than just an increase of the percent of 
fines. They also found that talc was less able to increase 
the flow compared to magnesium stearate. They suggested 
that magnesium stearate was able to decrease van der Waal's 
forces to a greater extent compared to talc. Perhpas talc 
would have been a more efficient glidant if the surf ace 
rugosity of the lactose powder particles used was high. 
Further increases in the concentrations of magnesium 
stearate and talc decreased the flow rates probably by 
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altering the particle size distribution of the lactose 
powder. 
The talcs used in this powder flow study are 
commercially available and their physical properties are 
shown in Table 1. The powder loose density ranged from 14 
to 26 lbs / ft 3 while the tapped density ranged from 37 to 58 
lbs / ft 3 . The median particle size ranged from 3 to 15um. 
The percent undersize, for <10 um particle size ranged from 
39 to 95% and for <20 um particle size ranged from 64 to 
99%. There is no correlation apparent between the talcs 
physical properties and-their glidant efficiencies . 
As shown in Table 3 and 4 the relative standard 
deviation values for flow rate and linearity data are 
extremely low indicating very highly reproducible results. 
The mass flow rate data of the powder flow study are shown 
in Figure l , 2 and 3 . Using quite low talc concentrations , 
it was found that Ultraglide 325 , Altalc 400 , Beaverwhite 
talcs gave maximal flow rate at 0.1% talc concentration. In 
addition Supra, Alabama 300 and Alabama 400 also gave 
maximal flow rate at 0.1% concentration. The remaining 4 
talcs, Altalc · 500, Ultraglide 200, Suprafino, Altalc 300 
gave increasing flow rate up to 0 . 25% talc concentration. 
Table 5 . compares the flow rate and linearity data 
for 0 . 1% and 0.25% of talcs concentrations . In summary, 
supra has best glidant action at 0.1% , while Altalc 500 has 
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TABLE 3 
Reproducibility of Flow Rates 
Percent 
Altalc 300 
0 
0.1 
Flow Rate (gm / sec) 
1 2 3 
10.79 10 . 83 10 . 84 
11.46 11 . 55 11 . 69 
TABLE 4 
Relative standard 
Deviation (%) 
0.28 
0.95 
Reproducibility of Linearity of Powder Flow 
Percent 
Altalc 300 
0 
0.1 
Linearity 
1 2 3 
19 . 78 19.80 19.76 
19.80 19.90 19.87 
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Relative Standard 
Deviation % 
0 . 1 
0.26 
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TABLE 5 
Comparisons of Mass Flow Rates and Linearity 
Values of Acetaminophen and Emcompress Powder Mixture 
Concentrations of Talcs 
0. 10% 
Talc Flow rate Linearity 
(G I sec) 
Al talc 500 11.83 19.86 
Supra 11.84 19 . 85 
Ultraglide 11.60 19.86 
200 
Al talc 300 11.57 19.86 
Supraf ino 11.44 19 . 78 
Altalc 400 11.68 19.80 
Ultraglide 11. 61 19.82 
325 
Alabama 400 11.57 19.81 
Beaverwhite 11.50 19.84 
325 
Alabama 300 11.46 19.80 
55 
0.25% 
Flow rate Linearity 
(G / sec) 
12.04 19.86 
11.52 19.85 
11.83 19.82 
11. 65 19.85 
11.68 19.86 
11.14 19.80 
11.54 19.82 
11.23 19.80 
11.03 19.84 
11.18 19.81 
( best glidant action at 0 . 1% and 0.25~ of talc 
concentrations. The glidant efficiency of 0 . 1% Supra or 
Altalc 500 is same as that of 0 . 25% Ul traglide 200. As the 
flow rate increased with addition of talc , linearity also 
tended to increase , although no statistically significant 
differences in linearity values could be shown. 
Tablet Lubricants Studies 
There are studies in the literature that have 
investigated the use of talc as tablet lubricant . Efficient 
lubrication in tablet manufacturing is of considerable 
importance in order to promote the production of elegant 
tablets at an optimum rate with minimum stress on the tablet 
press, by facilitating the ejection of tablets. Talc is 
particularly helpful in preventing the sticking and picking 
of tableting mass to the punch faces (10) . While magnesium 
stearate is more useful for preventing the binding of the 
tableting mass to the die wall (10) . The efficiency of 
lubricants may be evaluated by determination of their 
physical properties such as water solubility (11) , shear 
strength (12) and melting point (13). These studies report 
that efficient lubricants tend to have low water solubility, 
low shear strength and low melting point. However, critical 
review of the literature suggests that lubricant efficiency 
is better predicted by evaluation on instrumented tablet 
press compared to evaluation based on the physical and 
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chemical properties of the lupricants . The lubricant 
efficiency on an instrumented tablet press can be evaluated 
in a variety of ways . Addition of lubricant to a 
formulation increases the force transmitted to the lower 
punch and decreases the frictional force at die wall (14). 
The R-values range from 0.6 for poor lubricant to 1 . 0 for 
perfect lubricant. The R values have been criticized for 
not being sufficiently sensitive. Other studies have also 
measured frictional force at die wall and / or radial die wall 
force . Probably a better indicator of lubricant efficiency 
is the ejection force, since it takes into consideration the 
adhesion force as well as the frictional force at the die 
wall . The ejection energy (15) may be a more accurate 
indicator of lubricant efficiency. Decrease in ejection 
force or ejection energy values indicate improvement in 
lubricant efficiency . 
Lubricant Properties of Talcs 
The lubricant efficiencies of talcs were evaluated by 
measuring the force required for the ejection of 300 mg 
acetaminophen tablets. Using one way fixed effects ANOVA 
and the least significant difference test, the lubricant 
efficiency of 1% Altalc 300 and 1% Supra was found not to be 
significantly different from that of 0.25% magnesium 
stearate. One percent of Alabama 300 and the Altalc 400 was 
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15.3% less efficient while 1% Alabama 400 was 29.8% less 
efficient compared to 0.25% magnesium stearate. 
The lubricant efficiencies of talcs were also 
determined using model hydrochlorothiazide formulation as 
shown in Table 2. The lubricant efficiencies were evaluated 
using ejection force values. Compared to 1% Supra, the 
lubricant efficiency of 1% Alabama 300, 1% Altalc 400 and 1% 
Alabama 400 was 3 . 9% less efficient, while Altalc 300 was 
10% less efficient. 
Several studies have evaluated the efficiency of 
lubricants using ejection force values (13,14,15,16,17). 
The evaluation of lubricant efficiency of talc based on 
ejection force values as in this study and in the literature 
(11,14,15,17) indicates that on equal weight basis talc is 
less efficient than magnesium stearate. Numerous studies 
have shown that lubricant efficiency can be improved by 
increasing concentration of lubricant. Magnesium stearate 
lubricant action is due to formation of a film which coats 
the surfaces of the tableting mass (16,18), and the tooling. 
Talc is a laminar solid whose layers slip and roll over one 
another in the direction of motion (19). Lubricant 
efficiency of talc is unlikely to increase with increase in 
compaction force because this rolling over action of talc 
becomes restricted. In addition higher concentration of 
talc is required compared to magnesium stearate because talc 
forms a barrier of monoparticulate layer while magnesium 
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stearate forms a molecular film barrier (16 , 18). 
Furthermore , the lubricant efficiency of magnesium stearate 
increases with increasing mixing time , because it shears 
during mixing and becomes attached onto the unlubricated 
surfaces ( 18 , 20 ). Matsuda et al (15) showed that better 
lubricant efficiency was obtained when magnesium stearate 
and talc was mixed with granules just prior to compaction 
compared to incorporation of lubricant at the granulation 
stage . 
Both talc and magnesium stearate are hydrophobic 
lubricants (10 , 11). However, magnesium stearate is more 
efficient at covering the surfaces of the particles compared 
to talc (15) and therefore able to interfere with bonding 
between particles during consolidation . Therefore magnesium 
stearate has much greater deleterious effect than talc on 
tablet hardness (16,17,20,21) and percent friability. 
Furthermore , magnesium stearate prolongs disintegration time 
(16,20,22) and unlike talc, the magnesium stearate decreases 
the dissolution rate of drug (23,24) . Therefore there is 
merit in examining the possible use of magnesium and talc 
combinations (17) in order to optimize the lubricant 
efficiency and tablet performance properties. 
Tablet Properties 
The in vitro properties of the tablets made in this 
study from model acetaminophen formulations and model 
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hydrochlorothiazide formulation are shown in Table 6 and 7. 
The appearance of these tablets ~ere evaluated in a 
controlled, double blind cross over study. The model 
acetaminophen formulations tablets appearance were similar 
in all respects for various talcs and magnesium stearate 
lubricated tablets. However, the magnesium stearate only 
and the Altalc 400 lubricated tablets had slightly more 
cracked edges. In case of the hydrochlorothiazide 
formulation the magnesium stearate lubricated tablets had 
pitted top and bottom surfaces and slightly cracked edges. 
· These defects were absent in all talc lubricated tablets. 
The talc lubricated tablets of model acetaminophen 
or hydrochlorothiazide formulations were considerably harder 
in varying degrees compared to magnesium stearate and 
Alabama 300 lubricated tablets. Also the tablets 
lubricated with the talcs had better friability properties. 
In particular the Altalc 300, and Altalc 400 lubricated 
tablets gave considerably less friable tablets compared to 
magnesium stearate lubricated tablets. The disintegration 
time of talc lubricated tablets disintegration time ranged 
from 22 to 25 . seconds. There was no statistically 
significant difference in the dissolution rate of 
acetaminophen from 1% talc plus 0.25% magnesium stearate 
lubricated tablets compared to 0.5% magnesium stearate 
lubricated tablets as shown in Table 8. The dissolution 
rate of hydrochlorothiazide from 1% talc plus 0.2% magnesium 
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Tahle 6 
Properties of Acetaminophen Tahlets 
a h c d e Tablet RSD Percent Hardness Percent Percent 
Lubricant Wejghdmg) lleavier (Kg) Harder Friahjljty 
Alabama 400 306.8 O.JO 104.7 12.0 131.9 0.18 
Altaic 400 303 . 6f 0.41~ 103.6f ti.Ji 124.2i 0.07 
Alabama 300 300.Jf 0.68 102.5f 10.5 . 115.4 . 0.14 g I I Altaic JOO 299.4 0.47 1 102.2 10.2. 112.1 . 0.07 Supra 293.1 0.72 1 100.0 10.3 1 113.2 1 0.21 
~lagnesium 309.2 o .. 13g --- 9.1 100.0 0.30 
Stea rate 
a bMean of 20 tablets. 
Disintegration 
Time( sec) 
25 
25 
25 
25 
25 
25 
Relative standard deviation of tahlet weights. 
cHelative tablet weights were compared to those lubricated with Supra, because of 
ddifference in molecular weight between magnesium stearate and talcs. 
Mean of 10 tablets. 
eHelative tablet hardness were compared to those lubricated with 0.5% magnesium stear 
ate lubricated tablets. 
f ,g,h, iNo statistically significant differences. 
m 
l\) 
Table 7 
Properties of llydrochlorothiazide Tablets 
Tablet a Percent c llardness d Percent e Percent Disintegration 
RSDh l.uhricant Weight (mg) lleavier (Kg) Ila rd er Friability Time 
A It a I c JOO 246.6 0.28 l 0 2 . 3 5.3 120.5 0.04 20 
A I a hama JOO 245.0 0. l 61 10 t. 6 4.4 100.0 0. t 2 1 8 
Supra 243.3 (). J J 100.9 5. 1 h 115.9h 0.08 20 
A It a I c 400 242.2 o. 1 51 100.5 4.7h 106. 81 0.08 20 
A I a hama 400 24 l . 1 0.31 1 00. () 4.8 l 09. 1 l 0. 1 2 22 
Magnesium 2 5 7. 1 0.91 - - - 2.8 - - - 0.50 25 
Stea rate 
a bMean of 20 tab I e ts. 
Relative standard deviation of tahlet weights. 
cRelative tablet weights were compared to those luhricated with Alabama 400 
dhecause of difference in molecular weight hetween magnesium stearate and talcs. 
Mean of 1 0 t ab I e t s . 
e~elative tablet hardness were compared to those lubricated with Alabama JOO 
fbecriuse of greater percent of magnesium stearate used (Table 2). 
,g,'No statistically significant differences. 
(Sec) 
TABLE 8 
Dissolution Rate of Acetaminophen From Tablets 
Percent of drug dissolved * 
15 min 30 min 40 min 60 min 
Altalc 300 59.3(4.1) 81 . 4(1 . 2) 89 . 9(0.1) 97 . 6(2.5) 
Altalc 400 51.2(1.5) 72.0(2.4) 81.2(1.6) 93.4(1.2) 
Alabama 300 55 . 5(5 . 0) 74.7(6 . 4) 83 . 2(5.3) 93.6(0.2) 
Alabama 400 59.3(2 . 7) 79.4(1.7) 84.4(1.6) 93 . 5(1.5) 
Supra 60.2(6 . 4) 81.4(3.2) 90 . 3(4.2) 96 . 8(3.2) 
Magnesium 54 . 3(2 . 9) 81.5(1 . 4) 93.1(0.2) 99.4(0.5) 
Stearate 
*The value in parenthesis is standard deviation . 
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stearate lubricated tablets compared to 2.0% magnesium 
stearate lubricated tablets was statistically significantly 
different for example, at 10 minutes the percent of 
hydrochlorothiazide dissolved from magnesium stearate only 
lubricated tablet is 56% compared to 92% from talc 
lubricated tablets, see Table 9. The properties of tablets 
made from the model acetaminophen formulations to which 0.5% 
primogel had been added was evaluated after undergoing 
physical stability test as shown in Table 10. The tablets 
lubricated with 1% talc and 0.25% magnesium stearate had 
less cracked edges compared to tablets lubricated with 0.5% 
magnesium stearate. The open and closed container tablets 
showed a decrease in mean weight of about 2.5% while Altalc 
400 and Altalc 300 lubricated tablets showed a decrease in 
weight of 2.0% and_ 1.4% respectively. The hardness values 
remained unchanged compared to their initial values at the 
start of the physical stability test. The disintegration 
time values for talc and magnesium stearate only lubricated 
tablets was 25 seconds. 
The relationship between lubricant efficiency and 
effects of lubricants on tablet h~rdness has yet to be fully 
delineated. In case of magnesium stearate as the 
tablet lubricant, the decrease in tablet hardness correlates 
with the increase in disintegration time (16,20) because the 
hydrophobicity decreases the contact angle of water with 
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TABLE 9 
Dissolution Rate of llydrochlorothiazide From Tablets 
Magnesium 
Stea rate 
Altaic 300 
Altaic 400 
Alabama 300 
Alabama 400 
Supra 
Percent of Drug Dissolved* 
5 man. 10 min. 15 min. 25 min . 35 min. 60 min. 
34.5(4.5) 56 . 6(1 .4) 75 . 8(4.9) 89.0(2.3) 95.3(2 . 3) 99.2(0.8) 
78.0(1 .2) 89 . 8(1 .0) 96.4(1 .2) 98.2(0.6) 98.6(0 . 5) 98.8(0.7) 
78.6(2.0) 91 . 7(1 .5) 94.6(0.6) 98 . 4(0.9) 99 . 5(0.7) 100(0 . 0) 
83.1(2.6) 92.0(1 .5) 95.6(1 . 6) 99.0(0.9) 99.7(0.4) 100(0.0) 
78.9(0.8) 93.0(1.3) 96 . 2(1 .5) 99.8(0.4) 100 (O.O) 100(0.0) 
77.5(2.5) 92.0(2.0) 95 . 4(1 .0) 99.2(0.7) 99.7(0.3) 100(0.0) 
*The value in parenthesis is standard deviation . 
TABLE 10 
Properties of Acetaminophen Tablets After Physical 
Stability Test 
Decrease in Percent Mean Weight 
Container Altalc 300 
Open 2.5 
Close 1.4 
Altalc 400 
2.4 
2.0 
66 
Supra 
2.5 
2.4 
Magnesium 
Stearate 
2.5 
2 . 5 
( 
( 
capillary pore in the tablet (22). Levy and Gumtow found 
that magnesium stearate retarded the dissolution rate of 
salicylic acid , and that the presence of starch as 
disintegrant did not improve the dissolution from tablets 
lubricated with magnesium stearate (23). Similarly , a 
prolonged mixing of magnesium stearate in a formulation , 
decreased the dissolution rate of salicylic acid (20). The 
dissolution rate of salicylic acid and aspirin decreased 
somewhat exponentially with increase in magnesium stearate 
concentration but the presence of talc had no effect on 
dissolution rate (24). 
CONCLUSIONS 
The data from the literature and the present study 
clearly indicate that talc has excellent glidant properties 
and is likely to be of great value in remedying any powder 
flow problem . ~uite low concentrations of talc have a very 
substantial effect on powder flow. Although the lubricant 
efficiency of talc (as quantified by ejection forces) is 
less than equal weights of magnesium stearate, talc by 
itself or in combination with magnesium stearate has 
considerable potential as a lubricant. 
Tablets made with talc as a lubricant have a 
significantly better appearance and hardness than comparable 
tablets containing magnesium stearate . For some drugs at 
least the dissolution rate of talc lubricated tablets is 
67 
superior to those lubricated by magnesium stearate alone. 
Different sources of talc show significant differences in 
glidant and lubricant efficiency . In summary , the talcs 
studied in this investigation clearly merit careful 
consideration as pharmaceutical adjuvants . For 
hydrochlorothiazide , often regarded as the classic example 
of a drug liable to biological availability problems, 
tablets lubricated by talc have improved dissolution 
compared to similar tablets lubricated by magnesium stearate 
above. Additionally, for some systems talc can improve 
hardness , friability and appearance. It is noteworthy that 
different sources of talc show significant variation in 
their effect on tablet properties. Thus, companies using 
talc for pharmaceutical purposes should give attention to 
uniformity of the quality of the material which they use . 
Work on the pharmaceutical uses of talc is 
continuing in this laboratory and will be published in due 
course . 
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Use of Talc as a Major Component of a 
Direct Compression Tablets Matrix 
Shabbir. Dawoodbhai and Christopher T. Rhodes 
Department of Pharmaceutics 
University of Rhode Island 
Kingston, RI 02881-0809. 
Talcs in substantial percentages were evaluated for 
their potential as a direct compression matrix material. 
With commonly used excipients such as microcrystalline 
cellulose and lactose, the formulations were self 
lubricating and the tablets ejected easily. Tablets with 
very low friability, high crushing strength, rapid 
dissolution rates, good weight uniformity, content 
uniformity and potency of drugs were obtained. At similar 
compression forces, tablet hardness with 300 grade of 
Alabama , Altalc, and Beaverwhite talcs was significantly 
greater than corresponding 400 and 500 grades. 
Introduction 
Talc has been evaluated as a glidant and as a 
lubricant with anti-adherent properties on its own or in 
combination with magnesium stearate (1-6). It has been 
shown that talc has much less deleterious effect on tablet 
in vitro properties compared to magnesium stearate (2-8). 
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In particular the hardness of the tablets made with direct 
compression materials such as microcrystalline cellulose 
( 4 , 5 , 7 , 8 ) and of lactose ( 5- 8) is greatly decreased by 
magnesium stearate. Hence , we decided to investigate 
whether talc could be used in large percentages as a major 
component of tablet matrix in combination with commonly used 
direct compression excipients such as microcrystalline 
cellulose and lactose . Our objectives were to obtain 
formulations that had good flow and compressibility 
properties for commonly used drugs using talc as a major 
component in direct compression formulations. In addition 
it was hoped that these tablet formulations would have low 
friability , good hardness, rapid disintegration and 
dissolution rates. 
Materials 
The direct compression formulations had the 
following percentages (w / w) composition: 
Formula I - Hydrochlorothiazide 6 . 25% (Schering Corporation, 
Kenilworth , New Jersey), talc 21% or 26% (Cyprus Industrial 
Minerals Company, Mobile, Alabama) , Primogel 4% (Generichem 
Corporation, Little Falls, New Jersey), and Avicel PH-102 
68 . 75% or 63 . 75% (FMC , Philadelphia , Pennsylvania) , 80g 
mixed for 3 minutes 45 seconds . 
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Formula II - Niacin 6.25% (Sigma Chemical, St . Louis, 
Missouri) , talc 30%, and Avicel PH-102, 55g mixed for 3 
minutes 23 seconds. 
Formula III - Niacin 6.25%, talc 10%, Primogel 4% and direct 
tableting lactose 79.75% (Scheffield Products, Norwich, New 
York), lOOg mixed for 1 minute 32 seconds . 
Formula IV - Phenylpropanolamine 12.5% (Sigma Chemical, St. 
Louis , Missouri), talc 26% and Avicel PH-102 61.50%, 80g 
mixed for 5 minutes. 
Formula V - Theophylline 25.0% (Sigma Chemical, St. Louis, 
Missouri), talc 21.0%, and Avicel PH-102 50% , lOOg mixed for 
5 minutes 20· seconds. 
Formula VI - Magnesium stearate 1 or 2% (Fisher Scientific, 
Fair Lawn, New Jersey) was used in place of talc for 
formulas I to V above, with the above respective quantities 
and corresponding mixing times. The properties of the talcs 
used in this study are shown in Table 1. 
Method 
The components of the various tablet formulations 
were mixed in the turbula mixer. An instrumented Stokes B-2 
rotary tablet press was used as described previously (4). 
Five tablets were evaluated for appearance (magnifying 
glass), ten tablets were evaluated for friability (Erweka 
Friabilator; Chemical and Pharmaceutical Industry, New York, 
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Table 1: Properties of talcs used in this study. 
Talc Geographic Bulk Density(lbs/ff) Median Percent Undersize 
Source Loose Tapped Size( um) 10 um 20 um 
Al talc 300 Montana 20 48 6 75 95 
Al talc 400 Montana 16 41 4 90 98 
..;z Al talc 500 Montana 14 37 3 95 99 ~ Alabama 300 Alabama 19 51 5 68 86 
Alabama 400 Alabama 16 45 4 80 97 
Beaverwhite 300 Montana 14 37 5 73 89 
Beaverwhite 400 Montana 12 35 4 75 91 
Beaverwhite 500 Montana 11 27 3 81 95 
- -
Information obtained from Cyprus Industrial Minerals Company. 
( 
l 
New York) , and crushing strength (Erweka Hardness Tester; 
Chemical and Pharmaceutical Industry , New York , New York} . 
Six tablets were evaluated for disintegration time (USP 
Disintegration Time Tester , Vanderkamp ; Van- Kel Industries , 
Chatham , New Jersey) , and dissolution of drug (Basket or 
Paddle, USP ; Vanderkamp ; Van- kel Industries, Chatham, New 
Jersey). Dissolution test procedures specified in the USP 
monographs were used for hydrochlorothiazide and 
theophylline. For niacin and phenylpropanolamine the paddle 
method at 50 r.p . m. was used with 900 ml and 500ml 
respectively of degassed deionized distilled water as 
dissolution medium . Additionally , to ensure total release 
of drug, the agitation speed was increased to 150 r . p . m for 
45 minutes at the end of which a sample of dissolution 
medium was obtained, this sampling time is referred to as 
T . The samples concentration were measured on the Diode 
m 
Array Spectrophotometer (Hewlett Packard ; Loveland, 
Colarado) at the wavelengths specified in the USP . 
Dilutions of the sample were necessary for the theophylline 
tablets . 
Result and Discussion 
The appearance of all the tablets were 
pharmaceutically elegant . In general , the talc containing 
tablets had virtually no surface defects such as pitting , 
edge chipping or cracking , while slightly cracked or chipped 
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edges were occasionally found on the baseline formulation VI 
tablets . The talc containing tablets surface had matt 
appearance , and infrequently showed s l ight faint grey specs 
on the tablet surface or faint grey line on the side of the 
tablets , while the baseline tablets had a slightly more 
glossy appearance. 
The data for formula I (Tables 2 and 3) 
demonstrates that the tablets of weight with low relative 
standard deviation and good compressibility can be produced . 
The ejection forces (lubrication) were similar for all the 
talcs. At similar compression forces the tablet hardness 
with the 300 grade of the Alabama, Altalc , Beaverwhite , was 
statistically significantly greater than the corresponding 
400 and 500 grades. These tablets of formula I had very low 
friability and rapid disintegration times. The dissolution 
rate was similar from these talc containing tablets with 
high and low tablet hardness values . The dissolution rate 
of hydrochlorothiazide was rapid and exceeded the USP 
requirement of not less than 60% release by 30 minutes. The 
baseline formulation VI (Tables 3 and 4) had lower ejection 
force and similar properties as formulation I tablets with 
regard to weight variation, disintegration time and 
dissolution rate. In addition , both formula I and its 
baseline formula VI tablets had acceptable content 
uniformity and potency of hydrochlorothiazide tablets , as 
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Table 2: Properties of formula I tablets weighing 400mg. 
Talc Percent Compression Ejection Weight Hardness Percent Disintegration 
Force (KN) Force (KN) RSO Friability Time (seconds) 
Alabama 300 21. 0 13.9(0.3) 0.38(0.01) o. 3 12.4(0.5) 0.1 23 - 26 
-'2 Alabama 300 26.0 13.6(0.3) 0.42(0.01) 0.3 6.6(0.7) 0.3 26 - 30 
-'2 Alabama 400 21. 0 13.7(0 . 3) 0.40(0.01) 0.3 11.5(0.5) 0.1 21 - 23 
Alabama 500 21. 0 13.8(0.2) 0.38(0.01) 0.3 10.8(0.4) 0.1 21 - 22 
Al talc 300 21. 0 13.9(0.2) 0.39(0.01) 0.3 14.3(0.5) 0.2 20 - 23 
Al talc 400 21. 0 13. 7(0.2) 0.38(0.01) 0.3 11.2(0.3) 0.2 20 - 23 
Al talc 500 21. 0 13.7(0.3) 0.38(0.01) o. 3 10.0(0.8) 0.2 22 - 24 
Beaverwhite 300 21.0 13 . 8(0 . 2) 0 . 39(0.01) o. 3 13.4(0.4) 0.2 20 - 22 
Beaverwhite 400 21. 0 13.7(0.2) 0.39(0.01) 0.2 12.6(0.3) 0.2 22 - 26 
Beaverwhite 500 21. 0 13.8(0.3) 0.39(0.01) 0.3 11.l(l.l) 0.2 22 - 24 
Mag. Stearate l. 0 12.l(0.2) 0.07(0.00) 0.3 5.2(0.7) 0.7 7 - 12 
All values in parenthesis are standard deviations 
~ 
O> 
Table 3: Dissolution properties of hydrochlorothiazide 
from formula I and its formula VI tablets 
Talc or Formulation Percent of Drug Released at Time (minutes) 
Magnesium Stearate Percentage 
Alabama 300 
Alabama 300 
Alabama 400 
Alabama 500 
Al talc 300 
Al talc 400 
Al talc 500 
Beaverwhite 300 
Beaverwhite 400 
Beaverwhite 500 
Magnesium Stearate 
21.0 
26.0 
21.0 
21.0 
21.0 
21.0 
21.0 
21.0 
21.0 
21.0 
1.0 
30 40 Too 
89.6(3.1) 
87.5(2.9) 
83.6(3.5) 
89.2(4.6) 
97.2(1.2) 
86.2(3.3) 
85.8(2.5) 
90.1(0.5) 
89.5(1.0) 
88.9(1.9) 
85.2(11.3) 
93.0(2.1) 
92.4(3.3) 
87.5(4.1) 
93.8(4.0) 
101.2(1.3) 
91.4(3.1) 
91.6(2.4) 
94.4(0.5) 
93.5(1.1) 
93.5(1.5) 
92.7(5.7) 
99.4(0.6) 
100. 4 ( 1. 0) 
100. 5 ( 1. 2) 
100.0(0.8) 
104.7(0.6) 
100. 4 ( 1. 0) 
99.6(1.1) 
100.0(0.9) 
99.3(1.2) 
100.6(0.8) 
98.2(2.4) 
All values in parenthesis are standard deviations 
-;z 
(0 
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Table 4: Properties of formula VI tablets weighing 400mg 
Drug Percent Compression Ejection Weight Hardness Percent Disintegration 
Kg.Str. Force (KN) Force (KN) RSD Friability Time (minutes) 
Hydrochlorothiazide 
Niacin"' 
Niacin 
Phenylpropanolamine 
Theophylline 
1. 0 
2.0 
2.0 
2.0 
2.0 
12.1(0.2) 
11.9(0.2) 
13.8(0.2) 
8.5(0.1) 
11.9(0.2) 
"' Niacin tablets of weight 375mg. 
Mg.Str. refers to magnesium stearate. 
0.07(0.00) 0.3 
0.09(0.01) 0.3 
0.60(0.01) 0.3 
0. 11 ( 0. 00) 0. 3 
0.12(0.00) 0.3 
All values in parenthesis are standard deviations 
5.2(0.7) 
11.5(0.8) 
8.9(1.5) 
6.4(0.7) 
7.5(0.5) 
0. 7 
0.1 
0.3 
0.2 
0.2 
0.1 - 0.2 
0.6 - 0.9 
7.5 - 9.0 
0.2 - 0.4 
0.6 
( 
' 
determined by USP dissolution test. It is noteworthy that 
all the talc containing formulations hafi -considerably 
greater tablet crushing strength and lower friability 
compared to their baseline formulation. 
The data for the formula II (Tables 5 and 6) shows 
that tablets with high crushing strength, low percent 
friability, shorter disintegration time and rapid 
dissolution rate can be obtained with the talc present at 
the 30% level. The tablets weight relative standard 
deviation were very low and the properties of the tablets 
obtained with different talc grades were similar . The 
baseline formulation VI (Tables 4 and 6) had slightly lower 
ejection force, and lower relative standard deviation for 
tablet weight but prolonged disintegration time . The 
dissolution rate from the baseline formulation was faster 
compared to formula II tablets. The tablets of formula III 
(Tables 5 and 6) and its baseline formulation VI (Tables 4 
and 6) have very similar properties except that the formula 
III tablets have much greater hardness, and shorter 
disintegration time. 
Tables 7 and 8 show the data for formula IV. These 
tablets have very similar properties to their baseline 
formulation VI (Tables 4 and 8). However, the baseline 
formulation had lower ejection force and slightly shorter 
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-Table 5: Properties of formula II and formula III tablets weighing 400mg 
Talc Percent Compression Ejection Weight Hardness Percent Disintegration 
Force (KN) Force (KN) RSD Friability Time (minutes) 
()) 
Alabama 300 30.0 12.0(0.5) 0.34(0.01) 0.8 11.8(1.1) 0.3 0 .4 - 0.8 ...... 
Alabama 400 30.0 12.0(0.4) 0.34(0.0l) 0.7 11.3(0.3) o. 3 0.4 - 0.8 
Alabama 500 30.0 11.9(0.5) 0.33(0.0l) 0.7 10.6(0.6) 0. 3 0.4 - 0.8 
Alabama 300 10. O"' 14.1(0.2) 0.74(0.01) 0.2 11.7(1.2) 0.3 3.6 - 4.2 
* Refers to formula III 
All values in parenthesis are standard deviations 
•' 
~ 
Table 6: Dissolution properties of niacin from formula II, formula II I 
and their formula VI tablets 
Talc or Formulation Percent of Drug Released at Time (minutes) 
Magnesium Stearate Percentage 5 10 Too 
--()) 
t\) 
Alabama 300 30.0 50.4(3.7) 69.4(4.9) 104. 2( l. 0) 
Alabama 400 30.0 51.3(4.6) 71.6(3.6) 99.2(0.8) 
Alabama 500 30.0 51.9(6.3) 75.0(6.0) 97.8(1.4) 
Magnesium Stearate 2.0 69.5(4 . 6) 86.9(1.5) 100. 4 ( l. 9) 
Alabama 300 30.0 77.3(1.5) 97. 7(1.3) 99.7(2.l) 
Magnesium Stearate 1.0 85. 2 ( 11. 3) - 91.8(0.8) 
All values in parenthesis are standard deviations 
,. 
........... 
,......-... 
Table 7: Properties of formula IV and formula V tablets weighing 400mg 
Talc Percent Compression Ejection Weight Hardness Percent Dis integration 
Force (KN) Force (KN) RSD Friability Time (minutes) 
()) 
Vl Beaverwhite 300 26.0 8.4(0.2) 0.24(0.01) 0.3 7.0(0.6) 0 .1 0.8 - 1.0 
Beaverwhite 300 21.0 12.0(0.3) 0.27(0.01) 0.8 12.8(3.5) 0.1 o. 3 
All values in parenthesis are standard deviations 
,. 
.-.. 
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Table 8: Dissolution properties of phenylpropanolamine from formula IV 
and theophylline from formula V and their formula VI tablets 
Talc or Formulation Percent of Drug Released at Sampling Times 
Magnesium Stearate Percentage 1 2 
-
Beaverwhite 300 26.0 85 . 1(10.5) 94.9(7.7) 
Magnesium Stearate 2.0 81.4(9.6) 89.6(6.0) 
Beaverwhite 300 21.0 90.6(5.8) 92.6(4.9) 
Magnesium Stearate 2.0 96.8(1.5) 97.8(0.9) 
Formula IV sampling times in minutes were 5, 10 and Too 
Formula VI sampling times in minutes were 30, 40, and Too 
All values in parenthesis are standard deviations 
•' 
3 
100.0(4.1) 
100.0(2.2) 
99.7(0.8) 
97.9(0.5) 
-
( disintegration time compared to formula IV tablets. 
The formula V tablets (Tables 7 and 8) have much 
greater crushing strength, very low percent friability, 
rapid disintegration , higher ejection forces, and slightly 
higher tablet weight relative standard deviation compared to 
the baseline formulation VI tablets (Tables 4 and· 8). 
Although the dissolution of theophylline from the baseline 
formulation VI tablets was slightly more rapid compared to 
formula IV tablets, both formulations exceeded the USP 
requirement of not less than 80% release in 45 minutes. In 
addition, the tablets from both formulations had acceptable 
~ 
content uniformity and potency of theophylline as determined 
by the USP dissolution test. 
Talc, although an hydrophobic material like 
magnesium stearate, does not seem to have as deleterious 
effect on dissolution of drugs as does magnesium stearate 
(2-4,6). Using compressed disk of aspirin, salicylic acid 
and equimolar mixture of aspirin and salicylic acid an in 
increase in concentration of magnesium stearate from 0.1 to 
5% progressively slowed dissolution rate (2). While 0.1 to 
5% of talc did not affect the dissolution rates of these 
drugs (2). It has been postulated that the stearates soften 
and spread under compression to provide a more coherent 
coverage of matrix than talc (2-3). In this study we found 
that even with very large percentages of talc the 
dissolution rates of the drugs remained quite similar to 
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those obtained with the baseline formulations containing 1 
or 2% of magnesium stearate . Levy et al. ( 3 ) reported that 
initial dissolution rate of salicylic acid from rotating 
disk was faster with talc compared to magnesium stearate. 
Levy et al . (3) concluded that hydrophobic lubricants retard 
dissolution rate of drugs contained in compressed tablets by 
prolonging disintegration time and by reducing the area of 
interface between drug particle and the solvent. 
Another possible reason as to why talc has less 
deleterious effect than magnesium stearate is that due to 
its adsorption ability talc may not retard water penetration 
~ 
to the extent suggested by its hydrophobicity. Also an 
adsorbent like talc would provide a large surf ace area for 
adsorption of drugs from solution, thereby maintaining a 
high concentration gradient for the precipitated drug to 
redissolve. The commonly used pharmaceutical excipient such 
as microcrystalline cellulose has also been shown to adsorb 
drugs (9) . Wuster et al. (10) has shown that the presence 
of an adsorbent increases the dissolution by increasing the 
saturation concentration for the drug. 
Adsorption studies of drugs by talc have shown that 
talc has a much lower adsorption affinity and capacity 
compared to kaolin (11) and activated charcoal (12 , 13). 
Using activated attapulgite (14) , which is a similar mineral 
to talc , it was shown that the rate of drug absorption was 
less rapid compared to an aqueous solution. However, the 
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drug bioavailibility in presence of attapulgite was complete 
as with aqueous solution . Monkhouse etcai . (15 , 16) reported 
that dissolution of relatively insoluble drugs such as 
hydrochlorothiazide can be enhanced by miniscular drug 
delivery system , which involves rapid desorption of drug 
from the large surface area of adsorbent of silica type 
compounds. 
For plastically deforming materials the tensile 
strength and the crushing strengths of tablets are reduced 
by materials used as lubricants. This is because the 
coating of the particle surface by lubricant reduces the 
extent of bonding between particles during compression 
(5,7 , 8). Magnesium stearate was reported to markedly 
decrease the axial tensile strength relative to radial 
tensile strength for microcrystalline cellulose tablets even 
at 0.25% concentration. While the effects with talc up to 6 
to 8% on the axial to radial ratio of tensile strength was a 
moderate decrease for microcrystalline cellulose tablets 
(5). Jarosz and Parrott (5) concluded that for 
microcrystalline cellulose tablets the capping potential was 
greater with magnesium stearate compared to talc. It is 
note worthy that in this study that the tablets of 
hydrochlorothiazide and theophylline containing 
microcrystalline cellulose with 21% talc had greater 
crushing strength compared to their baseline tablets 
containing 1 or 2% magnesium stearate respectively. In 
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addition tablets of phenylpropanolamine containing 
microcrystalline cellulose with 26% talc had similar 
hardness compared to their baseline tablets containing 2% 
magnesium stearate. Also for anhydrous lactose tablets 
increase in magnesium stearate concentrations progressively 
decreased the ratio of axial to radial tensile strength. 
However , with talc a slight increase in ratio of axial to 
radial tensile strength was observed with anhydrous lactose 
tablets (5) . Therefore the capping potential for anhydrous 
lactose tablets was greater with magnesium stearate compared 
to talc . In this study niacin tablets containing lactose 
and 10% talc had greater tablet crushing strength compared 
to tablets containing 2% magnesium stearate. In general, 
the friability of all talc containing tablets was less or 
similar to their respective baseline formulations . Gadalla 
et al. (6) recently reported that 3% of talc was most 
suitable lubricant for formulation of double compressed 
aspirin tablets while magnesium stearate was found to be the 
worst suitable lubricant. 
Conclusions 
Talc can successfully be used as a major component 
of direct compression tablet formulation. The talc 
containing tablets prepared during this study had good 
weight uniformity, content uniformity and potency of the 
drugs. Tablets with very low friability, high crushing 
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strength, and rapid dissolution rates were obtained using 
talc in large percentages as a major component of tablet 
matrix with commonly used excipients such as 
microcrystalline cellulose and lactose. It is believed that 
the results presented in this paper strongly support the 
contention that talc may well have an important role to play 
as a major component in direct compression tablet matrices. 
The economic advantages of talc / microcrystalline cellulose 
matrices together with significant improvement of some 
tablet properties indicates that formulators may well find 
it advantageous to consider the use of these hybrid systems . 
... 
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Optimization of Tablet Formulations Containing Talc. 
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Abstract-An optimum direct compression tablet 
formulation of a conventional theophylline tablet was 
achieved using the technique of response surf ace methodologx 
and successive quadratic programming (SQP). The response 
surf aces were obtained from a second order uniform precision 
hexagonal design. The tablet formulation was optimized for 
mean in vitro dissolution time using friability, hardness, 
ejection force and disintegration time as constraints within 
the experimental region by the SQP algorithm. The response 
surface model was validated by preparing and evaluating the 
predicted formulation. The characteristics of the tablet 
formulation were analyzed by principal component analysis. 
Sensitivity analysis of optimal solution was performed for 
each constraint, while all remaining constraints were held 
constant. The robustness of the response surface model was 
evaluated by simulation for error in the compression force 
values due to its inherent variation. 
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Properties of drug delivery systems are affected by the 
characteristics of the drug and other formulation 
ingredients , and the processing stresses. Optimization 
techniques can help to achieve the principal objectives of 
any dosage form. Moreover, the optimal solution can be 
further used for trouble shooting of problems dur.ing 
manufacture (1). Computer optimization technique has been 
applied to tablets (1 - 4) and solid dispersions (5 , 6). 
Bohidar et al (4) optimized multiple potency tablets by 
computer optimization and with the additional use of a 
sequential prediction analysis technique. Optimization by _ 
use of the first order unconstrained optimization method has 
been reported for manufacture of capsules (7) and for 
enteric coating of tablets (8). Mathematical optimization 
techniques dealing with constrained non- linear programming 
problems, reported so far include classical Lagrangian 
method (9) used for tablet formulation, and more recently 
successive unconstrained minimization technique (SUMT) for 
solid dispersion (10). Mathematical optimization techniques 
can do all that the computer optimization technique do and 
have the additional advantage of providing a singular 
solution (10). More importantly, any successful 
optimization process should efficiently move toward the goal 
of the objective function and show robustness by its ability 
to achieve the optimal solution for a wide variety of 
problems (11). The purpose of constrained optimization is 
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to obtain values of independent variables that will produce 
the desired optimum response for the chosen objective 
function subject to various constraints (11). With 
constrained optimization problems, the optimal values for 
independent variables must simultaneously satisfy the 
constraints (11) . The objective of the present study was to 
evaluate an efficient and a robust optimization technique 
for obtaining solution to a non-linear programming problem. 
The technique consists of an equiradial hexagonal uniform 
precision design and successive quadratic programming. The 
aim was to increase the drug dissolution rate from the 
tablet without adversely changing other properties of the 
tablet. It is believed that this work represents the first 
publication dealing with these specific optimization methods 
for pharmaceutical purposes. 
THEORY 
Response surface methodology are sets of efficient 
experimental designs for use in the optimization process 
(12-14). Response Surface Methodology (RSM) attempts to 
model unknown functional relationships between the response 
variable and the independent variables by designed 
experiment. Suitable approximation to the true functional 
relationship can usually be achieved by a low order 
polynomial fitted in the relatively small region of interest 
as defined by the experimental range of the independent 
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variables. A response surface obtained from an experimental 
design can be of the first order and t~Pef ore follow the 
properties of proportionality and additivity. The response 
surface designs used in the literature include the first 
order designs such as simplex (7) and fractional factorial 
(8). If significant curvature is present in the true 
surface then a second order polynomial is fitted. The 
A 
complete second order response surface (Y) can be written as 
follows for n variables: 
h ~ k. (1) 
Where Xh and Xk are independent variables , b0 is the Y 
intercept , bh causes surface to shift along Xh and Xk axis, 
bhk(h < k) controls the surface rates of curvature , bhk(h = 
k) controls the surface rotation. 
Second Order Response surf ace Designs and their 
Properties- A second order response surf ace design requires 
that each of the quantitative factors, must take on at least 
three levels (14) . In addition the number of experimental 
runs must be greater than or equal to the number of 
coefficients in the second order model, for a given set of 
independent variables (12-14). At the same time it is 
desirable to use a design that allows a maximal return for 
minimum number of experiments. The ratio of the number of 
the experimental runs , to the maximum number of coefficients 
in the second order response surf ace model is called 
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redundancy (13) . The second order response surface designs 
in the literature have been based on factorial and 
fractional factorial central composite design ( 2-10). 
Experimental designs are further classified into orthogonal , 
rotatable and uniform precision types according to the 
variance properties of the predicted response (12 - 14) . An 
orthogonal non-rotatable design gives estimators of 
regression coefficients that are uncorrelated, that is the 
covariances between the pure second order coefficients are 
also zero . However , the variance of predicted response is a 
function of both distance and direction from center of an 
orthogonal non-rotatable design (12-14) . Variance of 
predicted response for a rotatable design is less than that 
of orthogonal design , unless the predicted response is being 
considered at the design center, and is only a function of 
distance from the center of the design , and not of the 
direction (12 - 14) . . Hence , rotatable designs are valuable in 
canonical analysis of response surfaces where rotation of 
design around its center would not change the variance of 
the predicted response. Therefore it is always worthwhile 
to use rotatable experimental design. Rotatable design 
property is obtained by choice of peripheral points position 
and does not depend on the number of center points. The 
equiradial designs consist of points equally spaced at a 
unit distance from the origin of a circle and are rotatable . 
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Conditions to be met for any experimental design to be ( 
rotatable are specified in (Eqs . 2- 5 ) (12-14) . 
n 
[i=l xhi xki 0 (h , k 1 , 2 , ..... l ; h ¢ k) ( 2) 
n 
[i=l xgi xhi xki 0 ( 3) 
n 
xf i xgi xhi xki 0 {( f , g) (h,k ) } ( 4) [i=l ¢ 
n 
[i=l 
4 
xhi 
n 3[i=l 
2 
xhi 
2 
xki (h # k) (5) 
To obtain a design which is both rotatable and orthogonal 
the number of center points required becomes large . For 
example , a 3*3 factorial is a non- rotatable , orthogonal 
experimental design and it would require seven additional 
center points with modified axial spacing of ±1.414 to have 
properties of rotatability and orthogonality. Hence, the 
use of uniform precision design in which the variance of 
predicted response is the same at design center as at any 
other region within a unit distance from design center . 
Repetition of an experimental trial under same controllable 
conditions allows determination of the estimate of mean sum 
of square pure error for the lack of fit test and a better 
estimate of the response at the design center . 
Additionally , replication of center points can allow 
experiments to be run in orthogonal blocks and permit 
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the attainment of uniform precision or orthogonal-rotatable 
design properties (12- 14) . The order of experiment should 
be randomized . Randomization assists in minimizing effect 
of any uncontrollable factors that exert a consistent bias 
(13). 
Optimization by Successive Quadratic Programming-Of all 
the methods compared for solving general nonlinear 
constrained optimization problem (Eqs. 6 - 9) , 
minimize F (x), 
subject to 
~(x) 0 , for k 
n JC E IR 
1 .. .. . , me 
1 . .... ,m 
(6) 
(7) 
(8) 
(9) 
the successive quadratic programming (S~P) algorithm was 
rated as the best with regard to efficiency (11) . The range 
of x are defined by its lower x1 and upper xu bound limits. 
In order to keep under consideration the curvature of the 
objective equation F(x) , the equality ~(x) and the 
inequality gj(x) constraints , a Lagrangian L(x,u,v) is 
formulated (Eq. 10) . The vk and uj are the Lagrange 
98 
( 
multipliers for equality and inequality constraints 
respectively. 
L(:x , u , v) (10) 
Lagrange multiplier is weight given to satisfy the 
constraints. 
Determination of Search Direction (d)-The SQP algorithm 
assumes all the functions of the model to be continously 
differentiable. The S~P method is based on the iterative 
formulations and solutions of quadratic programming 
subproblems. The subproblem are obtained using a quadratic 
approximation of the Lagrangian q(d;:x) (Eq. 11) and by 
linearizing the constraints (Eqs. 12-13). 
Subject to 
(11) 
~(d;:x) - ~(:x(t)) + V ~(x(t))Td 0 k l,..,K (12) 
j 1, . ., J (13) 
where :x:Tand dT represent the transpose of :x and d 
respectively. The effectiveness of a numerical iterative 
technique often depends on a good initial estimate of the 
vector for the independent variables involved (11,15). The 
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initial iteration requires a user supplied vector of 
independent variables as the starting point x . For the 
~ 0 
initial iteration the program assigns Lagrange multipliers a 
value of zero and the variable metric, that is the 
Lagrangian hessian matrix H(t) is set to identity matrix I. 
Therefore the initial search direction d
0 
is the steepest 
descent direction for the objective function . For the 
subsequent tth iteration, the continuosly updated xt vector 
is used to determine the gradient vector v F(x(t)) and the 
Lagrangian hessian matrix. The search direction dt is 
calculated such that it satisfies the resultant quadratic 
subproblem. Then the Lagr.ange multipliers for active 
equality and inequality constraints are calculated by 
equating them to the derivative of the quadratic 
approximation for the Lagrangian (Eq. 14). 
v q(d;x) v v h(d;x) + u v g(d;x) (14) 
For inactive constraints the Lagrange multipliers are equal 
to zero. 
Selection of Step Size Along Search Direction-To move a 
step closer toward optimum from poor initial values of the 
x 0 vector, we also need a value of step length«. 
Therefore, in order to force convergence toward optimum, we 
formulate a penalty function P(x,u,v), which would minimize 
the objective function and also satisfy the constraints . By 
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definition this penalty function is a non-differentiable 
function (Eq. 15). 
P(:x , u , v) F(:x) + [~=l ~ l ~(:x) I - [~=lo min(O,gj(:x)) (15) 
For the initial iteration, the penalty parameters are the 
absolute values of the lagrange multipliers. 
0 = 
For the tth iteration, the penalty parameters Cu(~)· o~t)) 
are selected according to the conditions (Eqs. 16-17) that 
ensure that convergence can be obtained. 
(t) 
u. = 
J 
max { I u ~ t) I • l / 2 ( u ~ t- l) + I u ~ t) I ) } 
J J J 
(17) 
A line search using quadratic interpolation is done to 
obtain the step length«, where O ~ « ~ 1. The step length 
« is obtained such that penalty function value at the 
current point :xt+l as obtained by (Eq. 18) 
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( 
is less than the penalty function value at previous point 
xt . This ensures that over n iterations the point xn will 
be such that the active constraint are satisfied so that the 
penalty terms become zero and thereby achieving the 
minimization of the orignal function . 
Check for Convergence Criteria-At this point the optimal 
solution is printed if the convergence criteria (11) of the 
SQP algorithm are satisfied. Otherwise the Lagrangian 
hessian matrix H(t) is updated. 
Broydon-Fletcher-Goldfarb-Shano (BFGS) Method for 
Updating the Lagrangian Hessian Matrix-The update of the 
Lagrangian hessian matrix H(t+l) using BFGS algorithm is 
-1 
such that it approaches H of the orignal function as with 
the Newton method. Thus the whole process starts with the 
steepest descent method and in the limit becomes the Newton 
method. The update of the Lagrangian hessian matrix 
(t+l) H depends on the closeness to the optimum solution, as 
indicated by the: 
(a) difference between current and the previous first 
derivatives of Lagrangian (Eq. 19) 
y V L( (t+l) (t+l) (t+l)) _ V L( (t) (t+l) (t+l)) (l 9 ) X X , U ,V X X ,U , V 
(b) difference between current and the previous search 
positions (Eq. 20) 
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z 
(t+l) (t) 
x - x (20) 
and (c) the previous Lagrangian hessian matrix H(t)_ The 
value of zTy (where zT represents the transpose of z) is 
used for obtaining the value of e according to the following 
conditions (Eq. 21-22), 
e 1 (21) 
otherwise 
e = (0.8 ZT H(t)z) / (zTH(t)z - zTy). (22) 
Next the value of y is modified into w according to (Eq. 23) 
w (23) 
The constraints 0.2 and 0.8 are arbitary and choosen from 
numerical experience (11,15). We then substitute these 
parameters into the BFGS updating formula (Eq. 24) to obtain 
the updated Lagrangian hessian matrix H(t+l). 
Updating the Lagrangian hessian matrix helps to improve the 
search direc.tion, since it converges to the hessian inverse 
as the optimum solution is approached. BFGS is the most 
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( successful quasi Newton method for keeping the Lagrangian 
hessian matrix positive definite for the minimization 
problem , provided the initial update matrix is also positive 
definite ( 11) . Hence , S~P combines the advantages of 
variable metric methods for constrained optimization 
calculations with the fast convergence of Newton ' s method 
( 11 , 15 ) . 
BXPBRIKBNTAL SECTION 
Materials-The direct compression formulations had the 
following percentage (w / w) composition: 
Theophylline 25 . 0% (Sigma Chemical, St. Louis , Missouri) , 
Beaverwhite 300 talc 15 . 0% (Cyprus Industrial Minerals 
Company, Mobile, Alabama) , corn starch 3 to 4% (Sigma 
Chemical , St. Louis, Missouri) and direct tableting lactose 
56 to 58% (Scheffield Products , Norwich , New York). 
Choices of Second Order Designs-The two factors 
equiradial designs requires fewer experimental runs than the 
central composite design, and gives improved design 
properties , see Table 1. The two independent variables 
studied consisted of a process variable (the compression 
force) and a formulation variable (the percent of 
disintegrant) , all other processing and formulation 
variables were kept constant . 
The effect of these two independent variable were studied 
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Table 1-Properties of Second Order Design 
Requiring Same Number of Experimental Runs 
for Two Independent Variables. 
Experimental Design 
3 * 3 Central Equiradial 
Properties Factorial Composite Hexagon 
Runs 9 9 9 
Redundancy 1. 5 1. 5 1. 5 
Orthogonal Yes No No 
Rotatable No Yes Yes 
Uniform 
Precision No No Yes 
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using the uniform precision equiradial hexagonal 
experimental design as shown in Table 2. 
Formulations and Preparation-The controlled conditions 
for material storage, processing and manufacturing were 
maintained at 24 ± 2°c and at relative humidity of 26 ± 3 %. 
All powders were sieved through sieve size of mesh size 20. 
The components of the various tablet formulations were mixed 
for 1.5 minutes in a WAB type T2C turbula mixer. The tablet 
formulations were compressed in a random order on the 
instrumented tablet press. An instrumented Stokes B-2 
rotary tablet press was used as described previously (16). 
The tooling consisted of a single standard concave set of 
punches of size 3 / 8 inch and its die. The compression and 
the ejection forces data were collected for 30 tablets, at a 
rate of 10 tablets per run. No tablet capping or laminating 
problems occurred during tablet manufacture. All the 
tablets were manufactured on the same day. The tablets were 
stored under the conditions defined above, in plastic 
bottles with well closed lids wrapped in parafilm. 
Determination of In Vitro Properties-Ten tablets were 
evaluated for crushing strength (Erweka Hardness Tester; 
Chemical and Pharmaceutical Industry, New York, New York). 
Six tablets were evaluated for friability, during which no 
tablet capping or lamination occurred (Erweka Friabilator; 
Chemical and Pharmaceutical Industry, New York, New York), 
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( Table 2-Experimental Design for Two factors 
Random Factor levels 
Experimental Order Coded Form Physical Units 
Unit Number Xl X2 Xl (KN) X2 (~w/w) 
1 2 1.0 0.000 15.11(0.30) 3 
2 5 0.5 0.866 13.38(0.31) 4 
3 6 -0.5 0.866 9.99(0.22) 4 
4 8 -1.0 0.000 8.45(0.18) 3 
5 1 -0.5 -0.866 9.97(0.23) 2 
( 6 9 0.5 -0.866 13.58(0.35) 2 
7 3 o.o o.o 11. 95 ( 0 . 19) 3 
8 4 o.o 0.0 11. 84(0. 27) 3 
9 7 0.0 0.0 11.77(0.29) 3 
Value in parenthesis are standard deviations 
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Six tablets were evaluated for disintegration time using 
discs (USP Disintegration Time Tester, Vanderkamp; Van-Kel 
Industries, Chatham, New Jersey). The apparatus (Paddle 
method, USP; Vanderkamp; Van-kel Industries, Chatham , New 
Jersey), dissolution medium and procedure suggested in the 
in the USP were applied to three tablets per formulation. 
Dissolution samples of 10 ml were withdrawn at 5, 10, 15, 
20, 30, 45 minutes intervals. The dissolution medium volume 
was kept constant by adding the same volume of fresh 
dissolution medium kept at the temperature of 37°c. 
Additionally, to ensure total release of drug, the agitation 
speed was increased to 150 R.P.M. for additional 45 minutes 
after all timed samples had been obtained, this sampling 
time is referred to as T . The samples were diluted and the 
~ 
concentration were measured on a Diode Array 
Spectrophotometer (Hewlett Packard; Loveland, Colarado) at 
the wavelengths of 272 nm as specified in the USP. The 
predicted formulation tablets were also analyzed similarly. 
Analysis of Data-The dependent variables consisted of 
the response variables such as ejection force and the 
resultant drug delivery system characteristics such as 
tablet mean in vitro dissolution time (MDT in vitro), 
crushing strength, disintegration time and friability. All 
the statistical and regression analysis procedure on the 
dependent variables were performed using statistical 
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analysis system (SAS) procedures. The dissolution data was 
fitted to Gompretz model (Eq. 23) (17),cu~ing non-linear 
regression analysis technique (Nonlin, SAS). 
(23) 
Where w is the percent drug dissolved at time t, ~ is the 
final value of percent drug dissolved, ~ and k are the roots 
of the Gompretz equation. The MDT in vitro was calculated 
using moment analysis; as the ratio of the area under 
dissolution rate-time curve and area under dissolution rate 
curve (18). The area under these curves were calculated by 
a computer using the trapezoidal rule. The response surface 
equations for MDT in vitro and friability were calculated 
using least squares multiple regression analysis (Reg, 
SAS). The least squares criteria for estimating 
coefficients for the equation emphasizes observed data 
points that have large residuals, which tend to have large 
sample variances, in order to minimize the sum of squares 
error . The reciprocal of the variance were used in the 
weighted least squares multiple regression analysis (17) 
(Reg, SAS) for ejection force, hardness, and disintegration 
time data. The weighted least squares emphasizes those 
points that have least sample variances and therefore 
overcomes the limitations of least squares method. The 
optimization was carried using International Mathematical 
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and statistical libraries (IMSL) fortran subroutines. The 
characteristics of the tablet formulation was evaluated 
using principal component analysis (19) (Prin Comp, SAS). 
The simulation study was carried using a program written in 
SAS basic (20). 
RESULTS AND DISCUSSION 
Response Variables-The dissolution profiles for the 
tablets are shown Figures 1-3, and the parameters for the 
Gompretz equation are shown in Table 3. The tablet 
properties obtained from the experimental design are shown 
in Table 4. 
Regression Models-The response surface equations (Table 
5) for the MDT in vitro, the hardness, and disintegration 
time were linear, while those for ejection force and 
friability were non-linear and therefore the problem was 
solved by non-linear programming. The P values indicated 
that the equations are highly statistically significant. 
The R square and the R square with adjusted degrees of 
freedom values, and the lack of fit test at 5% significance 
level for the regression equations indicate that the 
goodness of fit were satisfactory. The relationship between 
the response variable and the controllable variables were 
explored by means of three dimensional plots and the contour 
plots which show contour lines of equal response and the 
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40 45 
( Table 3-The Parameters Obtained by Non-linear Regression 
Analysis. 
Formulation Gompretz Equation Parameters MDT in vitro 
Number a: {3 k (hours) 
1 103.996 6.421 0 . 1054 0.3573 
2 100.657 8 . 748 0.1806 0.2536 
3 101.216 7.853 0.2700 0. 1646 
4 95 . 206 8.705 0.3089 0. 1496 
5 101.336 9.444 0.257 0.1847 
6 107.805 4.819 0.0707 0.4038 
7 98.001 6.771 0.1555 0 . 2652 
8 97.007 7.369 0. 1607 0 . 2657 
9 101.767 8.078 0.1479 0.2963 
Optimized 95.242 5.249 0.1125 0.3154 
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Table 4. Experimental Values of Re~ponse Variables 
Experimental Ejection Weight Hardness Percent Disintegration MDT 
Unit Force ( ll) X RSD ( Y.g) Friability Time (minutes) (hr) 
...... 
613.2(10.8) 0.3531 13.48(1.58) 8.63(0.28) ...... 1 0.294 0.3573 
(JI 2 581.2(26.7) 0.4224 11.82(1.32) o. 344 6.0l(O. 30) 0.2536 
3 450.5(18.6) 0.4066 8.99(0.90) 0.419 3.44(0.09) 0.1646 
4 397.1(21.8) 0.3674 7.65(0.66) 0.496 3.37(0.15) 0.1496 
5 462.8(21.8) 0.3633 8.97(0.69) 0.422 5.44(0.21) 0.1847 
6 603.9(14.3) 0.4045 13.27(1.70) 0.291 9.U(0.48) 0.4038 
1 542.4(27.7) 0.3042 10.67(1.37) 0.353 6.07(0.35) 0.2652 
8 533.5(28.9) 0.4072 10.71(1.01) 0.296 5.68(0.31) 0.2657 
9 533.0(30.2) 0.3616 10.25(1.34) 0.328 6.53(0.21) 0.2963 
Value in parenthesis are standard deviations 
MDT is mean in vitro dissolution time 
..-
...-, 
Table 5. Multiple Regression Analysis Equation for Each Response Variable 
Parameters/ Ejection Hardness Percent Disintegration MDT 
Summary Force (N) (Kg) Friability Time (minutes) (hr) 
BO 537. 838 10.596 0.3395 6.0105 0.2601 
....... Bl(Y.l) 118. 262 3.039 -0.1017 2. 7426 0.1206 
....... 
(J) B2(X2) - - - -1.3497 -0. 0492 
Bll ( Xl *Xl) -38.780 - 0.0624 
B22(X2*X2) 
Bl2(Xl*X2) 
R Square 0.9774 0.9739 0.8888 0.9812 0.8693 
ADJ R-SQ . 0. 9699 0.9702 0.8518 0.9749 0.8257 
F Value 130. 038 261. 544 23.989 156.586 19.945 
Prob>F 0.0001 0.0001 0.0014 0.0001 0.0022 
MDT is mean in___yi_tr_o dissolution time. 
( 
direction in which the gradient has steeper value are shown 
in Figure 4-11 . In general , the MDT in vitro is widely used 
as a dissolution index for comparison of dissolution 
behaviour . 
Optimization-The MDT in vitro as the objective function 
was minimized so as to obtain rapid dissolution rate . The 
constraints used were that tablet hardness should be ~ 12 
kg , the disintegration time should be ~ 7.5 minutes , the 
friability be ~ 0.3 percent , and the ejection force should 
be ~ 605 Newtons . Additional constraints were the 
experimental limits placed on values of x1 and x2 . The 
optimum solution values for the independent variables 
satisfied all the constraints simultaneously and provided an 
optimal value for the objective function. 
Optimal Solution-The formulation according to the 
optimal solution was prepared as shown in Table 6 . The 
comparison of predicted and experimental values for optimum 
formulation showed very good agreement and are shown in 
Table 7. A model is valid if despite its inexactness in 
representing the system, it can give a reasonable prediction 
of a systems performance. 
Sensitivity Analysis-Sensitivity analysis in the 
vicinity of the optimal solution was performed in order to 
monitor change in response to minor modifications in the 
values of the constraints . The objective function of the 
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MDT in vitro was minimized by the SQP, after modifying the 
intercept of the constraint being evaluated . Sensitivity 
analysis for each constraint was performed while all other 
constraints were maintained unchanged . The resulting x1 and 
x2 values obtained were used to calculate the new MDT in 
vitro . For hardness the values altered ranged from 12.54 to 
12 . 85 kg and values below 12.54 kg did not alter x1 and x2 . 
For disintegration the values below 6.593 minutes produced 
infeasible solution , values above 6.593 minutes produced no 
change in x1 and x2 solution. For ejection force values 
below 597 . 55 Newtons produced infeasible solution, while 
values above 597.55 Newtons produced no change in x1 and x2 . 
For friability the values altered ranged from 0 . 3060 to 
0.2984. Friability values below 0.2984 produced infeasible 
solution , while values above 0.3060 produced no further 
change in x1 and x2 . The sensitivity of the optimal 
solution to the changes in the constraints are shown in 
Figure 12 and 13 . A one percent change in the hardness and 
the friability values resulted in 1.53% and 4 . 31% change in 
MDT in vitro time respectively. The sensitivity 
coefficients for the optimal solution values for hardness 
and friability were derived using rate method. The 
sensitivity coefficients were found to be 1 . 02 and -1.43 
with respect to hardness and friability respectively. From 
these results it is clear that the MDT in vitro is more 
126 
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Table 6-0ptimum Formulation at Compression 
Force of 13.91(0.29) KN 
Ingredients 
Theophylline 
Beaverwhite 300 
Corn Starch 
Lactose 
Percent w/w 
25.0 
15.0 
4.0 
56.0 
Value in parenthesis is standard deviation. 
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Table 7-Comparison of Predicted and Ezperirnental Values of Response 
Variables for Optimum Formulation. 
Optimum Ejection Weight Hardness Percent Disintegration MDT 
Formulation Force (II) % RSD ( Y-g) friability Time (minutes) (hr) 
Constraints ~605 x 112 
Predi~ted 597.55 0.3531 12.54 
Experimental 584.15(17.93) 0.2994 12.27(1.44) 
Value in parenthesis are standard deviations. 
HOT is mean 1n ~'Li1I{l. dissolution ti~e. 
~ 0.3 .n.5 
0.2'H9 6.593 o.n45 
0.2323 t.57(0.29) 0.3154 
--.. 
( sensitive to changes in friability compared to hardness. The 
negative sign of the sensitivity coefficient indicated that 
increase in friability results in decreased MDT in vitro, 
while increase in tablet hardness increases the MDT 
in vitro as expected. 
Principal Component Analysis-Principal component 
analysis was performed using standardized scores to 
determine the principal factors that characterize the tablet 
formulation. The first principal component explained 92.8% 
of the total standardized variance as shown in Table 8. The 
remaining principal components did not greatly help to 
explain the standardized variance and therefore were not 
considered any further. All the tablet properties show 
approximately equal correlation coefficient with the first 
principal component as shown in Table 9. Therefore the 
first principal component represents the overall tablet 
physical properties. In other words measurements of all 
these tablet properties are of approximately equal 
importance in defining the characteristic of the formulated 
tablet. The information from all these measured variables 
would explain 92.5% of the characteristics of the formulated 
tablet. 
Simulation of Variations in Compression Forces-
Regression analysis by least squares method used for 
estimating response surface model coefficients rest on two 
129 
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Table 8-Variance Analysis of the First Four 
Principal Componets. 
Principal 
Components 
1 
2 
3 
4 
Eigenvalues 
3.71034 
0.18140 
0 . 08344 
0.02481 
Total Variance 3.99999 
Propor·tion 
0 . 927587 
0.045350 
0 . 020861 
0 . 006202 
Total % Relative Information 100.0 
132 
Cumttlative 
0.92759 
0 . 97294 
0 . 99380 
1 . 00000 
( 
Table 9-Coefficicuts of Eigenvectors Associated 
with First Two Principal Components. 
Tablet 
Properties 
Hardness 
Friability 
Disintegration Time 
MDT in vitro 
Principal Component 
l 2 
0.502862 
-0.485033 
0.502054 
0.509720 
0.035710 
0 . 819638 
0.524148 
0.228447 
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( main assumptions that a cause and effect relationship exist between independent variables Cx1 , . . Xk)~and dependent 
variable (Y) measured with experimental error, and that the 
independent variable values can be measured without error . 
Since compression force values have standard deviations we 
randomly perturbed x1 values to see its effects on the 
values of response surface equations coefficients in a 
simulation study (20). Hence, the coefficients of the 
response surf aces were obtained using simulation for changes 
according to the experimentally observed standard deviation 
in compression force values . If the optimum value is 
unaffected by changes in neighbourhood of a parameter, then 
that parameter has low sensitivity, and therefore having a 
precise value for that parameter will not be crucial to 
finding the true optimum (20). The equations obtained from 
simulation study have the coefficients in close agreement 
with those actually obtained from experiment. The 
coefficient values obtained from the simulation experiment 
are shown in Table 10. Furthermore, these equations were 
used for obtaining the optimal solution using same 
constraints as with actual experiment. The optimal solution 
obtained was very similar, suggesting the use of 4% corn 
starch and 14.21 KN of compression force. This suggests 
that the response surface model generated by uniform 
precision hexagonal design is a robust one. 
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Table 10-Sirnulation Generated Coefficients of the Response Surfaces. 
Parameters Ejection Hardness Percent Disintegration MDT 
summary Force (N) (Kg) Friability Time (minutes) (hr) 
BO 533.556(5.173) 10.604(0.090) 0.3388(0.004) 6.0186(0.087) 0 . 2605(0.003) 
....... Bl(Xl) 115.335(4.621) 3.006(0.127) -0.0999(0.005) 2.7268(0.124) 0.1202(0.005) ~ 
Ol B2(X2) - - - J -1.3578(0.159) -0.0494(0.005) 
Bll(Xl*Xl) -31.423(8.220) - 0.0635(0.011) 
B22(X2*X2) 
Bl2(Xl*X2) 
R Square 0.9798 0.9648 0.8859 0.9791 0.8719 
ADJ R-SQ. 0.9731 0.9598 0.8479 0.9721 0.8292 
F Value 179.772 218.890 24.209 166.417 21.203 
Prob>F 0.0001 0.0001 0. 0016 0.0001 0.0023 
--- ---- ----- -- - - ---------- ·---·------ ·· - -----
Value in parenthesis are standard deviations. 
MDT is mean in _ _ytir_o dissolution time. 
The computer search method has the disadvantage of 
frequently giving a plural solution for suitable 
formulations (10). With the classical Lagrangian method, it 
can become difficult to solve the resultant set of 
simultaneous equations especially for nonlinear problems. 
Therefore a numerical method such as successive 
unconstrained optimization technique (SUMT) or SQP must be 
used to locate the optimal solution point. The SQP method 
is more efficient and robust compared to previously 
published optimization techniques including SUMT (11). The 
SQP method can also be used to obtain solution to the 
problems solved by the previously published optimization 
methods. 
CONCLUSIONS 
A mathematical optimization technique novel to the 
pharmaceutical sciences has been applied to obtain an 
optimum formulation of conventional theophylline tablets. 
The uniform precision hexagonal experimental design provided 
a robust response surface model . The constrained nonlinear 
optimization problem was efficiently optimized by use of the 
SQP algorithm. Properties of the optimal formulation agreed 
well with the predicted profile. Sensitivity analysis 
performed showed that the optimal solution was sensitive to 
changes in hardness and friability. 
136 
( REFERENCES 
1. Schwartz, J. B.; Flamholz, J. R.; Press, R. H. J. 
Pharm. Sci. 1973, 62, 1165-1170. 
2. Schwartz, J. B.; Flamholz, J. R.; Press, R. H. J. 
Pharm. Sci. 1973, 62, 1518-1519. 
3. Down. J. R. B.; Miller. R.A.; Chopra. S. K.; Millar. J. 
F. Drug Dev. Indus. Pharm. 1980, 6, 311-330. 
4. Bohidar, N. R.; Bavitz, J. F.; Shiromani, P. K. Drug 
Dev. Indus. Pharm. 1986, 12, 1503-1510. 
5. Takayama. K.; Nambu. N.; Nagai. T. Chem. Pharm. Bull. 
1983, 31, 4496-4450. 
6. Takai. T.; Takayama. K.; Nambu. N.; Nagai. T. Chem. 
Pharm. Bull. 1984, 32, 1942-1947. 
7. Shek, E.; Ghani, M.; Jones, R. E. J. Pharm. Sci. 1980, 
69, 1135-1142. 
8. Dincer. S.; Ozdurmus. S. J. Pharm. Sci. 1977, 67, 
1070-1073. 
9. Fonner.Jr., D. E.; Buck. J. R.; Banker, G. S. J. Pharm. 
Sci. 1970, 59, 1587-1596. 
10. Takayama. K.; Imaizumi. H.; Nambu. N.; Nagai. T. Chem. 
Pharm. Bull. 1985, 33, 292-300. 
11. Reklatis. G. V.; Ravindran. A.; Ragsdell. K. M. 
Engineering Optimization: Methods and Applications; 
John Wiley and Sons, Inc. New York, New York, p.438-
458, 1983. 
12. Box. G. E. P.; Draper. N. R.; Smith. H. Empirical 
137 
Model Building and Response Surface; John Wiley and 
Sons, Inc. New York, New York, p.508-515, 1987 . 
13. Biles . W. E .; Swain . J. J. Optimization and Industrial 
Experimentation; John Wiley and Sons, Inc. New York, 
New York, p.135 - 147, 1980. 
14 . Myers. R. H. Response Surface Methodology. Allyn and 
Bacon, Boston Massachusetts , p.126-173, 1971. 
15. Powell. M. J . D. A Fast Algorithm for Nonlinearly 
Constrained Optimization Calculations in Numerical 
Analysis, Dundee 1977 (G.A Watson, Ed.), Lecture Notes 
in Mathematics No. 630 , Springer-Verlag, New York, 
1978. 
16 . Dawoodbhai. S.; Chueh. H. R.; Rhodes. C. T. Drug Dev. 
Indus. Pharm. 1987 , 13, 2441-2457. 
17. Draper . N. R.; Smith. H. Applied Regression Analysis; 
John Wiley and Sons, Inc. New York, New York, p.108-
111, 511-512, 1980. 
18. Tanigawara. Y.; Yamaoka. K.; Nakagawa . T.; Uno . T. 
Chem. Pharm. Bull. 1982, 30, 1088-1090. 
19 . Bohidar, N. R. ;Schwartz, J. B. ;Restaino, F. A. J. 
Pharm. Sci. 1975, 64, 966-969. 
20 . Chatterjee. S.; Hadi . A.S. Sensitivity Analysis in 
Linear Regression; John Wiley and Sons, Inc. New York, 
New York, p.261-262, 1988. 
138 
( Section III. 
( 
139 
( 
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Table 1 . O 
Dissolution Method in Matrix and Lubricant Study . 
Dissolution 
Drug Medium 
Niacin Water 
Hydrochlorothiazide O. lN Hcl 
Phenylpropanolamine Water 
Theophylline Water 
* 
Volume 
900ml 
900ml 
500ml 
900ml 
* Agitation 
Type RPM 
Paddle 
Basket 
Paddle 
Paddle 
75 
150 
50 
50 
Double distilled and deionized water, freshly 
de - aerated. 
145 
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0) 
Tah1e 2 
Ultra- Violet P...nalys is of Dissolution Sample 
i..n Matrix and Lubricant Study 
UV Wave- E:>.."tinction Coeffjcient 
Drug Jcn~th(nm) Literature Observed. 
*. Niacin 262 22.34 34.85 
Hydrochlorothjazide 272 64 . 50 61.64 
Phenylpropanolamine 204 - 42.28 
Theophylline 272 53.00 57 .03 
• Unj ts : m~V(ml C'Jn) 
** In methanol 
* Correlation 
Coefficient 
0.9998 
0.9998 
0.9998 
0.9998 
...... 
~ 
...;z 
The Tables 3 and 4 a.re Part of the Mmmcript II 
. Table 3 
Formulations and Tableting Iata of Lubricant Study for 
Hydrochlorothiazide (lo.mi) 
** Magnesium Matrix Compression 
Lubricant Stearate Avicel PH-102 Force (KN) 
Al.talc 300 (l.mi) 0.2% 88.8mi 5.60 (0.09) 
Al.talc 400 (l.mi) 0.2% 88.80li 4.97 (0 .08) 
Alababarna 300 ( 1 . mi) 0.2% 88 . 8CJ!{, 5.12 (0.00) 
Alab3.barna 400 ( 1 . mi) 0.2% 88.8mi 5.12 (0.00) 
Supra (l.mi) 0.2% 88.8mi I 5.19 co.ooY 
Magnesium stearate 2.mi 88.Qm, 6.10 (0.08) 
-
** Values in parenthesis are standard deviations. 
-, 
** Ejection 
Force (N) 
55.80 (2.22) 
52.63 (1.67) 
52 . 40 ( 1. 93) 
53.15 (0.67) 
50.75 (2.48) 
47.28 (1.38) 
....... 
~ 
CX> 
Table 4 
Formulations and Tableting re.ta of Lubricant Study for 
Aootaminophen (5.~) 
** Magnesium Hatrix Compression 
Lubricant Stearate Avicel PH- 102 Foroo (KN) 
Altalc 300 (l.~) 0.25% 93.75% 7.72 (0 .08) 
Altalc 400 (l.~) 0.25% 93.75% 7.85 (0.09) 
Alababama 300 ( 1. ~) 0.25% 93.75% 7.66 (0.10) 
Alababam.3. 400 (l.~) 0.25% 93.75% 8.25 (0.10) 
Supra (l.~) 0.25% 93.75% 7 .02 (0.07) 
Hagnesium stearate 2.~ 94.~ 8.73 (0.09) 
-
** Values in parenthesis al'e stam;:nd dC'1iati ons. 
** Ejection 
Foroo (N) 
70.4 (5.9) 
82.6 (6.5) 
80.6 (7.0) 
. 
9.1. 9 (7.4) 
69.l (6.3) 
72.8 (6.7) 
""' 
Tables 5 to 13 are Unpublished P.dditional D:ita for the Manuscript II study. 
Table 5 
Formulations airl_ Tableting D:ita of Lubricant Study for 
Hydrochlorothiazide (10.(Jl(,) 
. 
** ** Disintegrant Ea.tr ix Compression Ejection 
* Lubricant Primo~el Avicel PH-102 Force (KN) Force (N) 
...... 
~ Eeaverwhite 30) (l.IB>) i.m, 87.8ffii 5.30 (0.09) 65.89 (5.26) <O 
Il3averwhite 400 (l.(Jl(,) 1. (Jl(, 87.8~ 5.34 (0.08) 72.86 (7.61) 
. 
. 
BeavGrwhite 500 (l.(Jl(,) l.mi 87.8mi 5.27 (0.09) 74.47 (6.25) 
Supra ( 1. (Jl(,) l.IB> 87.8~ 5.50 (0.09) 66._4-8 (5.98) 
Ultraglide 325 (l.m,) 1. (Jl(, 87.8ffi> 5.46 (0.08) 70.90 (5.08) 
Alabama 500 (l.mi) l.Ol(i 87.8m. 5.31 (0.08) 69.39 (5.04) 
* Plus Magnesium stearate 0.2%. 
** Values in parenthesis are stan.:lard deviations. 
....... 
(Jl 
0 
Table 6 
Formulations arrl. Tableting Le.ta of Lubricant Study for Niacin, Phenylpropanolamine 
arrl. Theophylline 
* ** ** Lubricant Disintegrant Matrix Coffipression Ejection 
Drug Primogel Aviool PH- 102 Foroo (KN) Foroo (N) 
Niacin (10.()',{,) 13eaverwhite 300 (l.ffi,) 1. ()',{, 91.55% 5.61 (0.12) 71. 77 (2. 94) 
13eaverwhite 500 (l.()',{,) l.ffi, 91.55% 5.52 (0 .09) 72.68 (3.04) 
Phenyl propanol- Beaverwhi te 400 ( 1. ()',{,) - 78.8()',{, 6.28 (0 . 11) 344.62 (23 .66) 
a.rn:lne (20.()',{,) 13eaverwbite 500 (l.()',{,) - 78.8()',{, 6.14 (0.10) 337. 26 (17 . 31) 
Theophylline Beaverwhite 300 (l .()',{,) 1. ()',{, 57.8()',{, 5.32 (0 . 15) 155.37 (4 .43) 
( 40 . ()',{,) Beave1vhite 400 (1. m,) 1. ()',{, 57.8()',{, 5.29 (0.15) 149 . 52 (4.21) 
* Plus .Magnesium Stearate 0 .2%. 
** Values in parenthesis are standard deviations . 
~ 
-I-' 
(11 
I-' 
~. 
Table 7 
Baseline Formulations an:i Tableting re.ta for Lubricant Study Using Magnesium 
Stearate as Lubricant. 
** ** Matrix Magnesium Disintegrant Compression Ejection 
Drug Avicel PH-102 Stearate Primo gel Force (KN) Force (KN) 
Niacin 87.mi 2.mi i.mi 5 . 12 (0.07) 60.83 (7 . 12) 
(lo.mi) 
Hydrochlorothiazide 87.mi 2.mi i.mi 5.49 (0.08) 45.53 (3 .76) 
(lo.mi) 
Phenylpropaholam:ine 78.8% 2.mi - 6.02 (0.08) 70.74 (4 .24) 
(20.mi) 
Theophylline 58.mi i.mi i.mi 5 .00 (0.11) 00 .28 (4.95) 
( 40. CPk) 
** Values in parenthesis are stan:iard deviations. 
,,... 
....... 
(JI 
tv 
Table 8 
Prop:?rties of Hydrochlorothiazide Tablets Prepare:::l in Lubricant SLw.ly. 
Lubrieant 
Beaverwhite :#300 
Beaverwhite il100 
Beaverwhite 41500 
Supra 
Ultraglide :#325 
Al talc 4t 500 
Ha~nesium Stearate 
Tablet a 
Weight (mg) 
250.2(0.32) 
251. 2 ( 0 . 31) 
249.9(0.31) 
251. 9(0. 30) 
252.0(0.23) 
251.0(0.24) 
250.6(0.26) 
Hardnessb 
(Kg) 
4.2(0.2) 
3.8(0.1) 
4.2(0.2) 
4.2(0.2) 
4.4(0.2) 
4.4(0.2) 
0.9(0.2) 
Percentc Co111pacti-
llardcr bi.lity 
112.5 0.80 
lC0.0 0.70 
114.7 0.79 
110 .9 0.76 
116.8 0 .80 
116.3 0 .82 
-- 0.16 
~alues in parenthesis are relative stan::iard deviations. 
l\;aiues ill parenthesis are stardi::i.Jtl duviatj_ons. 
~sing hardness value of BeaveNhite t400 tablets as l~. 
~~ot using p:?rf oratei plastic discs. 
Percent 
Friability 
0.016 
0.012 
0.040 
0.012 
0.036 
0.044 
0.93 
Disintegrationd 
Ti.Ire (secs) 
14-16 
14-15 
14-16 
13-17 
16- 18 
15-17 
30--45 
,,... ..... 
..... 
OJ 
VI 
Table 9 
Dissolution Properties of Hydrochlorothiazide Tablets 
Lubricate::! with Talc arrl Magnesium Stearate Combination 
as Compare::! to Magnesium Stearate Only 
Percent Drug DissolvOO.a 
Lubricant Ti.Ire (Minutes) b 
40 T 30 
CD 
Beaverwhite 4300 00.6 (5.3) 92.3 (4 . 5) 99.4 (1.8) 
Beaverwhite HOO 99.6 (2.9) 102. l (2 .4) 104.9 (0.7) 
Beaverwhite 4500 91.2 (1.9) 94.4 (1.5) 97.2 (2.5) 
Magnesium Stearate 85.5 (6.2) 00.4 (4.9) 100.9 (1.5) 
(Baseline) 
8vaiues in parenthesis a.I~ starriard deviations. 
~otal possible release of drug from tablet, 
as at ti.Ire equal to in£iI1ity. 
---... 
....... 
C.Jl 
~ 
Table 10 
Pro:p3rties of Niacin, Theophyllille arrl. Phenylpropanolamine Tablets 
Prepared in the Lubricant Study 
Drug and 
Lubricant 
T~leta 
Wt. (mg) 
Hardnessb Percentc Compac- Percent Disilltegrationd 
(kg) Harder tibility Friability Ti.ire (sec) 
Niacin 
Beaverwhite #300 249.7(0.40) 5.6(0.3) 100.0 1.01 
Beaverwhite #500 250.0(0.32) 5.7(0.5) 100.9 1.03 
Hagnesium Stearate 250.0(0.26) 3.3(0.3) - 0.64 
Phenylpropanolamine 
Beaverwhite #400 250.8(0.44) 4.3(0.2) 102.9 0 .68 
Beaverwhite #500 250.1(0.21) 4 . 1(0.2) 100.0 0.67 
Hagnesium Stearate 252.0(0.23) 1.5(0.3) - 0.26 
Theophyllille 
Beaverwhite #300 251.5(0.59) 5.4(0.3) 100 .0 1.01 
Beaverwhite #400 251. 5(0. 54) 5 .4(0.2) 100 .9 1.02 
Hagnesium Stearate 250.1(0.40) 3.4(0.1) - 0.66 
Ciyalues in parenthesis are relative standard deviations. 
~alues ill parenthesis are standard. deviations. 
~sillg the lower hardness value of tablet for a d.J1..lg as l~. 
~ot usillg :p3rforatoo plastic discs. 
0.12 7-9 
0.11 8-10 
0.33 13-17 
0.09 16-19 
0.07 16-19 
0.56 8-10 
0.05 6- 8 
0.05 5..:..5 
0.12 8- 10 
-
...... 
Ol 
Ol 
,... 
Table 11 
Dissolution Properties of Tablets Containing Niacin. 
Study 
Lubricant 
Baseline 
Lubricant 
Beaverwhi te # 300 
Beaverwhite 41500 
Percent Drug Dissolvaia 
Tine (Mlimtes) 
5 
101.7(3.2) 
103 .4(1.8) 
10 
Magnesium Stearate 94.3(2.1) 
105 .8(0.6) 
105.4(0.6) 
sx:>.5(1.9) 
C\Taiues in parenthesis are standard deviations. 
Tb 
a> 
107 .4(1.0) 
107 .4(1.8) 
97.3(1.9) 
~otal possible release of drug from tablet, as at time equal to infinity. 
~ith Lactose instead Avioel PH- 102. 
,.,..-... 
' 
Table 12 
Dissolution Properties of Tablets Containing Theophylline 
Percent Drug Dissolve.'.l.a 
Study Lubricant Tine (Minutes) 
....... 
30 45 ~ 
(D 
OJ 
m 
Lubricant Beaverwhite 413CXJ 93.9(3.6) 93.6(2.5) 100 .0(1.2) 
Beaverwhite #400 ~ .. 9(3.0) 93. 7(1.6) 97 .7(0.8) 
Baseline Magnesium Stea.rate 93.2(1.2) 97.7(0.9) 98.6(0.5) 
ayalues in parenthesis are standard deviations. 
~otal possible release of drug from tablet, as at tine equal to infinity. 
Table 13 
Dissolution Properties of Tablets Containing Phenylpropanolamine 
Percent Drug Dissolverla 
Study Talc Tirre (Minutes) 
5 10 Tb 
CJ) 
...... 
(JI 
..;z 
Lubricant Beaver"White 4400 64.5(9.1) 80.8(8.2) 100.0(1.7) 
BeaveNhite 4500 76 .0(11 .6) 90.4(5.9) 100.0(1.1) 
Baseline Magnesium Stearate 85.1(10.5) 93.9(6.7) 100.0(4.0) . 
~alues in parenthesis are standard deviations. 
~otal possible release of drug from tablet, as at tirre equal to lllf:inity. 
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Appendix B: Patent 
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PHARMACEUTICAL TABLET MATRIX 
CONTAINING TALC AS AS A MAJOR COMPONENT 
BACKGROUND OF THE INVENTION 
The present invention relates to pharmaceutical 
5 compounds in tablet form. More particularly , the 
invention relates to pharmaceutical compounds tableted 
by a direct - compression process in which talc is present 
as a major component of the tablet matrix . 
In the production of tableted pharmaceutical 
10 compounds the active substances are normally combined 
with auxillary agents, termed ''matrix ingredients" 
herein, the quantity of which is often greater than that 
of the active substances . The matrix ingredients 
generally comprise diluent and binding substances, 
15 disintegrants and lubricants, including , for example , as 
a diluent, sugar or the like ; as a binder , cellulose, 
cellulose derivatives, such as the microcrystalline 
cellulose, Avicel PH-102, or lactose; as a 
disintegrator, modified starches, such as Primogel ; and 
20 as lubricants, talc or magnesium stearate. 
The formulation of pharmaceutical tablet 
compositions must be such as to enable the economic 
production of tablets having the desired properties of, 
inter .a..J..i.a, hardness, friability, appearance, 
25 disintegration and tablet weight control . In the past 
163 
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( the aforementioned properties have been derived largely 
~ 
from the proper selection of binder materials among 
which cellulose and cellulose derivative materials have 
been prominent. However, since such binder materials 
5 are relatively expensive, it is desirable for economic 
considerations, to reduce to a minimum the amount 
required for obtaining the foregoing desirable 
properties. 
It is to the achievement of these ends, therefore, 
10 that the present invention is directed. 
SUMMARY OF THE INVENTION 
Stated briefly, the present invention provides 
( novel matrix compositions for pharmaceutical compounds 
that are particularly adapted for tableting by direct 
15 compression processes, characterized by being high in 
talc content. It now has been discovered that binary 
mixtures of talc and binders, particularly 
microcrystalline cellulose or lactose, can be used to 
make excellent tablets for commonly used drugs and 
20 vitamins. Such compositions will contain up to 40 
weight percent talc. 
It is, accordingly, an object of the invention to 
reduce the cost of pharmaceutical compounds that are 
tableted by direct compression processes. 
164 
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It is further object of the invention to provide a 
novel matrix composition for tableted pharmaceutical 
compounds produced by a direct compression process 
wherein talc is employed, not only as a lubricant and 
5 glidant , but also as a bulk-contributing component 
and as a supplement to bonding agents. 
Other objects , aspects and advantages of the 
invention will become apparent from a considerations of 
the specification and claims that follow . 
10 DETAILED DESCRIPTION OF THE INVENTION 
Talc is a material designated "generally regarded 
as safe" by the U.S. Food and drug Administration. It 
has been widely used in the pharmaceutical industry as a 
glidant or lubricant in tablets, as a filler in hard 
15 gelatin capsules, as a tablet coating , and as a major 
component of many topically applied powders. Where used 
as a glidant or lubricant in a compressed tablet, talc 
is incorporated into the formulation at relatively low 
levels , normally very much less than ten percent. When 
20 used as a filler, diluent or bulking agent in hard 
gelatin capsule, somewhat higher concentrations, e.g., 
up to twenty percent, may be used. 
It has now been discovered that talc, which is a . 
relatively inexpensive material, can be combined in 
25 significantly large amounts with known , more expensive 
165 
matrix materials to produce by direct compression 
methods tablets having the desirable characteristics of 
reduced cost, improved hardness, improved friability, 
excellent tablet weight control, improved appearance and 
5 rapid disintegration . Moreover, because of the presence 
of talc , no seperate glidant or lubricant is required 
for production purposes so that the economics of the 
product are still further enhanced. 
Tablet formulations according to the invention 
10 comprise matrix materials in preponderant amount, i.e., 
at least 75 percent by weight. The matrix materials are 
mixtures of lubricant and binder in which the lubricant 
component is essentially talc in amounts ranging from 
10.0 to about 40.0 weight percent, preferably from about 
15 20.0 to about 25.0 percent. The binder component may be 
a conventional binder material, for example, 
microcrystalline cellulose, or lactose. 
In order that those skilled in the art can more 
fully understand the invention, the following examples 
20 are set forth. These examples are provided solely for 
purpose of illustration, and should not be taken as 
expressing limitations on the invention unless so 
confirmed by appended claims. All parts and percentages 
given hereinafter are by weight, unless otherwise 
25 stated. 
166 
The procedure followed in preparing the 
constituent ingredients for the respective examples was 
essentially uniform. The ingredients as listed in each 
example, were mixed in particulate form in a Turbula 
5 mixer and, thereafter, compressed in a Stokes B-2 rotary 
press into tablets, each weighing a nominal 400 mg. The 
compression and ejection forces generated in the press 
were measured by piezo-electric transducers located in 
the press eyebolt and in the ejection cam, 
10 respectively. The tablets were compressed at a fixed 
press setting for·each formulation with the press speed 
set at 25 revolutions per minute and the die fill 
adjusted to obtain tablets of the desired weight. In 
all cases the respective talcs utilized were those 
15 provided by, and bearing the designations of Cyprus 
Industrial Minerals Company, Denver, Colarado. The 
results reported reflect the properties of tablets 
produced by such talcs in various particle sizes. Talcs 
identified by the size designation, "300", for example, 
20 have a median particle size of 6 um. and size 
distribution in which 95% of the particles are finer 
than 20 um. and 12% are finer than 1 um. The size 
designation, "400'', indicate a talc having a median 
particle size of 4 um. and size distribution in which 
25 99% of the particles are finer than 45 um. and 16% are 
finer than 1 um. The size designation, "500'', indicate 
167 
a talc having a median particle size of 3 um. and size 
distribution in which 95% of the particles are finer 
than 10 um. and 18% are finer than 1 um. 
In the examples, Alabama talcs were compared using 
5 niacin formulations; Alabama, Altalc & Beaverwhite talcs 
were compared using hydrochlorothiazide formulations; 
and Beaverwhite 300 talc was used for formulations of 
the phenylpropanolamine and the theophylline tablets. 
The following tests were performed to evaluate the 
10 in vitro propeties of the tablets: 
Tablet Appearance 
Five randomly selected tablets were examined with a 
magnifying glass and the presence or abscence of the 
following relevant characteristics were observed: 
15 texture uniformity, e.g., absence of mottling, 
smoothness of surface or abscence of pitted surfaces, 
presence of black specks or lines; surface finish, e.g., 
shining or matt look; and chipping or cracking at the 
tablet edge. 
20 Tablet Wei~ht Uniformity 
Twenty tablets were weighed on an electronic 
mettler analytical balance and the relative weight 
deviation observed. 
168 
Tablet Crushin~ Stren~th (Hardness) 
The crushing strength values of ten tablets were 
determined on an Erweka Hardness Tester. Since 
formulation compactibility is the ratio of tablet 
5 hardness to compression pressure and, since the surface 
of the testing element is constant throughout the tests, 
compactibility was calculated as the ratio of hardness 
to compression force. 
Tablet Friability 
10 Ten tablets were dedusted and their initial 
collective weight determined. The tablets were then 
tumbled in a Roche-type friabilator for four minutes at 
25 revolutiions per minute after which the final 
collective weight was determined and the percent 
15 friability computed using the formula: 
Percent Friability = Initial Wei~ht - Final Wei~ht * 100 
Initial Weight 
Tablet Disinte~ration Times 
The disintegration times of six tablets were 
20 determined using the USP method of disintegration. 
While the usual procedure required the placement of 
plastic caps above the tablets, such caps were not 
employed where the tablets disintegrated rapidly. 
169 
Examples 1 to 16 
The compositions of the formulations tested and the 
press forces employed in the direct compression 
tableting procedures with respect to each respective 
5 formulation are as shown in Table I. Baseline 
formulations (see Table II) in which magnesium stearate, 
a commonly employed tableting lubricant, was used in 
place of talc in the matrix, were prepared for the 
compilation of comparative data. In the baseline 
10 formulation, as reported in Table II, tablets of 400 mg . 
weight were prepared by the same direct compression 
process employed for preparing the tablets of the 
invention; however, the tablets of Niacin, Avicel PH-102 
( and magnesium stearate were only 375 mg . weight due to 
15 limitations by the then existing press setting. 
Comparisons of the properties of the respective tablets 
produced in accordance with the invention against those 
of the baseline tablets are reported in Table III. 
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TABT.E I 
IOR\Lil...\TION At\'D TABLET CDv1PACrION Di\TA 
E.'<AMPLE r.mr, i>.1.1:m1x DIS IN"lffiRANf a:MPRESS I0\1* EJECrION* 
TAI!: CT!l IER (PR Ir..fXJEL) fDRCE (KN) fDRCE (N) 
5 1 Niacin (6.25%) A I a barna JOO Av i c e I Pl I - 10 2 - - - 11.96 (0.48) 343.87 (10.63) 
(JO .mo) ( 63. 7'3fo) 
2 Niacin (6.2'3fo) Alabama 400 Av i c e I PII - 10 2 - - - 11.97 (0.44) 340.09 (8.91) 
(30.mo) ( 6J. 7'3fo) 
3 Niacin (6.2'3fn) A I a hama 500 Av i c e I Pl I - 10 2 - - - 11 . 9 3 ( 0. 50) 331. 70 (12.0) 
10 (JO. C1Yn) (63.75%) 
4 Niacin (6.25%) Alabama JOO Lactose ( 4. m'o) 14.08 (0.20) 735.51 (3.37) 
( 10. ffi'o) ( 79. 7'3fo) 
....... 
-'1 
5 l~drochlorothiazide Alabama 300 Av i c e I PI I - 1 0 2 (4. Wo) 13.87 (0.25) 378.49 (5.17) ....... 
( 6. 2'3fo) (21 .Olo) (68.75%) 
. 
15 6 Ifydrochlorothiazide Alabama 400 Avicel PII - 102 (4 .Wo) • 13.65 (0.26) 400.82 (5.27) 
( 6. 2':Rn) (21.m'n) ( 68. 7'3fo) 
7 Jfydrochlorothiazide A I a ha.ma 500 Avicel Pll - 102 ( 4. OYo) 13.75 (0.22) 381.98 (5.39) 
(6.25%) (21.CYi'o) (68.75%) 
8 I Jyd r o ch Io rot hi a z id e Alabama JOO Av ice I PII - 102 (4 .OO'o) 13.62 (0.30) 421.69 (13.12) 
20 (6.25%) (26.0%) (63.75%) 
9 I !yd ro ch Io rot h i a z id e Al ta I c JOO Av ice I Pll - 102 (4.<JYo) 13.87 (0.19) 392.46 (5.58) 
(6.25%) (21.070) ( 68. 7'3fo) 
TAnI.E I (cont'd) 
IDR\L'IATIO:-l AND TAnI..ET mn)ACTICY.'1 Q.\TA 
EXNv1Pl.E rnu; 1\1.\'m I:\ DISINTIXJRANT 0Jv1PR~SSICY.'1* EJECTICX·.J* 
TALC amm (PRIMXJEL) TDRCE (KN) TDRCE (N) 
5 10 lfydrochlorothiazide Altaic 400 Av i c e I Pl!- 10 2 ( 4. 07/o) 13.71 (0.21) 382.32 (3.89) 
(6.25%) (21 .mo) (68.75%) 
11 I !yd ro ch Io rot hi a z id e Al ta I c 500 Av i c e I Pl I - 1 0 2 (4 .Wo) 13.71 (0.25) 380.53 (6.02) 
...... ( 6. 2511/o) ( 2 1 . crro) (68.75P/o) 
-'2 
!:\) 
12 lfydrochlorothiazide neaverni1i te 300 Av i c e I PII - 10 2 ( 4. m'o) 13.84 (0.21) 393.97 (5.71) 
10 ( 6. 25P/o) (21.m'o) ( 68. 79'1/o) 
13 lfydrochlorothiazide Ileavernhite 400 Avicel PII-102 (4 .Wo) 13.69 (0.20) 391.25 (4.24) 
(6.25%) (21.m'o) ( 68. 79'1/o) 
14 lfydrochlorothiazide neaverwhite 500 Av i c e I PII - 10 2 (4.WoJ 13.83 (0.27) 392.69 (6.91) 
( 6. 29'1/o) C 21 . rrfo) ( 68. 79'1/o) 
15 15 Phe ny I prop a no I amine Beaverv.hite JOO Av i c e I Pl I - 10 2 - 8.44 (0.22) 240.18 (4.68) 
( 12. 5(11'o) ( 26. ITTo) ( 61. 5Wo) 
16 Theophy 11 i ne neaverwhite 300 Avicel Pil - 102 (4 .Wo) 1L96 (0. 30) 269.36 (9.81) 
( 25. m'o) (21.070) ( 50. ffi'o) 
* Values in parenthesis are standard deviations. 
TABl .E I I 
BASELINE IffiVUIATIO.\JS AND TA111.ETll\G J}.\TA USIJ\G M\GNESllM SIT'..ARATE AS LUBRICANT 
* * EXA'v1Pl.E 11~UG 1\¥.m I'\ i\\.\Gi';l:S IU.1 DI S I NTlIJRANT aMPR ES S I O\J EJECTION 
s· 11~,\RA11: PR Hv!XJEL H:)l~CE (KN) IDRCE (N) 
5 A Niacin (6.67%) Av i c e I PI I - 1 0 2 'Eo - 11.89 (0.19) 86.85 (4.58) 
(91.33%) 
...... 
~ 
~ n Niacin (6.67%) Lactose 'Eo ( 4 . CJ1'o) 13.78 (0.18) 567.26 (10.72) 
(87.33%) 
c Ily d ro ch I o r o t h i a z i de Av ice 1 Pil-102 1% (4.0%) 12 . 06 ( 0 . 1 8) 74.39 (2.44) 
10 (6.25%) (88.75%) 
D Pheny I pro pa no 1 amine Av i c e 1 Pl I - to 2 2% - 8.46 (0.13) 106.72 (3.85) 
( 1 2. 5<Pln) (85 . 5f1¥o) 
E Theophy I Ii ne Av ice 1 PI! - 102 'Eo ( 4 . ()'/o) 11 . 86 ( 0. 1 7) 114.96 (3.46) 
(25.0%) ( 69. O()Yo ) 
* 15 Values in parenthesis are standard deviations 
TAnLE 111 
<TMPARATIVE PJH)J>ERTI ES ()F T..'\BI .ETS ()F 11\VEt,rfJO:"J VS. nA.SELINE TAnT.ETS 
E'{Mfl>LE I IARfl'.JESS ( l ) PERO'.Nf CThlPACTI BI LITY PERCJNf DIS INITIJRATION( 4 ) 
(KG) I LA.lm!J~ rn!ABILITY TIME (SEC.) 
5 1 11.8 (1.1) 111 . 3 0.98 0.26 24 - 48 
2 11.3 (0.3) 106.6 0.94 0.28 24 - 48 
f-' 3 10.6 (0.6) 100. 0 ( 2 ) 0. 89 0.25 24 - 48 
~ 
~ 
MSELINE A 11.5 (0.8) - 0.97 0 .14 36 - 54 
4 11.7 (1.2) - 0. 83 0.26 216 - 252 
10 MSELINE n 8.9 (1.5) - 0.65 0.26 450 - 540 
5 12.4 (0.5) 124.0 0.90 0.08 26 - 30 
6 11 .5 (0.5) 115. 0 0. 84 0.12 21 - 23 
7 10.8 (0.4) 108.0 0.78 0.07 21 - 22 
8 6.6 (0.7) - 0.48 0.34 23 - 26 
15 9 14.3 (0.5) 143.0 1.03 0. 17 20 - 23 
10 11.2 (0.3) 112. 0 0.81 0. 17 20 - 23 
11 10.0 (0.8) 100. 0 ( 3 ) 0. 72 0. 19 22 - 24 
....... 
-'2 
(JI 
T..\1\1.E Ill (con't) 
CTlvfPAIV\TIVE PROP!Jffl ES OF T.·\nl .ETS OF I i\\'IJ\'TIO>J VS. lll\SELINE TAnT.CTS 
5 
10 
EXA:\1PJ .E 
12 
13 
14 
11ASEl.I NE C 
15 
11ASELINE D 
16 
TlA.SEl. I NE E 
I IA.Rr:NESS ( 1 ) 
(KG) 
13.4 (0.4) 
12.6 (0.3) 
11.1 (1.1) 
5.2 (0.7) 
7.0 (0.6) 
6.4 (0.7) 
12.8 (3.5) 
7.5 (0.5) 
PERONr 
I l.\RDI '.R 
1'.M.0 
126.0 
111 . 0 
-
-
-
-
-
(Th IP . .\CT I BI I. I TI' 
0.97 
0.92 
0. 80 
0. -13 
0 . 82 
0.75 
1.07 
0.63 
( l )V. I . I . I d I . . a ues 1n parent1es1s are stancar cev1at1ons. 
PERCTNT 
FRIAnILITY 
0. 18 
0.21 
0. 19 
0. 72 
0. 13 
0.24 
0.04 
0. 18 
( 2 )Using hardness value of Alabama #500 tablets as 100% 
15 C3 )Using hardness value of Altaic #500 tahlets as 100% 
c '1 )u · r 1 1 · ·' · sing per oratcc p ast1c u1scs. 
DISI!'rfEGRATI0~( 4 ) 
THv1E (SEC.) 
20 - 22 
22 - 26 
22 - 24 
7 - 11 
50 - 60 
20 - 25 
15 - 16 
34 - 36 
·: ' 
With particular reference to the data reported in 
Table III as to Tablet Hardness, niacin tablets having 
Avicel PH - 102 plus Alabama 300 or Alabama 400 talcs were 
statistically significantly harder as compared to those 
5 in which Alabama 500 was matrix element . The hardness 
values of niacin tablets employing Alabama 300 or 
Alabama 400 talcs were similar to those of tablets 
containing the baseline formulation . 
For hydrochlorothiazide, all of the various talcs 
10 tested showed considerably greater hardness as compared 
to the concerned baseline formulation. Tablets 
containing Altalc 300 as the matrix component were 
statistically significantly harder than those employing 
Beaverwhite 300, which are, in turn, significantly 
15 harder than tablets containing either Alabama 300 or 
Beaverwhite 400 talc in the matrix . Slightly less hard 
hydrochlorothiazide tablets were obtained from 
formulations containing either Alabama 400 , Alabama 500 , 
Altalc 400 or Beaverwhite 500 talcs in their matrices. 
20 No statistically significant differences exist among 
these latter mentioned talcs. The tablets exhibiting 
the lowest hardness values are those containing Altalc 
500 in the matrix . For phenylpropanolamine and, 
similarly , for theophylline, talc-containg matrices 
25 generally produced statistically significantly harder 
176 
tablets compared with those containing the respective 
baseline formulations. 
As regards Tablets Friability , for niacin the 
tablet formulations containing talc and Avicel PH-102 
have a percent friability that is about twice that of 
5 the baseline formulation . Those formulated with talc 
and lactose had the same percent friability as the 
baseline formulation. For hydrochlorothiazide , tablets 
produced with Alabama talcs had the lowest friability, 
10 while those produced with Altalc and Beaverwhite had 
similar friability characteristics. The percent 
friability for all tablets produced in accordance with 
the invention was a mere fraction of those having the 
( baseline formulation. 
15 The percent friability of phenylpropanolamine and 
theophylline tablets made with talc is two to four times 
lower than tablets produced with their respective 
baseline formulations. 
As regards Tablet Disintegration, the 
20 disintegration times of the niacin and theophylline 
tablets containing talc in their matrices were about 
half the disintegration times for their respective 
baseline formulations. The talc-containing tablets 
including hydrochlorothiazide and phenypropanolamine as 
25 active ingredients disintegrated in about three times as 
their respective baseline formulations. 
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From the foregoing it will be appreciated that 
-pharmaceutical tablets having an elevated concentration 
of talc in their matrix exhibit highly beneficial 
properties. They are relatively inexpensive to produce, 
5 have a pharmaceutically elegant appearance, exhibit good 
hardness or crushing strength. 
While the foregoing description is directed 
primarily to the preferred embodiments and practices of 
the invention, it will be apparent to those skilled in 
10 the art that changes and modifications of the described 
concepts can readily be made without departing from the 
spirit and scope of the invention as defined by the 
following claims. 
CLAIMS 
1. A pharmaceutical composition in compressed 
tablet form comprising a pharmaceutically active 
ingredient contained in a tablet matrix comprising at 
least about 10 weight percent talc, said matrix 
comprising a preponderance of the total weight of said 
tablet. 
2. A tablet as recited in claim 1 in which said 
matrix comprises at least about 75 percent of the total 
weight of said tablet. 
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3. A tablet as recited in claim 1 in which talc is 
present in the matrix in an amount Q~ from about 10 to 
about 45 weight percent based upon the total weight of 
said matrix. 
4. A tablet as recited in claim 3 in which said 
matrix comprises at least about 50 weight percent of 
microcrystalline cellulose or lactose as a binder 
material , based on the total weight of the matrix . 
5. A tablet as recited in claim 4 in which the 
binder material is present in the matrix in an amount of 
from about 75 to about 95 percent by weight based on the 
total weight of said matrix. 
6. A tablet as recited in claim 5 in which the 
binder material is microcrystalline cellulose. 
7. A tablet as recited in claim 5 in which the 
binder material is lactose. 
8. A pharmaceutical composition in compressed 
tablet form comprising a dosage portion of active 
ingredient including from about 10 up to 40 weight 
percent talc, and the remainder including pharmaceutical 
diluent and binder materials . 
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9. The pharmaceutical composition as recited in 
~laim 8 having a matrix containing said talc said binder 
material . 
10. The pharmaceutical composition as recited in 
claim 9 in which said diluent and binder materials 
include microcrystalline cellulose, lactose and starch. 
11. The pharmaceutical composition as recited in 
claim 10 in which said talc has a median particulate 
si ze of from about 3 to about 6 microns . 
12. The pharmaceutical composition as recited in 
either claim 10 or claim 11 in which the matrix 
composition is about 21 weight percent talc and about 
68.75 weight percent microcrystalline cellulose. 
13. The pharmaceutical composition as recited in 
claim 12 including starch as a disintegrant. 
14 . The pharmaceutical composition as recited in 
either claim 10 or claim 11 in which the matrix 
composition is about 10 weight percent talc and about 80 
weight percent lactose. 
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15. The pharmaceutical composition as recited in 14 
including starch as a disintegrant. 
AB SR TRACT 
Pharmaceutically acceptable tablets in which talc 
in amounts from about 10 to about 40 weight percent 
exists together with a binding agent in the matrix. 
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Appendix C: Software. 
( 
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l 
This is the start of the SAS programs for plotting 
percent theophylline released from three tablets per 
formulation . The bars represent range of values. 
For random order formulation number 1 to 3: 
1 //RLOlOl JOB (RLOlOl), ' SHABBIR ' , TIME=(0,59) , MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 // GO . FTllFOOl DD SYSOUT=A , HOLD=YES 
1 // GO . FT12F001 DD SYSOUT=A , HOLD=YES 
1 // GO . IN DD DSN=RLOlOl . SASJOIN,DISP=OLD 
1 // GO.QMSOUT DD SYSOUT=A , DEST=QMS1,0UTLIM=5000 
1 // GO . SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS=(BLACK) HSIZE=6 
VSIZE=6 
10 NOTEXT82 NOCIRCLEARC NOCHARACTERS 
10 NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL NODASH 
10 HANDSHAKE=XONXOFF GSFLEN=200 
10 GEND='8D8A'X GSFNAME=QMSOUT GSFMODE=REPLACE; 
1 OPTIONS LS=72; 
1 DATA NONLINl; 
1 INPUT Xl Yl @@; 
1 CARDS; 
1 00.0 00.0 
2 
2 
5.0 
5 . 0 
9.34 
9.23 
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2 5.0 10.13 
1 10.0 50 . 96 
1 10 . 0 37 . 43 
1 10.0 52.33 
1 15.0 89 . 97 
1 15 . 0 78.45 
1 15 . 0 87 . 49 
1 20.0 100 . 29 
1 20. 0 91. 03 
1 20.0 97 . 88 
1 30.0 102 . 28 
1 30.0 95.88 
1 30 . 0 100.20 
1 45.0 102.81 / * T =104.47 
CD 
1 45.0 99.87 T =105.25 
CD 
1 45.0 101.39 T =104.51 */ 
CD 
2 
1 PROC NLIN DATA=NONLINl BEST=500 PLOT METHOD=MARQUARDT ; 
1 MODEL Yl= B2*EXP(-BO *EXP(-Bl*Xl)) ; 
1 PARMS BO= 5 . 0 TO 15.0 BY 1 . 0 
7 Bl= 0 . 0 TO 2.00 BY 0.50 
7 B2= 98.0 TO 102.0 BY 1.0 ; 
1 DER.B0=-B2*EXP(-BO *EXP(-Bl *Xl)) *( EXP(-Bl*Xl)); 
1 DER.Bl=B2*EXP(-BO*EXP(-Bl*Xl))*(Xl*BO*EXP(-Bl*Xl)); 
1 DER . B2=EXP(-B0 *[ 6-(-Bl *Xl)); 
1 OUTPUT OUT=BBl P=PREDICTl R=RESIDl ; 
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1 
1 
1 
1 
1 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
OPTIONS LS=72; 
DATA NONLIN2; 
INPUT Xl Y2 @@; 
CARDS; 
00 . 0 00.0 
5.0 7.99 
5 . 0 7 . 00 
5.0 7.76 
10.0 12 . 17 
10 . 0 12 . 29 
10.0 14.34 
15.0 19 . 02 
15.0 22.34 
15.0 33.61 
20.0 34.47 
20.0 43 . 73 
20.0 58.77 
30.0 75 . 57 
30.0 86 . 62 
30.0 88.63 
45.0 92.21 ! * 
45.0 99 . 41 
45.0 97.03 
T =105.03 
CD 
T =105.37 
CD 
T =104.34 * ! 
CD 
1 PROC NLIN DATA=NONLIN2 BEST=500 PLOT METHOD=MARQUARDT; 
1 MODEL Y2= B2*EXP(-BO*EXP(-Bl*Xl)); 
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1 PARMS BO= 5.0 TO 15.0 BY 1. 0 
7 Bl= 0 . 0 TO 2 . 00 BY 0 . 50 
7 B2= 93 . 0 TO 99.0 BY 2 . 0; 
1 DER.B0 =-B2*EXP( - BO *EXP (-Bl *Xl) )*( EXP( - Bl *Xl)); 
1 DER . Bl=B2 *EXP (-BO *EXP( - Bl *Xl) )*( Xl *BO *EXP(-Bl *Xl)); 
1 DER.B2=EXP(-BO *EXP( - Bl *Xl)) ; 
1 OUTPUT OUT=BB2 P=PREDICT2 R=RESID2; 
1 OPTIONS LS=72 ; 
1 DATA NONLIN3 ; 
1 INPUT Xl Y3 @@; 
1 CARDS ; 
1 00.0 00.0 
2 5 . 0 7 . 65 
2 5.0 7 . 99 
( 2 5.0 6.98 
1 10 . 0 16.84 
1 10.0 28.33 
1 10.0 17.75 
1 15.0 45 . 12 
1 15.0 55.49 
1 15.0 53.21 
1 20.0 68 . 14 
1 20.0 78 . 39 
1 20.0 76.09 
1 30 . 0 85.72 
1 30 . 0 92 . 89 
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( 
1 30.0 90.57 
1 45 . 0 92 . 79 I * T =103.68 
00 
1 45 . 0 100.27 T =101.57 
00 
1 45.0 102.24 T =103.79 * I 
00 
2 
1 PROC NLIN DATA=NONLIN3 BEST=500 PLOT METHOD=MAR~UARDT ; 
1 MODEL Y3= B2 *EXP(-BO *EXP(-Bl*Xl)) ; 
1 PARMS BO= 5.0 TO 15 . 0 BY 1.0 
7 Bl= 0.0 TO 2 . 00 BY 0.50 
7 B2= 93 . 0 TO 102 . 0 BY 3.0; 
1 DER . BO=-B2 *EXP(-BO *EXP(-Bl *Xl)) *( EXP( - Bl*Xl)) ; 
1 DER . Bl=B2 *EXP ( -BO *EXP(-Bl *Xl)) *( Xl *BO *EXP(-Bl*Xl)); 
1 DER.B2=EXP(-BO *EXP(-Bl *Xl)) ; 
1 OUTPUT OUT=BB3 P=PREDICT3 R=RESID3; 
1 DATA JOIN; SET BBl BB2 BB3 ; 
1 GOPTIONS NOTEXT82; 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
1 ' FIGURE 1: DISSOLUTION CURVES .. . FORMULATIONS 1 TO 3 '; 
1 TITLEl H=l2 A=90 F=TRIPLEX ; / * PUSH LEFT TO RIGHT */ 
1 TITLE2 H=l2 A=O F=TRIPLEX; / * PUSH TOP TO BOTTOM */ 
1 PROC GPLOT DATA=JOIN; 
7 
12 
12 
7 
PLOT Yl * Xl PREDICTl*Xl=': ' 
Y2 * Xl PREDICT2*Xl=' +' 
Y3 * Xl PREDICT3 *Xl='- ' / OVERLAY 
HAXIS=AXIS2 VAXIS=AXISl ; 
AXISl VALUE=(F=TRIPLEX H=l.5) 
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13 LABEL=(F=TRIPLEX H=l . 5 A=90 R=O 'PERCENT RELEASED') 
13 ORDER= 0 TO 110 BY 10; 
7 AXIS2 VALUE=(F=TRIPLEX H=l.5) 
13 LABEL= ( F=TRIPLEX H=l.5 ' TIME (MINUTES) ' ) MINOR=NONE 
13 
13 
13 
13 
13 
13 
13 
1 // 
ORDER= 0 TO 45 BY 5 ; 
SYMBOLl V=C=BLACK I=HILOT 
SYMBOL2 V=C ; 
SYMBOL3 V=C=BLACK I=HILOT 
SYMBOL4 V=C; 
SYMBOL5 V=C=BLACK I=HILOT 
SYMBOL6 V=C ; 
SAS programs for random order formulation number 4 to 6: 
1 //RLOlOl JOB (RLOlOl), 'SHABBIR ' , TIME=(0,59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 // GO.FTllFOOl DD SYSOUT=A,HOLD=YES 
1 //GO.FT12F001 DD SYSOUT=A , HOLD=YES 
1 //GO.IN DD DSN=RLOlOl.SASJOIN,DISP=OLD 
1 //GO.QMSOUT DD SYSOUT=A , DEST=QMS1 , 0UTLIM=5000 
1 // GO.SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS=(BLACK) HSIZE=6.5 
VSIZE=6 . 5 
10 NOTEXT82 NOCIRCLEARC NOCHARACTERS 
10 NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL NODASH 
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10 HANDSHAKE=XONXOFF GSFLEN=200 
10 GEND= ' 8D8A ' X GSFNAME=~MSOUT GSFMODE=REPLACE; 
1 OPTIONS LS=72 ; 
1 DATA NONLIN4 ; 
1 INPUT Xl Y4 @@; 
1 CARDS; 
1 00 . 0 00.0 
2 5 . 0 9 . 23 
2 5.0 7.09 
2 5.0 7 . 43 
1 10.0 22.87 
1 10 . 0 15 . 93 
1 10.0 18.20 
1 15 . 0 66.91 
1 15.0 39.42 
1 15.0 46.27 
1 20.0 83.80 
1 20.0 70 . 12 
1 20.0 67.60 
1 30 . 0 92.22 
1 30.0 93.52 
1 30.0 81.08 
1 45.0 100.16 / * T =102 . 48 
CD 
1 45.0 102.27 T =104.51 
CD 
1 45.0 90.60 T =104.31 * / 
CD 
2 
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1 PROC NLIN DATA=NONLIN4 BEST=500 PLOT METHOD=MAR~UARDT; 
1 MODEL Y4= B2 *EXP(-BO *EXP(-Bl*Xl)); 
1 PARMS BO= 5.0 TO 10 . 0 BY 1.0 
7 Bl= 0.0 TO 2.00 BY 0.50 
7 B2 = 91 . 0 TO 102 . 0 BY 3.0; 
1 DER . BO=-B2 *EXP ( -BO *EXP ( -Bl *Xl)) *(EXP(-Bl*Xl)); 
1 DER.Bl=B2 *EXP(-BO *EXP (-Bl *Xl)) *( Xl *BO *EXP(-Bl *Xl)) ; 
1 DER.B2=EXP(-BO *EXP(-Bl *Xl )); 
1 OUTPUT OUT=BB4 P=PREDICT4 R=RESID4; 
1 OPTIONS LS=72; 
1 DATA NONLIN5; 
1 INPUT Xl Y5 @@; 
1 CARDS; 
1 00 . 0 00.0 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
5.0 
5.0 
5.0 
10.0 
10.0 
10.0 
15.0 
15.0 
15 . 0 
20.0 
20.0 
20 . 0 
7.76 
7.43 
7.20 
20.82 
23.09 
21.50 
50.85 
62.25 
54.96 
76. 10 
83.30 
84.79 
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1 30.0 92.28 
( 1 30 . 0 99.22 
1 30.0 95 . 05 
1 45.0 99 . 88 / * T =1 05.38 
CD 
1 45.0 102.00 T =104.68 
CD 
1 45.0 99 . 94 T =105.10 * I 
CD 
2 
1 PROC NLIN DATA=NONLIN5 BEST=500 PLOT METHOD=MAR~UARDT; 
1 MODEL Y5= B2 *EXP(-BO*EXP(-Bl *Xl)); 
1 PARMS BO= 5.0 TO 10.0 BY 1. 0 
7 Bl= 0.0 TO 2.00 BY 0.50 
7 B2= 98 . 0 TO 102.0 BY 1. O; 
1 DER.BO=-B2 *EXP(-BO*EXP(-Bl*Xl))*(EXP(-Bl*Xl)) ; 
1 DER.Bl=B2*EXP(-BO *EXP(-Bl *Xl)) *( Xl*BO*EXP(-Bl *Xl)) ; 
1 DER . B2=EXP(-BO *EXP(-Bl *Xl)); 
1 OUTPUT OUT=BB5 P=PREDICT5 R=RESID5; 
1 OPTIONS LS=72; 
1 DATA NONLIN6; 
1 INPUT Xl Y6 @@; 
1 CARDS; 
1 00.0 00.0 
2 5.0 10.46 
2 5.0 15.98 
2 5 . 0 12.04 
1 10.0 49.94 
1 10.0 60.40 
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1 10.0 69.96 
1 15 . 0 90.30 
1 15.0 84.62 
1 15 . 0 91. 66 
1 20.0 97.43 
1 20 . 0 91. 91 
1 20.0 96.07 
1 30.0 99.51 
1 30.0 102 . 92 
1 30.0 100.75 
1 45.0 100.92 / * T =104.87 
Q) 
1 45 . 0 103.34 T =104.66 
Q) 
1 45 . 0 104.45 T =104.61 */ 
Q) 
2 
1 PROC NLIN DATA=NONLIN6 BEST=500 PLOT METHOD=MAR~UARDT; 
1 MODEL Y6= B2*EXP(-BO*EXP(-Bl*Xl)); 
1 PARMS BO= 5 . 0 TO 10.0 BY 1 . 0 
7 Bl= 0.0 TO 2 . 00 BY 0.50 
7 B2= 100.0 TO 105.0 BY 1.0; 
1 DER.BO=-B2*EXP(-BO*EXP(-Bl*Xl))*(EXP(-Bl*Xl)); 
1 DER . Bl=B2*EXP(-BO*EXP(-Bl*Xl))*(Xl*BO*EXP(-Bl*Xl)); 
1 DER.B2=EXP(-BO*EXP(-Bl*Xl)); 
1 OUTPUT OUT=BB6 P=PREDICT6 R=RESID6; 
1 DATA JOIN; SET BB4 BB5 BB6; 
1 GOPTIONS NOTEXT82; 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
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1 ' FIGURE 2: DISSOLUTION CURVES ... FORMULATIONS 4 TO 6'; 
1 TITLEl H=14 A=90 F=TRIPLEX; / * PUSH LEFT TO RIGHT* / 
1 TITLE2 H=14 A=O F=TRIPLEX; / * PUSH TOP TO BOTTOM */ 
1 PROC GPLOT DATA=JOIN ; 
7 
12 
12 
PLOT Y4 * Xl PREDICT4 *Xl =': I 
Y5 * Xl PREDICT5 *Xl='+ ' 
Y6 * Xl PREDICT6 *Xl= '-' / OVERLAY 
HAXIS=AXIS2 VAXIS=AXISl ; 
7 AXISl VALUE= ( F=TRIPLEX H=l . 5) 
13 LABEL=(F=TRIPLEX H=l . 5 A=90 R=O 'PERCENT RELEASED') 
13 ORDER= 0 TO 110 BY 10 ; 
7 AXIS2 VALUE =( F=TRIPLEX H=l.5) 
13 LABEL=(F=TRIPLEX H=l.5 'TIME (MINUTES)') MINOR=NONE 
13 
13 
13 
13 
13 
13 
13 
1 // 
ORDER= 0 
SYMBOLl 
SYMBOL2 
SYMBOL3 
SYMBOL4 
SYMBOL5 
SYMBOL6 
TO 45 BY 5 
' 
V=C=BLACK I=HILOT 
V=C; 
V=C=BLACK I=HILOT 
V=C ; 
V=C=BLACK I=HILOT 
V=C; 
SAS programs for random order formulation number 7 to 9. 
1 //RL0101 JOB (RL0101) , ' SHABBIR ' ,TIME=(0,59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT ~MSl 
1 // EXEC SAS 
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I 
l 
1 //GO.FTllFOOl DD SYSOUT=A , HOLD=YES 
1 //GO.FT12F001 DD SYSOUT=A , HOLD=YES 
1 //GO.IN DD DSN=RLOlOl.SASJOIN , DISP=OLD 
1 // GO . ~MSOUT DD SYSOUT=A,DEST=~MS1,0UTLIM=5000 
1 //GO.SYSIN DD * 
1 GOPTIONS DEVICE=~MS1200E COLORS=(BLACK) HSIZE=6.5 
VSIZE=6 . 5 
10 NOTEXT82 NOCIRCLEARC NOCHARACTERS 
10 NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL NODASH 
10 HANDSHAKE=XONXOFF GSFLEN=200 
10 GEND='8D8A'X GSFNAME=~MSOUT GSFMODE=REPLACE ; 
1 OPTIONS LS=72; 
1 DATA NONLIN7; 
1 INPUT Xl Y7 @@; 
1 CARDS; 
1 00.0 00 . 0 
2 5.0 6.30 
2 5.0 6.08 
2 5.0 6 . 53 
1 10.0 13.99 
1 10.0 16.16 
1 10.0 16.84 
1 15.0 29.85 
1 15.0 35.56 
1 15.0 56 . 38 
1 20.0 57.02 
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( 
1 20 . 0 57.45 
1 20.0 89.76 
1 30.0 86.65 
1 30.0 90.27 
1 30.0 103 . 71 
1 45 . 0 95.33 / * T =106.02 
CD 
1 45 . 0 98.87 T =105.28 
CD 
1 45.0 104 . 72 T =105.27 */ 
CD 
2 
1 PROC NLIN DATA=NONLIN7 BEST=500 PLOT METHOD=MARQUARDT; 
1 MODEL Y7= B2*EXP(-BO*EXP(-Bl*Xl)); 
1 PARMS BO= 5.0 TO 10.0 BY 1.0 
7 Bl= 0.0 TO 2.00 BY 0.50 
7 B2= 95.0 TO 104.0 BY 3.0; 
1 DER.BO=-B2*EXP(-BO *EXP(-Bl*Xl))*(EXP(-Bl*Xl)); 
1 DER.Bl=B2*EXP(-BO*EXP(-Bl*Xl)) *( Xl*BO*EXP(-Bl*Xl)); 
1 DER.B2=EXP(-BO*EXP(-Bl *Xl)); 
1 OUTPUT OUT=BB7 P=PREDICT7 R=RESID7; 
1 OPTIONS LS=72; 
1 DATA NONLIN8; 
1 INPUT Xl Y8 @@; 
1 CARDS; 
1 00.0 00.0 
2 5.0 9 . 45 
2 5.0 20.36 
2 5 . 0 12.60 
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( 
{ 
1 10.0 52.33 
1 10.0 69.73 
1 10.0 74.28 
1 15.0 71 . 90 
1 15.0 89 . 84 
1 15.0 95.92 
1 20.0 80 . 65 
1 20 . 0 94 .1 2 
1 20.0 98.67 
1 30.0 87.89 
1 30.0 96.61 
1 30.0 100.19 
1 45.0 94.30 I* T =105.53 
CD 
1 45.0 98 . 79 T =104 . 72 
CD 
1 45.0 102.06 T =103.48 */ 
CD 
2 
1 PROC NLIN DATA=NONLIN8 BEST=500 PLOT METHOD=MARQUARDT; 
1 MODEL Y8= B2 *EXP(-BO *EXP(-Bl*Xl)); 
1 PARMS BO= 5.0 TO 10 . 0 BY 1.0 
7 Bl= 0.00 TO 2.00 BY 0.5 
7 B2= 94 TO 102 BY 2; 
1 DER.B0=-B2*EXP(-BO*EXP(-Bl*Xl))*(EXP(-Bl*Xl)); 
1 DER.Bl=B2*EXP(-BO *EXP(-Bl *Xl)) *(Xl*BO *EXP(-Bl*Xl)); 
1 DER.B2=EXP(-BO*EXP(-Bl *Xl)); 
1 OUTPUT OUT=BB8 P=PREDICT8 R=RESID8; 
1 OPTIONS LS=72; 
196 
1 DATA NONLIN9; 
1 INPUT Xl Y9 @@; 
1 CARDS ; 
1 00.0 00.0 
2 5.0 7.09 
2 5 . 0 6.75 
2 5 . 0 7 . 65 
1 10.0 11 . 95 
1 10.0 11 . 38 
1 10.0 12.52 
1 15 . 0 19 . 36 
1 15.0 17 . 19 
1 15 . 0 19. 14 
1 20 . 0 34.36 
1 20.0 25 . 00 
1 20.0 30 . 16 
1 30 . 0 64.65 
1 30.0 56.10 
1 30.0 72.01 
1 45.0 86.63 I * T =103.83 
a> 
1 45 . 0 80.72 T =103.21 
a> 
1 45.0 93 . 84 T =104.52 * I 
a> 
2 
1 PROC NLIN DATA=NONLIN9 BEST=500 PLOT METHOD=MAR~UARDT ; 
1 MODEL Y9= B2 *EXP(-BO *EXP(-Bl*Xl)); 
1 PARMS BO= 5.0 TO 10.0 BY l. 0 
( 
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7 
7 
Bl= 0.0 TO 2 . 00 BY 0 . 50 
B2= 80.0 TO 94 . 0 BY 3 . 0 ; 
1 DER . B0= - B2 *EXP (-BO *EXP (-Bl *Xl ))*( EXP (-Bl *Xl)); 
1 DER.Bl =B2 *EXP(-BO *EXP (-Bl *Xl) )*( Xl *BO *EXP(-Bl *Xl)) ; 
1 DER.B2 =EXP (-BO *EXP ( -Bl *Xl )); 
1 OUTPUT OUT=BB9 P=PREDICT9 R=RESID9 ; 
1 DATA JOIN ; SET BB7 BB8 BB9 ; 
1 GOPTIONS NOTEXT82 ; 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
1 ' FIGURE 3: DISSOLUTION CURVES .. . FORMULATION 7 TO 9 '; 
1 TITLEl H=l4 A=90 F=TRIPLEX ; / * PUSH LEFT TO RIGHT */ 
1 TITLE2 H=l4 A=O F=TRIPLEX; / * PUSH TOP TO BOTTOM */ 
1 PROC GPLOT DATA=JOIN ; 
7 PLOT Y7 * Xl PREDICT7 *Xl= ': I 
12 Y8 * Xl PREDICT8 *Xl= '+' 
12 Y9 * Xl PREDICT9 *Xl= '-' / OVERLAY 
HAXIS=AXIS2 VAXIS=AXISl ; 
7 AXISl VALUE= ( F=TRIPLEX H=l . 5 ) 
13 LABEL=(F=TRIPLEX H=l .5 A=90 R=O ' PERCENT RELEASED ') 
13 ORDER= 0 TO 110 BY 10; 
7 AXIS2 VALUE=(F =TRIPLEX H=l . 5) 
13 LABEL=(F=TRIPLEX H=l.5 ' TIME (MINUTES)') MINOR=NONE 
13 
13 
13 
13 
ORDER= 0 TO 45 BY 5 ; 
SYMBOLl V=C=BLACK I=HILOT 
SYMBOL2 V=C; 
SYMBOL3 V=C=BLACK I =HILOT 
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13 SYMBOL4 V=C ; 
( 13 SYMBOL5 V=C=BLACK I=HILOT 
13 SYMBOL6 V=C ; 
1 II 
SAS program for optimum formulation. 
1 // RLOlOl JOB ( RLOlOl ), ' SHABBIR ' ,MSGCLASS=W 
1 / *ROUTE PRINT DSPl 
1 / *JOBPARM LINES=5 
1 II EXEC SAS 
//GO.FTllFOOl DD SYSOUT= * 
1 // GO . FT12F001 DD SYSOUT= * 
1 // GO . SYSIN DD * 
1 OPTIONS LS=72 ; 
1 DATA NONLIN ; 
( 1 INPUT Xl y @@ ; / * FOR OPTIMAL FORMULATION * I 
1 CARDS ; 
1 00 . 0 00.0 
2 5 . 0 7.58 
2 5.0 7.74 
2 5 . 0 7.42 
1 10.0 14.69 
1 10 . 0 15 . 20 
1 10 . 0 20.43 
1 15.0 28.24 
1 15.0 27.74 
1 15 . 0 46.33 
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( 
1 20. 0 51. 46 
1 20 . 0 47 . 68 
1 20 . 0 68 . 23 
1 30 . 0 77.51 
1 30 . 0 73 . 87 
1 30.0 90.59 
1 45 . 0 89 . 37 / * T =105 . 53 
Q) 
1 45.0 87 . 19 T =103 . 23 
Q) 
1 45.0 97 . 30 T =103 . 85 */ 
Q) 
2 
2 PROC PRINT ; 
1 PROC NLIN DATA=NONLIN BEST=500 PLOT METHOD=MAR~UARDT ; 
1 MODEL Y= B2 *EXP(-BO *EXP(-Bl *Xl ) ) ; 
1 PARMS BO = 0 . 0 TO 7.0 BY 1 . 0 
7 Bl= 0.0 TO 2.00 BY 0 . 50 
7 B2= 87.0 TO 97 . 0 BY 2 . 0 ; 
1 DER.B0= - B2 *EXP(-BO *EXP(-Bl *Xl) )*( EXP(-Bl *Xl)) ; 
1 DER . Bl=B2 *EXP(-BO *EXP( - Bl *Xl) )*( Xl*BO *EXP(-Bl *Xl)) ; 
1 DER.B2=EXP(-BO *EXP( - Bl *Xl)) ; 
1 OUTPUT OUT=B P=PREDICT R=RESID ; 
1 PROC PLOT DATA=B ; PLOT Y*Xl PREDICT *Xl= ' P ' / OVERLAY 
VPOS=22 ; 
19 PLOT RESID *Xl / VREF =O VPOS=22 ; 
1 // 
This is the end of SAS programs for fitting dissolution data 
to Gompretz model by non- linear regression analysis. 
200 
( 
( 
This is the start of the SAS program for plotting 
disintegration time data, for three dimensional 
and contour plots. 
1 //RL0101 JOB (RL0101), ' SHABBIR ' ,TIME=(0,59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 //GO.FTllFOOl DD SYSOUT=A,HOLD=YES 
1 //GO.FT12F001 DD SYSOUT=A,HOLD=YES 
1 //GO.IN DD DSN=RLOlOl.SASJOIN,DISP=OLD 
1 //GO.QMSOUT DD SYSOUT=A,DEST=QMS1,0UTLIM=5000 
1 //GO.SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS=(BLACK) HSIZE=6.3 
VSIZE=6.3 
10 
10 
NOTEXT82 NOCIRCLEARC NOCHARACTERS 
NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL 
NODA SH 
10 HANDSHAKE=XONXOFF GSFLEN=200 
10 GEND='8D8A'X GSFNAME=QMSOUT GSFMODE=REPLACE ; 
1 GOPTIONS NOTEXT82; 
1 OPTIONS LS=72; 
1 DATA HARDNESS; 
1 INPUT Xl X2 Y; 
1 XlSQR Xl * Xl; 
1 X2SQR X2 * X2; 
201 
( 1 XlX2 Xl * X2; 
1 CARDS; 
2 1.0 0.0 8.63 
2 0.5 0.866 6.01 
1 -0.5 0 . 866 3 . 44 
1 -1. 0 0.0 3.37 
1 -0 . 5 - 0.866 5 . 44 
2 0.5 -0.866 9. 13 
2 0.0 0.0 6.07 
2 0.0 0.0 5.68 
2 0.0 0.0 6.53 
... 
2 
1 DATA CONTOURS , 
( 1 DO Xl= -1.0 TO 1. 0 BY 0.2; 
2 DO X2= -0.900 TO 0.900 BY 0.1; 
4 Z= 6.0105+ 2.7426 *Xl - l.3497*(X2) 
4 OUTPUT; 
4 END; 
2 END; 
2 PROC PRINT; 
. 1 PROC GCONTOUR DATA = CONTOURS 
4 PLOT Xl * X2 = z ; 
1 TITLEl; 
1 TITLE2 H=5 A=90 F=TRIPLEX; / *PUSH LEFT TO RIGHT* / 
1 TITLE3 H=l2 A=O F=TRIPLEX; /* PUSH TOP TO BOTTOM* / 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
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( 
l 
2 FIGURE 4:CONTOUR PLOT OF DISINTEGRATION DATA'; 
1 PROC G3D DATA = CONTOURS 
4 PLOT Xl * X2 = Z ; 
4 TITLEl; 
1 TITLE2 H=l5 A=90 F=TRIPLEX; / *PUSH LEFT TO RIGHT* / 
1 TITLE3 H=lO A=O F=TRIPLEX; / *PUSH TOP TO BOTTOM* / 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
2 FIGURE 5:3-D PLOT OF DISINTEGRATION DATA ' ; 
1 // 
This is the end of the SAS program for plotting 
disintegration time data, for three dimensional 
and contour plots. 
This is the start of the SAS program for plotting 
ejection force data, for three dimensional 
and contour plots. 
1 // RLOlOl JOB (RLOlOl), 'SHABBIR' ,TIME=(0,59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 //GO.FTllFOOl DD SYSOUT=A,HOLD=YES 
1 //GO.FT12F001 DD SYSOUT=A,HOLD=YES 
1 // GO.IN DD DSN=RLOlOl.SASJOIN,DISP=OLD 
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( 
1 //GO.QMSOUT DD SYSOUT=A, DEST=QMS1 , 0UTLIM=5000 
1 //GO.SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS= ( BLACK) HSIZE=6.0 
VSIZE =6.0 
10 
10 
NOTEXT82 NOCIRCLEARC NOCHARACTERS 
NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL 
NODA SH 
10 HANDSHAKE =XONXOFF GSFLEN=200 
10 GEND= ' 8D8A ' X GSFNAME=QMSOUT GSFMODE=REPLACE; 
1 GOPTIONS NOTEXT82 ; 
1 OPTIONS LS=72 ; 
1 DATA HARDNESS ; 
1 INPUT Xl X2 Y; 
1 XlSQR Xl * Xl ; 
1 
1 
1 
2 
2 
1 
1 
1 
2 
2 
2 
2 
X2SQR 
XlX2 
CARDS; 
1. 0 
0.5 
- 0.5 
- 1. 0 
- 0.5 
0.5 
0.0 
0.0 
0.0 
X2 * X2; 
Xl * X2; 
0.0 613.2 
0.866 581.2 
0.866 450.5 
0.0 397.1 
-0.866 462.8 
-0.866 603 . 9 
0.0 542.4 
0.0 533.5 
0.0 533.0 
204 
( 
( 
2 
1 DATA CONTOURS ; 
1 DO Xl= -1.0 TO 1.0 BY 0.2; 
2 DO X2= -0.900 TO 0.900 BY 0 . 1; 
4 Z= 537.838+ 118 . 262*Xl - 38.780*(Xl**2) 
4 OUTPUT; 
4 END; 
2 END; 
2 PROC PRINT; 
1 PROC GCONTOUR DATA = CONTOURS 
4 PLOT Xl * X2 = Z ; 
1 TITLEl; 
1 TITLE2 H=5 A=90 F=TRIPLEX; / *PUSH LEFT TO RIGHT* / 
1 TITLE3 H=l2 A=O F=TRIPLEX; /* PUSH TOP TO BOTTOM* / 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
2 FIGURE 6:CONTOUR PLOT OF EJECTION FORCE 
DATA'; 
1 PROC G3D DATA CONTOURS 
4 PLOT Xl * X2 = Z ; 
4 TITLEl; 
4 TITLE2 '3-D PLOT OF EJECTION FORCE DATA'; 
1 TITLEl; 
1 TITLE2 H=l5 A=90 F=TRIPLEX; / *PUSH LEFT TO RIGHT* / 
1 TITLE3 H=lO A=O F=TRIPLEX; / *PUSH TOP TO BOTTOM* / 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
2 FIGURE 7:3-D PLOT OF EJECTION FORCE DATA'; 
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1 // 
This is the end of the SAS program for plotting 
ejection force data, for three dimensional 
and contour plots . 
This is the start of the SAS program for plotting 
friability data, for three dimensional 
and contour plots . 
1 //RLOlOl JOB (RLOlOl), ' SHABBIR ' , TIME=(0 , 59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 //GO.FTllFOOl DD SYSOUT=A,HOLD=YES 
1 //GO.FT12F001 DD SYSOUT=A , HOLD=YES 
1 //GO.IN DD DSN=RLOlOl . SASJOIN,DISP=OLD 
1 //GO.QMSOUT DD SYSOUT=A,DEST=QMS1,0UTLIM=5000 
1 //GO.SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS=(BLACK) HSIZE=6.0 
VSIZE=6 . 0 
10 
10 
NOTEXT82 NOCIRCLEARC NOCHARACTERS 
NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL 
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( 
NO DASH 
HANDSHAKE=XONXOFF GSFLEN=200 
10 GEND= ' 8D8A ' X GSFNAME=~MSOUT GSFMODE=REPLACE; 
1 GOPTIONS NOTEXT82; 
1 OPTIONS LS=72; 
1 DATA HARDNESS; 
1 INPUT Xl X2 Y; 
1 XlSQR 
1 X2SQR 
l XlX2 
CARDS; 
l. 0 
2 0.5 
1 -0. 5 
1 -1. 0 
l - 0.5 
2 0.5 
2 0 . 0 
2 0.0 
2 0 . 0 
2 
Xl * Xl; 
X2 * X2; 
Xl * X2; 
0.0 0.294 
0.866 0.344 
0.866 0.419 
0.0 0.496 
-0.866 0.422 
-0.866 0.291 
0.0 0 . 353 
0.0 0.296 
0 . 0 0.328 
1 DATA CONTOURS 
' 
1 DO Xl= -1. 0 TO l. 0 BY 0.2; 
2 DO X2= -0.900 TO 0 . 900 BY 
4 Z= 0.3395- 0.1017*Xl + 
4 OUTPUT; 
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0 . 1; 
0.0624*(Xl**2) 
( 
4 END ; 
2 END ; 
2 PROC PRINT ; 
1 PROC GCONTOUR DATA = CONTOURS 
4 PLOT Xl * X2 = Z ; 
1 TITLEl ; 
1 TITLE2 H=5 A=90 F=TRIPLEX ; / *PUSH LEFT TO RIGHT */ 
1 TITLE3 H=l2 A=O F=TRIPLEX ; / *PUSH TOP TO BOTTOM */ 
1 FOOTNOTEl H=l . 5 F=TRIPLEX 
2 FIGURE 8:CONTOUR PLOT OF FRIABILITY DATA ' ; 
1 PROC G3D DATA = CONTOURS 
4 PLOT Xl * X2 = Z ; 
1 TITLEl ; 
1 TITLE2 H=l5 A=90 F=TRIPLEX ; / *PUSH LEFT TO RIGHT* / 
1 TITLE3 H=lO A=O F=TRIPLEX ; / *PUSH TOP TO BOTTOM */ 
1 FOOTNOTEl H=l . 5 F=TRIPLEX 
2 FIGURE 9:3- D PLOT OF FRIABILITY DATA'; 
1 // 
This is the end of the SAS program for plotting 
friability data, for three dimensional 
and contour plots . 
This is the start of the SAS program for plotting 
mean in vitro dissolution time data , for three 
208 
( 
dimensional and contour plots. 
1 // RLOlOl JOB (RLOlOl), 'SHABBIR' ,TIME=(0,59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 //GO.FTllFOOl DD SYSOUT=A,HOLD=YES 
1 //GO.FT12F001 DD SYSOUT=A,HOLD=YES 
1 //GO.IN DD DSN=RLOlOl.SASJOIN,DISP=OLD 
1 //GO.QMSOUT DD SYSOUT=A,DEST=QMS1,0UTLIM=5000 
1 // GO.SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS=(BLACK) HSIZE=6.0 
VSIZE=6.0 
10 
10 
NOTEXT82 NOCIRCLEARC NOCHARACTERS 
NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL 
NO DASH 
10 HANDSHAKE=XONXOFF GSFLEN=200 
10 GEND='8D8A'X GSFNAME=QMSOUT GSFMODE=REPLACE; 
1 GOPTIONS NOTEXT82; 
1 OPTIONS LS=72; 
1 DATA HARDNESS; 
1 INPUT Xl X2 Y; 
1 XlSQR Xl * Xl; 
1 X2SQR 
1 XlX2 
1 CARDS; 
X2 * X2; 
Xl * X2; 
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2 1.0 0.0 0.3573 
2 0.5 0.866 0.2536 
1 -0.5 0.866 0. 1646 
1 -1. 0 0.0 0. 1496 
1 -0 . 5 -0.866 0. 1847 
2 0.5 -0.866 0.4038 
2 0.0 0 . 0 0 . 2652 
2 0.0 0.0 0.2657 
2 0 . 0 0 . 0 0.2963 
2 
1 DATA CONTOURS ; 
1 DO Xl= -1.0 TO 1.0 BY 0.1; 
2 DO X2= -0.900 TO 0.900 BY 0.1; 
4 Z= 0.2601+ 0.1206*Xl - 0.0492 *( X2) 
4 OUTPUT; 
4 END; 
2 END; 
2 PROC PRINT; 
1 PROC GCONTOUR DATA = CONTOURS 
4 PLOT Xl * X2 = Z ; 
1 TITLEl; 
1 TITLE2 H=5 A=90 F=TRIPLEX; / *PUSH LEFT TO RIGHT* / 
1 TITLE3 H=l2 A=O F=TRIPLEX; / *PUSH TOP TO BOTTOM* / 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
2 ' FIGURE lO:CONTOUR PLOT OF MEAN DISSOLUTION TIME DATA'; 
1 PROC G3D DATA = CONTOURS ; 
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4 PLOT Xl * X2 = Z ; 
1 PROC GCONTOUR DATA = CONTOURS 
4 PLOT Xl * X2 = Z ; 
1 TITLEl ; 
1 TITLE2 H=15 A=90 F=TRIPLEX ; / *PUSH LEFT TO RIGHT */ 
1 TITLE3 H=lO A=O F=TRIPLEX; / *PUSH TOP TO BOTTOM * / 
1 FOOTNOTEl H=l.5 F=TRIPLEX 
2 FIGURE 11 : 3- D PLOT OF MEAN DISSOLUTION TIME DATA'; 
1 // 
This is the end of the SAS program for plotting 
mean in vitro dissolution time data, for three 
dimensional and contour plots. 
This is the start of the SAS programs for plotting 
optimum mean in vitro dissolution time as a function 
of hardness and friability constraints. 
1 //RL0101 JOB (RL0101), ' SHABBIR' ,TIME=(0,59),MSGCLASS=W 
1 / *JOBPARM L=20 
1 / *ROUTE PRINT QMSl 
1 // EXEC SAS 
1 //GO.FTllFOOl DD SYSOUT=A,HOLD=YES 
1 //GO . FT12F001 DD SYSOUT=A,HOLD=YES 
1 //GO . IN DD DSN=RLOlOl.SASJOIN,DISP=OLD 
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( 
1 //GO.QMSOUT DD SYSOUT=A,DEST=QMS1 , 0UTLIM=5000 
1 //GO . SYSIN DD * 
1 GOPTIONS DEVICE=QMS1200E COLORS=(BLACK) HSIZE=6 
VSIZE =6 
10 NOTEXT82 NOCIRCLEARC NOCHARACTERS 
10 NODISPLAY NOPROMPT NOPOLYGONFILL NOFILL 
NODASH 
10 
10 
HANDSHAKE=XONXOFF GSFLEN=200 
GEND='8D8A'X GSFNAME=QMSOUT GSFMODE=REPLACE ; 
1 OPTIONS LS=72; 
1 DATA ALLHARD ; 
1 INPUT HD MDl 
1 HDl=(HD-12.680) / 0.1149; 
1 MDll=(MDl-0.3002) / 0.0046; 
1 HDlSQR=HDl*HDl; 
1 CARDS; 
2 12.54 0.2945 
2 12.55 0 . 2950 
2 12 . 6 0.2970 
2 12.65 0.2990 
2 12.7 0.3010 
2 12.75 0.3030 
2 12.8 0.3050 
2 12.85 0.3069 
2 
1 DATA ALLFR; 
212 
1 INPUT FR MD4 ; 
1 FRl=(FR-0.3009) / 0.0023; 
1 MD4l=(MD4-0.2919) / 0 . 0095; 
1 FRlSQR= FRl * FRl; 
1 CARDS; 
5 0.2984 0.3068 
5 0.2986 0.3046 
5 0.2988 0.3026 
5 0.2990 0.3010 
5 0.2991 0.3002 
5 0.2992 0.2995 ~ 
5 0.2993 0.2988 
5 0.2994 0.2981 
5 0.2995 0.2975 
5 0.2996 0.2967 
5 0.2997 0.2962 
5 0.2998 0.2955 
5 0.2999 0.2950 
5 0.3000 0.2945 
5 0.3001 0.2940 
5 0.3002 0.2934 
5 0.3003 0.2929 
5 0.3004 0.2924 
5 0.3005 0.2919 
5 0.3006 0.2914 
5 0.3008 0.2905 
213 
5 
5 
5 
5 
5 
5 
5 
5 
2 
0 . 3010 
0.3020 
0 . 3030 
0 . 3040 
0 . 3050 
0.3055 
0 . 30575 
0 . 3060 
0.2897 
0.2854 
0 . 2818 
0 . 2786 
0.2755 
0 . 2741 
0 . 2734 
0.2732 
2 PROC PRINT DATA=ALLHARD; 
2 VAR HD MDl HDl MDll; 
2 TITLE ' HARDNESS VS MDT IN STAND.SCORE ALL 
CONSTRAINTS I ; 
2 PROC PRINT DATA=ALLFR; 
2 VAR FR MD4 FRl MD41 
2 TITLE 'FRIABILITY VS MDT IN STAND.SCORE ALL 
CONSTRAINTS I ; 
1 PROC PLOT DATA = ALLHARD; 
4 PLOT MDll *HDl 
2 FOOTNOTEl H=l.5 F=TRIPLEX 
1 FIGURE 1 : OPTIMUM MDT IN VITRO AS FUNCTION 
OF HARDNESS CONSTRAINT'; 
1 TITLEl H=l2 A=90 F=TRIPLEX ; /* PUSH LEFT TO RIGHT */ 
1 TITLE2 H=l2 A=O F=TRIPLEX; /* PUSH TOP TO BOTTOM* / 
1 PROC GPLOT DATA = ALLHARD; 
4 PLOT MDl*HD / OVERLAY HAXIS=AXIS2 VAXIS=AXISl; 
214 
7 AXISl VALUE=(F=TRIPLEX H=l.5) 
13 LABEL=(F =TRIPLEX H=l . 5 A=90 R=O 'TABLET 
HARDNESS (KG)'); 
11 / * ORDER= 0 TO 110 BY 10; */ 
7 AXIS2 VALUE=(F=TRIPLEX H=l.5) 
13 LABEL=(F=TRIPLEX H=l.5 ' MDT IN VITRO 
(HOURS)'); 
7 / * ORDER= 0 TO 45 BY 5 ; */ 
2 TITLE ' HARDNESS VS MDT IN STAND.SCORE ALL 
CONSTRAINTS'; 
1 PROC PLOT DATA =ALLFR; 
4 PLOT MD41* FRl 
2 FOOTNOTEl H=l.5 F=TRIPLEX 
1 FIGURE 2: OPTIMUM MDT IN VITRO AS FUNCTION 
OF PERCENT FRIABILTY'; 
1 TITLEl H=l2 A=90 F=TRIPLEX; / *PUSH LEFT TO RIGHT* / 
1 TITLE2 H=l2 A=O F=TRIPLEX; / *PUSH TOP TO BOTTOM* / 
1 PROC GPLOT DATA =ALLFR; 
4 PLOT MD4*FR / OVERLAY HAXIS=AXIS2 VAXIS=AXISl; 
7 AXISl VALUE=(F=TRIPLEX H=l.5) 
13 LABEL=(F=TRIPLEX H=l.5 A=90 R=O 'PERCENT 
FRIABILITY'); 
11 / * ORDER= 0 TO 110 BY 10; */ 
7 AXIS2 VALUE=(F=TRIPLEX H=l.5) 
13 LABEL=(F=TRIPLEX H=l.5 'MDT IN VITRO 
(HOURS)'); 
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2 / *TITLE ' FRIABILITY VS MDT IN STAND.SCORE ALL 
CONSTRAINTS ' ; * / 
2 PROC STEPWISE DATA=ALLHARD; 
2 MODEL MDll =HDl HDlSQR / STEPWISE MAXR DETAILS ; 
2 / *TITLE ' HARDNESS VS MDT IN STAND.SCORE ALL 
CONSTRAINTS '; * I 
2 PROC STEPWISE DATA=ALLFR ; 
2 MODEL MD4l=FR1 FRlSQR / STEPWISE MAXR DETAILS ; 
2 / *TITLE ' FRIABILITY VS MDT IN STAND.SCORE ALL 
CONSTRAINTS '; * I 
1 // 
This is the end of the SAS programs for plotting 
optimum mean in vitro dissolution time as a function 
of hardness and friability constraints. 
This is the start of the SAS program for calculating 
the response surface equation for crushing strengths 
of the tablets obtained from nine formulations of the 
optimization study . The weights used are the 
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1 
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1 
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2 
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1 
1 
reciprocal of the variance of each tablet formulation 
mean . 
llRLOlOl JOB ( RLOlOl) , 'SHABBIR ' , NOTIFY=RLOlOl , 
MSGCLASS=W 
/ *ROUTE PRINT DSPl 
l *JOBPARM LINES =5 
II EXEC SAS 
11 *0.FTllFOOl DD DSN=URI.RLOlOl . RESULTl,DISP=OLD 
ll *O.FT12F001 DD DSN=URI.RL0101.RESULT2,DISP=OLD 
llGO.FTllFOOl DD SYSOUT= * 
llGO.FT12F001 DD SYSOUT= * 
llGO . SYSIN DD * 
OPTIONS LS =72 ; 
DATA HARDNESS ; 
INPUT Xl X2 Yl W; 
XlS!;)R Xl * Xl; 
X2S!;)R X2 * X2; 
XlX2 Xl * X2; 
CARDS; 
1. 0 0.0 13.475 0.3996 
0.5 0 . 866 11.820 0.5739 
- 0.5 0 . 866 8.985 1.2291 
- 1. 0 0.0 7 . 655 2 . 2957 
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f 1 
2 
2 
2 
2 
2 
- 0.5 
0 . 5 
0.0 
0.0 
0 . 0 
-0.866 8.965 
- 0 . 866 13 . 270 
0.0 10.670 
0.0 10.710 
0.0 10.245 
2.0823 
0.3468 
0.5312 
0.9745 
0.5561 
1 PROC REG DATA=HARDNESS; WEIGHT W; 
1 MODEL Yl= Xl / ALL ; 
1 OUTPUT OUT=STATS P=PREDICT R=RESIDUAL; 
1 PROC PLOT DATA=STATS; 
1 PLOT RESIDUAL * Xl ='U'; 
1 PLOT RESIDUAL * X2 = ' V' ; 
1 PLOT RESIDUAL * XlX2 = ' W'; 
1 PLOT RESIDUAL * PREDICT ='X'; 
1 PROC PRINT; 
1 // 
This is the end of the SAS program for calculating 
the response surface equation for crushing strengths 
of the tablets obtained from nine formulations of the 
optimization study. 
This is the start of the SAS program for calculating 
the response surface equation for disintegration time 
data of the tablets obtained from nine formulations 
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( of the optimization study. The weights used are the 
c -
reciprocal of the variance of each tablet formulation 
mean . 
1 //RLOlOl JOB(RLOlOl) , ' SHABBIR ' , NOTIFY=RLOlOl, 
MSGCLASS =W 
1 / *ROUTE PRINT DSPl 
1 / *JOBPARM LINES =5 
1 II EXEC SAS 
1 // *0.FTllFOOl DD DSN=URI . RLOlOl.RESULTl,DISP=OLD 
1 //* 0 . FT12F001 DD DSN=URI.RL0101.RESULT2,DISP=OLD 
.... 
1 //GO.FTllFOOl DD SYSOUT= * 
1 //GO.FT12F001 DD SYSOUT= * 
1 //GO.SYSIN DD * 
1 OPTIONS LS=72 ; 
1 DATA HARDNESS; 
1 INPUT Xl X2 Yl W; 
1 XlSQR Xl * Xl ; 
1 X2SQR X2 * X2 ; 
1 XlX2 Xl * X2 ; 
1 CARDS ; 
2 1. 0 0.0 8.625 12 . 398 
2 0.5 0.866 6 . 014 11.261 
1 - 0 . 5 0.866 3 . 444 132 . 118 
1 - 1. 0 0.0 3 . 367 45.043 
1 - 0 . 5 - 0 . 866 5 . 439 22.461 
( 
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( 2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
( 
0.5 - 0.866 9 . 128 4.432 
0 . 0 0 . 0 6.072 8 . 210 
0.0 0 . 0 5 . 683 10. 142 
0 . 0 0.0 6 . 533 21.836 
PROC REG DATA=HARDNESS; WEIGHT W; 
MODEL Yl = Xl X2 / ALL ; 
OUTPUT OUT=STATS P=PREDICT R=RESIDUAL; 
PROC PLOT DATA=STATS ; 
PLOT RESIDUAL * Xl = ' U'; 
PLOT RESIDUAL * X2 = ' V ' ; 
... 
PLOT RESIDUAL * XlX2 = ' W'; 
PLOT RESIDUAL * PREDICT = ' XI ; 
PROC PRINT ; 
II 
This is the end of the SAS program for calculating 
the response surface equation for disintegration time 
data of the tablets obtained from nine formulations 
of the optimization study . 
This is the start of the SAS program for calculating 
the response surface equation for ejection force data 
of the tablets obtained from nine formulations of the 
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optimization study . The weights used are the 
reciprocal of the variance of each tablet formulation 
mean. 
1 // RLOlOl JOB ( RLOlOl ), ' SHABBIR ' ,NOTIFY=RLOlOl , 
MSGCLASS =W 
1 / *ROUTE PRINT DSPl 
1 / *JOBPARM LINES=5 
1 // EXEC SAS 
1 // *0.FTllFOOl DD DSN=URI.RLOlOl.RESULTl , DISP=OLD 
1 // *0 . FT12F001 DD DSN=URI.RL0101.RESULT2,DISP=OLD 
1 // GO . FTllFOOl DD SYSOUT= * 
1 // GO . FT12F001 DD SYSOUT= * 
1 //GO . SYSIN DD * 
1 OPTIONS LS=72; 
1 DATA HARDNESS; 
1 INPUT Xl X2 Yl W; 
1 Yl =Yl / 1000; 
1 XlSQR Xl * Xl; 
1 X2SQR X2 * X2; 
1 XlX2 Xl * X2; 
1 CARDS; 
2 
2 
1 
1 
1. 0 
0.5 
- 0 . 5 
- 1. 0 
0 . 0 613.17 
0.866 581.18 
0.866 450.53 
0.0 397.05 
8573 . 4 
1402.7 
2890 . 5 
2104 . 2 
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( 1 
2 
2 
2 
2 
2 
-0.5 
0.5 
0.0 
0 . 0 
0.0 
-0.866 462 . 77 
- 0 . 866 603.90 
0.0 542 . 36 
0 . 0 533 . 49 
0 . 0 532.99 
2104.2 
4890.2 
1303.3 
1197.3 
1096.4 
1 PROC REG DATA=HARDNESS; WEIGHT W; 
1 MODEL Yl= Xl XlS~R / ALL; 
1 OUTPUT OUT=STATS P=PREDICT R=RESIDUAL; 
1 PROC PLOT DATA=STATS; 
1 PLOT RESIDUAL * Xl ='U'; 
1 PLOT RESIDUAL * X2 ='V'; 
1 PLOT RESIDUAL * XlX2 ='W'; 
1 PLOT RESIDUAL * PREDICT ='X'; 
1 // 
This is the end of the SAS program for calculating 
the response surface equation for ejection force data 
of the tablets obtained from nine formulations of the 
optimization study. 
This is the start of the SAS program for calculating 
the response surface equation for percent friability 
data of the tablets obtained from nine formulations 
of the optimization study. 
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( 
( 
1 //RLOlOl JOB(RLOlOl ), ' SHABBIR' ,NOTIFY=RLOlOl, 
MSGCLASS =W 
1 / *ROUTE PRINT DSPl 
1 / *JOBPARM LINES =5 
1 // EXEC SAS 
1 // *0.FTllFOOl DD DSN =URI . RLOlOl.RESULTl,DISP=OLD 
1 // *0.FT12F001 DD DSN=URI.RL0101 . RESULT2,DISP=OLD 
1 //GO.FTllFOOl DD SYSOUT =* 
1 // GO.FT12F001 DD SYSOUT= * 
1 // GO.SYSIN DD * 
1 OPTIONS LS=72; 
1 DATA HARDNESS ; 
1 INPUT Xl X2 Yl 
1 XlSQR Xl * Xl ; 
1 X2SQR 
1 XlX2 
1 CARDS; 
X2 * X2 ; 
Xl * X2 ; 
2 1.0 0.0 0 . 294 
2 
1 
1 
1 
2 
2 
2 
2 
0 . 5 
- 0.5 
- 1. 0 
-0.5 
0.5 
0.0 
0.0 
0 . 0 
0.866 0.344 
0.866 0.419 
0.0 0 . 496 
-0.866 0 . 422 
-0 . 866 0.291 
0.0 0.353 
0.0 0.296 
0.0 0 . 328 
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2 
1 PROC REG DATA=HARDNESS ; 
1 MODEL Yl = Xl XlS~R / ALL ; 
1 OUTPUT OUT=STATS P=PREDICT R=RESIDUAL; 
1 PROC PLOT DATA=STATS; 
1 PLOT RESIDUAL * Xl =' U'; 
1 PLOT RESIDUAL * X2 = ' V'; 
1 PLOT RESIDUAL * XlX2 = ' W' ; 
1 PLOT RESIDUAL * PREDICT =' X'; 
1 PROC PRINT; 
1 // 
This is the end of _the SAS program for calculating 
the response surface equation for percent friability 
data of the tablets obtained from nine formulations 
of the optimization study . 
This is the start of the SAS program for calculating 
the response surface equation for mean in vitro 
dissol~tion data of the tablets obtained from nine 
formulations of the optimization study. 
1 //RLOlOl JOB(RLOlOl) , ' SHABBIR ' ,NOTIFY=RLOlOl, 
MSGCLASS=W 
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1 / *ROUTE PRINT DSPl 
1 / *JOBPARM LINES=5 
1 // EXEC SAS 
1 // *0 . FTllFOOl DD DSN=URI . RLOlOl.RESULTl , DISP=OLD 
1 // *0.FT12F001 DD DSN=URI.RL0101.RESULT2 , DISP=OLD 
1 //GO.FTllFOOl DD SYSOUT= * 
1 // GO.FT12F001 DD SYSOUT =* 
1 //GO . SYSIN DD * 
1 OPTIONS LS=72; 
1 DATA HARDNESS; 
1 INPUT Xl X2 Yl 
1 X1S"1R 
1 X2S"1R 
1 XlX2 
1 CARDS; 
2 
2 
1 
1 
1 
2 
2 
2 
2 
2 
l. 0 
0 . 5 
-0.5 
-1. 0 
-0.5 
0.5 
0.0 
0.0 
0.0 
Xl * Xl; 
X2 * X2; 
Xl * X2; 
0.0 0.3573 
0.866 0.2536 
0.866 0. 1646 
0.0 0. 1496 
-0.866 0.1847 
-0.866 0 . 4038 
0.0 0 . 2652 
0.0 0 . 2657 
0.0 0.2963 
1 PROC REG DATA=HARDNESS; 
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1 
1 
1 
1 
1 
1 
1 
1 
1 
MODEL Yl= Xl X2 / ALL; 
OUTPUT OUT=STATS P=PREDICT R=RESIDUAL; 
PROC PLOT DATA=STATS; 
PLOT RESIDUAL * Xl ='U'; 
PLOT RESIDUAL * X2 ='V'; 
PLOT RESIDUAL * XlX2 ='W'; 
PLOT RESIDUAL * PREDICT ='X'; 
PROC PRINT; 
II 
This is the end of the SAS program for calculating 
the response surface equation for mean in vitro 
dissolution data of the tablets obtained from nine 
formulations of the optimization study. 
This is the start of the SAS programs for performing 
the principal component analysis, for the nine tablet 
formulations in the optimization study. 
1 //RLOlOl JOB(RL0101), 'SHABBIR' ,NOTIFY=RL0101, 
MSGCLASS=W 
1 / *ROUTE PRINT PRO 
1 / *JOBPARM LINES=5 
1 // EXEC SAS,PLOTDSN= ' RLOlOl.PLOTFILE' ,REWIND=YES 
1 // *0 . FTllFOOl DD DSN=URI.RLOlOl.RESULTl,DISP=OLD 
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( 1 ll *O.FT12F001 DD DSN=URI.RL0101.RESULT2,DISP=OLD 
1 llGO.FTllFOOl DD SYSOUT =* 
1 llGO.FT12F001 DD SYSOUT= * 
1 ll GO . SYSIN DD * 
1 DATA HARDNESS; 
1 INPUT EU $1-7 HD FR DT MD 
1 HD=(HD- 10 . 6456) 1 (1.9680); 
1 FR=(FR-0.360333) 1(0.07103); 
1 DT=(DT-6 . 03333) 1 (1.96457); 
1 MD=(MD-0.260089) 1 (0.08553); 
1 CARDS; 
1 ONE 13.48 0.294 8.63 0 . 3573 
1 TWO 11.82 0.344 6 . 01 0.2536 
1 THREE 8.99 0.419 3.44 0.1646 
1 FOUR 7.65 0.496 3.37 0. 1496 
1 FIVE 8.97 0.422 5.44 0.1847 
1 SIX 13.27 0.291 9. 13 0 . 4038 
1 SEVEN 10.67 0 . 353 6.07 0.2652 
1 EIGHT 10.71 0.296 5.68 0.2657 
1 NINE 10.25 0.328 6.53 0 . 2963 
2 
1 PROC PRINCOMP STD COV OUT=PRIN 
4 VAR HD FR DT MD 
1 PROC PRINT 
1 I I 
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This is the end of the SAS programs for performing 
the principal component analysis , for the nine tablet 
formulations in the optimization study . 
This is the start of the SAS program for formating 
and printing the simulation results . 
1 // RLOlOlM JOB(RLOlOl), ' SHABBIR' ,NOTIFY=RLOlOl, 
MSGCLASS=W,TIME=(0,59) 
1 / *ROUTE PRINT DSPl 
1 / *JOBPARM LINES=lO 
1 // EXEC SAS 
1 // GO.FTllFOOl DD SYSOUT=* 
1 // GO.FT12F001 DD SYSOUT= * 
1 // GO.DATAIN DD DSN=RL0101.P,DISP=OLD 
1 //GO.SYSIN DD * 
1 OPTIONS NOCENTER; 
1 DATA ONE; INFILE DATAIN ; INPUT #1 CHAR $CHAR80. ; 
1 DEP=SUBSTR(CHAR , 2,3) ; 
1 MODEL=SUBSTR(CHAR , 10,5); 
1 RSQUARE=SUBSTR(CHAR , 40 , 8); 
1 DATA T ; SET ONE; 
4 IF DEP='DEP' THEN DO; 
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4 Y=SUBSTR(CHAR,16,2); 
4 OUTPUT T; 
4 END ; 
4 KEEP Y; 
1 DATA TWO ; SET ONE; 
4 IF MODEL='MODEL ' THEN DO; 
4 F=INPUT(SUBSTR(CHAR,54,7) , 7 . 3); 
4 P=INPUT(SUBSTR(CHAR , 65,9),9.4); 
4 OUTPUT TWO; 
4 END; 
4 KEEP F P; 
1 DATA THREE; SET ONE; 
1 IF RSQUARE='R-SQUARE' THEN DO; 
R_SQUARE=INPUT(SUBSTR(CHAR,52,9),9.4); 
32 OUTPUT THREE; END; 
4 KEEP R_SQUARE; 
1 DATA FOUR; SET ONE; 
1 IF RSQUARE='ADJ R- SQ' THEN DO; 
ADJ_R_SQ=INPUT(SUBSTR(CHAR,52,9),9.4); 
32 OUTPUT FOUR; END; 
4 KEEP ADJ_R_SQ; 
1 DATA ALL; MERGE T TWO THREE FOUR; 
1 TITLE' DATA OF FILE ALL AFTER MERGE NO SORT'; 
1 PROC PRINT DATA=ALL; 
2 /* PROC SORT; BY Y;* / 
1 PROC SORT DATA=ALL; BY Y F P R_SQUARE ADJ_R_SQ; 
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1 TITLE' DATA OF FILE ALL AFTER SORT'; 
1 PROC PRINT DATA=ALL; 
1 PROC MEANS DATA=ALL N MEAN STD MIN MAX; 
1 BY Y 
3 VAR F P R_SQUARE ADJ_R_SQ; 
1 // 
This is the end of the SAS program for formating 
and printing the simulation results. 
This is the start of the SAS program for simulating 
new compression force values within the standard 
deviations limits and obtaining the response surface 
equations for mean values of tablet in vitro 
properties as orignally obtained for the nine 
formulations of the optimization study. 
1 // RLOlOl JOB(RLOlOl), 'SHABBIR' ,NOTIFY=RLOlOl, 
MSGCLASS=W,TIME=4 
1 / *ROUTE PRINT LOCAL 
1 / *JOBPARM LINES=lO 
1 // EXEC SAS 
1 // *0.FTllFOOl DD DSN=URI.RLOlOl.RESULTl,DISP=OLD 
1 // *0.FT12F001 DD DSN=URI . RL0101.RESULT2,DISP=OLD 
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( 1 //GO . FTllFOOl DD SYSOUT =* 
1 //GO . FT12F001 DD SYSOUT=* 
1 //GO . SYSIN DD * 
1 OPTIONS LS =72 ; 
1 DATA HARDNESS ; 
1 INPUT Xl X2 Yl Y2 Y3 Y4 Y5 
1 XlSQR Xl * Xl ; 
1 X2SQR X2 * X2 ; 
1 XlX2 Xl * X2 ; 
1 CARDS ; 
2 1. 0 0.0 0.3573 8 . 63 0.294 13.48 613.2 
2 0.5 0 . 866 0 . 2536 6.01 0.344 11 . 82 581 . 2 
1 -0 . 5 0 . 866 0 .1646 3 . 44 0.419 8 . 99 450 . 5 
1 - 1. 0 0 . 0 0 .1496 3 . 37 0.496 7.66 397.1 
1 - 0.5 - 0 . 866 0. 1847 5.44 0 . 422 8.97 462.8 
2 0.5 -0.866 0.4038 9.13 0.291 13.27 603 . 9 
2 0 . 0 0.0 0.2652 6 . 07 0.353 10.67 542 . 4 
2 0.0 0.0 0.2657 5 . 68 0.296 10.71 533.5 
2 0 . 0 0.0 0 . 2963 6 . 53 0.328 10.25 533 . 0 
2 
2 DATA NEW; 
1 DO M=l TO 30; 
1 *--------STARTING VALUES FOR ENDOGENOUS------- ; 
2 Yl =O; Y2 =0; Y3=0; Y4=0 ; Y5 =0; 
1 DO N=l TO 9; 
2 Yl=O ; Y2 =0 ; Y3 =0 ; Y4=0 ; Y5=0 ; 
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1 *-------GENERATE EXOGENOUS----------------; 
1 IF N=l THEN DO; Mll =l.O; Sll=.088; Ml2=0; 
1 Xl = Mll + Sll *NORMAL(l23871); X2=Ml2; 
1 XlSQR=Xl *Xl; 
1 Yl=0.3573;Y2=8.625;W2=12 . 398; Y3=0.294 ; 
1 Y4=13.475;W4=0.3996;Y5=613.17;W5=0.0086; 
1 END; 
1 ELSE IF N=2 THEN DO; M21=0.5;S21=0.09l;M22=0.866; 
1 Xl= M21 + S2l*NORMAL(l23871); X2=M22; 
1 ~lSQR=Xl*Xl; 
1 Yl=0.2536;Y2=6.014;W2=11.26l;Y3=0.344; 
1 Y4=11.820;W4=0.5739;Y5= 581.18;W5=0.0014; 
1 END; 
1 ELSE IF N=3 THEN DO; M31=-0.5;S31=0.065;M32=0.866; 
1 Xl= M31 + S3l *NORMAL(l23871); X2=M22; 
1 XlSQR=Xl*Xl; 
1 Yl=0.1646;Y2=3.444;W2=132.118;Y3=0.419; 
1 Y4=8.985;W4=1.229l;Y5=450.53;W5=0.0029; 
1 END; 
1 ELSE IF N=4 THEN DO; M41=-l.O;S41=0.052;M42=0.00; 
1 Xl= M41 + S4l*NORMAL(l23871); X2=M42; 
1 XlSQR=Xl*Xl; 
1 Yl=0.1496;Y2=3 . 367;W2=45 . 043;Y3=0.496; 
1 Y4=7.655;W4=2.2957;Y5=397.05;W5=0.0021; 
1 END; 
1 ELSE IF N=5 THEN DO; M51=-0.5;S51=0.067;M52=-0.866; 
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( 1 Xl= M51 + S5l*NORMAL(l23871); X2 =M52; 
1 XlSQR=Xl *Xl; 
1 Yl=0.1847;Y2=5.439;W2=22.46l;Y3=0.422; 
1 Y4=8.965;W4=2.0823;Y5=462.77;W5=0.0021; 
1 END; 
1 ELSE IF N=6 THEN DO; M61=0.5 ; S61=0.102 ; M62=-0 . 866 ; 
1 Xl= M61 + S6l *NORMAL(l23871) ; X2=M62; 
1 XlSQR=Xl *Xl; 
1 Yl=0 . 4038;Y2=9.128;W2=4.432;Y3=0.291; 
1 Y4=13.270;W4=0.3468;Y5=603.90 ; W6=0.0049; 
1 END; 
1 ELSE IF N=7 THEN DO ; M71=0 . 0;S71=0.056 ; M72=0.0; 
1 Xl= M71 + S7l*NORMAL(l23871); X2=M72; 
1 XlSQR=Xl*Xl; 
1 Yl=0.2652;Y2=6.072;W2=8 . 210;Y3=0.353 ; 
1 Y4=10.670;W4=0.5312;Y5=542 . 36;W5=0.0013; 
1 END; 
1 ELSE IF N=8 THEN DO; M81=0 . 0;S81=0 . 079;M82=0.0; 
1 Xl = M81 + S8l *NORMAL(l23871) ; X2 =M82; 
1 XlSQR=Xl*Xl; 
1 Yl=0.2657;Y2=5.683;W2=10.142;Y3=0.296; 
1 Y4=10 . 710;W4=0.9745;Y5=533.49 ; W5=0.0012; 
1 END; 
1 ELSE IF N=9 THEN DO;M91=0.0;S91=0.085;M92=0.0; 
1 Xl= M91 + S9l *NORMAL(l23871); X2=M92; 
1 XlSQR=Xl*Xl; 
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1 Yl=0.2963;Y2=6.533;W2=21.836;Y3=0 . 328; 
1 Y4=10.245 ; W4=0.556l;Y5=532.99 ; W5 =@.U01 ; 
13 END; 
1 OUTPUT; 
1 END; 
1 END; 
1 PROC PRINT DATA=NEW; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
1 DATA Al; SET NEW; 
1 IF (_N_ <=9) ; 
1 PROC PRINT DATA=Al 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
1 DATA A2 ; SET NEW; 
1 IF (_N_ >9 AND _N_ <=l8); 
1 PROC PRINT DATA=A2 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A3; SET NEW; 
1 IF (_N_ >l8 AND _N_ <=27); 
1 PROC PRINT DATA=A3 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A4 ~ SET NEW ; 
1 IF (_N_ >27 AND _N_ <=36) ; 
1 PROC PRINT DATA=A4 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
1 DATA A5; SET NEW; 
1 IF (_N_ >36 AND _N_ <=45) ; 
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( 1 PROC PRINT DATA=A5 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A6; SET NEW; 
1 IF (_N_ >45 AND _N_ <=54); 
1 PROC PRINT DATA=A6 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A7; SET NEW ; 
1 IF (_N_ >54 AND _N_ <=63); 
1 PROC PRINT DATA=A7 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A8; SET NEW; 
1 IF (_N_ >63 AND _N_<=72); 
1 PROC PRINT DATA=A8 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A9; SET NEW; 
1 IF (_N_ >72 AND _N_ <=81); 
1 PROC PRINT DATA=A9 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA AlO; SET NEW; 
1 IF (_N_ >81 AND _N_ <=90); 
1 PROC PRINT DATA=AlO; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA All; SET NEW; 
1 IF (_N_ >90 AND _N_ <=99 ); 
1 PROC PRINT DATA=All; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
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( 1 DATA Al2; SET NEW; 
1 IF (_N_ >99 AND _ N_ <=l 08) ; 
1 PROC PRINT DATA=Al2 , 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al3 ; SET NEW ; 
1 IF (_N_ >l08 AND _ N_ <=ll7) ; 
1 PROC PRINT DATA=Al3 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al4; SET NEW; 
1 IF (_N_>ll7 AND _ N_ <=l26); 
1 PROC PRINT DATA=Al4 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al5; SET NEW; 
1 IF (_N_ >l26 AND _ N_ <=l35); 
1 PROC PRINT DATA=Al5 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al6; SET NEW; 
1 IF (_N_>l35 AND _N_<=l44); 
1 PROC PRINT DATA=Al6 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al7; SET NEW; 
1 IF (_N_>l44 AND _N_ <=l53); 
1 PROC PRINT DATA=Al7 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al8; SET NEW; 
1 IF (_N_ >l53 AND _N_ <=l62); 
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1 PROC PRINT DATA=Al8 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA Al9; SET NEW; 
1 IF (_N_ >l62 AND _N_ <= l71); 
1 PROC PRINT DATA =Al9 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
1 DATA A20; SET NEW; 
1 IF (_N_ >l71 AND _N_<=l80); 
1 PROC PRINT DATA=A20; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A21 ; SET NEW; 
1 IF (_N~> l80 AND _ N_ <= l89); 
1 PROC PRINT DATA=A21; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
1 DATA A22; SET NEW; 
1 IF (_N_ >l89 AND _N_<=l98); 
1 PROC PRINT DATA=A22 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
1 DATA A23; SET NEW; 
1 IF (_N_>l98 AND _N_ <= 207) ; 
1 PROC PRINT DATA=A23 , 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A24; SET NEW; 
1 IF ( _N_ >207 AND _N_<=216); 
1 PROC PRINT DATA=A24 ; 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5 ; 
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( 
DATA A25; SET NEW; 
l IF (_N_ , 216 AND _N_ <=225); 
1 PROC PRINT DATA=A25 , 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A26; SET NEW; 
1 IF (_N_ >225 AND _ N_ <=234); 
1 PROC PRINT DATA=A26 , 
1 VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
1 DATA A27; SET NEW; 
1 IF (_N_ >234 AND _N_ <=243); 
~ PROC PRINT DATA=A27 ; 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
DATA A28; SET NEW; 
IF (_N_ >243 AND _N_ <=252); 
PROC PRINT DATA=A28 , 
VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
DATA A29; SET NEW; 
IF (_N_ >252 AND _N_ <=261); 
PROC PRINT DATA=A29 , 
VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
DATA A30 ; SET NEW; 
IF (_N_ >261 AND _N_ <=270); 
PROC PRINT DATA=A30; 
VAR Xl X2 Yl Y2 Y3 Y4 Y5; 
PROC REG DATA=Al OUTEST=AOll; 
MODEL Yl=Xl X2 , 
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1 PROC REG DATA=Al OUTEST=A012;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=Al OUTEST=A013 ; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al OUTEST=A014;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al OUTEST=A015;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #l' , 
1 PROC REG DATA=A2 OUTEST=A021; 
1 MODEL Yl =Xl X2 , 
1 PROC REG DATA=A2 OUTEST=A022;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=A2 OUTEST=A023; 
1 MODEL Y3=Xl XlS~R; 
1 PROC REG DATA=A2 OUTEST=A024 ; WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A2 OUTEST=A025 ; WEIGHT W5 ; 
1 MODEL Y5=Xl XlS~R; 
1 TITLE 'END OF SIMULATION #2' , 
1 PROC REG DATA=A3 OUTEST=A031; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=A3 OUTEST=A032;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A3 OUTEST=A033; 
1 MODEL Y3=Xl XlS~R; 
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( 1 PROC REG DATA=A3 OUTEST=A034;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A3 OUTEST=A035;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE ' END OF SIMULATION #3 ' , 
1 PROC REG DATA=A4 OUTEST=A041; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=A4 OUTEST=A042;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A4 OUTEST=A043; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A4 OUTEST=A044;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A4 OUTEST=A045 ; WEIGHT W5 ; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #4' , 
1 PROC REG DATA=A5 OUTEST=A051 ; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A5 OUTEST=A052 ; WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=A5 OUTEST=A053; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A5 OUTEST=A054;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A5 OUTEST=A055;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
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( 1 TITLE 'END OF SIMULATION i5' ; 
1 PROC REG DATA=A6 OUTEST=A061 ; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A6 OUTEST=A062;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=A6 OUTEST=A063; 
1 MODEL Y3=Xl XlS~R; 
1 PROC REG DATA=A6 OUTEST=A064;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A6 OUTEST=A065;WEIGHT W5; 
1 MODEL Y5=Xl XlS~R; 
1 TITLE 'END OF SIMULATION i6' , 
1 PROC REG DATA=A7 OUTEST=A071; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=A7 OUTEST=A072;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=A7 OUTEST=A073; 
1 MODEL Y3=Xl XlS~R; 
1 PROC REG DATA=A7 OUTEST=A074;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A7 OUTEST=A075;WEIGHT W5; 
1 MODEL Y5=Xl XlS~R; 
1 TITLE 'END OF SIMULATION i7'; 
1 PROC REG DATA=A8 OUTEST=A081; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=A8 OUTEST=A082;WEIGHT W2; 
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( 
( 
1 MODEL Y4=Xl; 
1 PROC REG DATA=AlO OUTEST=Al05;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #10'; 
1 PROC REG DATA=All OUTEST=Alll; 
1 MODEL Yl=Xl X2 ; 
c -
1 PROC REG DATA=All OUTEST=All2;WEIGHT W2 ; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=All OUTEST=All3; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=All OUTEST=All4;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=All OUTEST=All5;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #11' ; 
1 PROC REG DATA=Al2 OUTEST=Al21; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=Al2 OUTEST=Al22;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=Al2 OUTEST=Al23; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al2 OUTEST=Al24;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al2 OUTEST=Al25;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #12' 
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1 PROC REG DATA=Al3 OUTEST=Al31; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=Al3 OUTEST=Al32;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=Al3 OUTEST=Al33; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al3 OUTEST=Al34;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al3 OUTEST=Al35;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #13' , 
1 PROC REG DATA=Al4 OUTEST=Al41; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=Al4 OUTEST=Al42;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=Al4 OUTEST=Al43; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A14 OUTEST=Al44;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al4 OUTEST=Al45;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #14' , 
1 PROC REG DATA=A15 OUTEST=Al51; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=A15 OUTEST=Al52;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
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( 1 PROC REG DATA=Al5 OUTEST=Al53; 
1 MODEL Y3=Xl XlSQR ; 
1 PROC REG DATA=Al5 OUTEST=Al54;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al5 OUTEST=Al55;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #15' 
' 
1 PROC REG DATA=Al6 OUTEST=Al61; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=Al6 OUTEST=Al62;WEIGHT W2; 
1 MODEL Y2=Xl X2 
' 
... 
1 PROC REG DATA=Al6 OUTEST=Al63; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al6 OUTEST=Al64;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al6 OUTEST=Al65;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #16' 
' 
1 PROC REG DATA=Al7 OUTEST=Al71; 
1 MODEL Yl=Xl X2 
' 
1 PROC REG DATA=Al7 OUTEST=Al72;WEIGHT W2; 
_1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=Al7 OUTEST=Al73; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al7 OUTEST=Al74;WEIGHT W4; 
1 MODEL Y4=Xl; 
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( 
1 PROC REG DATA=Al7 OUTEST=Al75;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE ' END OF SIMULATION #17'; 
1 PROC REG DATA=Al8 OUTEST=Al81; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=Al8 OUTEST=Al82;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=Al8 OUTEST=Al83; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al8 OUTEST=Al84;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al8 OUTEST=Al85;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #18' , 
1 PROC REG DATA=Al9 OUTEST=Al91; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=Al9 OUTEST=Al92;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=Al9 OUTEST=Al93; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=Al9 OUTEST=Al94;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=Al9 OUTEST=Al95;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #19'; 
1 PROC REG DATA=A20 OUTEST=A201; 
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( 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A20 OUTEST=A202;WEI,.GHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A20 OUTEST=A203; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A20 OUTEST=A204;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A20 OUTEST=A205;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #20'; 
1 PROC REG DATA=A21 OUTEST=A211; 
1 MODEL Yl=Xl X2 , 
1 PROC REG DATA=A21 OUTEST=A212;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A21 OUTEST=A213; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A21 OUTEST=A214;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A21 OUTEST=A215;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #21' ; 
1 PROC REG DATA=A22 OUTEST=A221; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A22 OUTEST=A222;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A22 OUTEST=A223; 
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1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A22 OUTEST=A224;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A22 OUTEST=A225;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #22' , 
1 PROC REG DATA=A23 OUTEST=A231; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A23 OUTEST=A232;WEIGHT W2; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A23 OUTEST=A233; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A23 OUTEST=A234;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A23 OUTEST=A235;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #23' ; 
1 PROC REG DATA=A24 OUTEST=A241; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A24 OUTEST=A242;WEIGHT W2; 
1 MODEL Y2=Xl X2 , 
1 PROC REG DATA=A24 OUTEST=A243; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A24 OUTEST=A244;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A24 OUTEST=A245;WEIGHT W5; 
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( 1 MODEL Y5=Xl XlSQR; 
1 TITLE 'END OF SIMULATION #24' ; 
1 PROC REG DATA=A25 OUTEST=A251; 
1 MODEL Yl=Xl X2 
' 
1 PROC REG DATA=A25 OUTEST=A252;WEIGHT W2; 
1 MODEL Y2=Xl X2 
' 
1 PROC REG DATA=A25 OUTEST=A253; 
1 MODEL Y3=Xl XlSQR; 
1 PROC REG DATA=A25 OUTEST=A254;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A25 OUTEST=A255;WEIGHT W5; 
... 
1 MODEL Y5=Xl XlSC\)R; 
1 TITLE 'END OF SIMULATION #25' ; 
( 1 PROC REG DATA=A26 OUTEST=A26 l ; 
1 MODEL Yl=Xl X2 
' 
1 PROC REG DATA=A26 OUTEST=A262;WEIGHT W2; 
1 MODEL Y2=Xl X2 
' 
1 PROC REG DATA=A26 OUTEST=A263; 
1 MODEL Y3=Xl XlSC\)R; 
1 PROC REG DATA=A26 OUTEST=A264;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A26 OUTEST=A265;WEIGHT W5; 
1 MODEL Y5=Xl XlSC\)R; 
1 TITLE 'END OF SIMULATION #26' ; 
1 PROC REG DATA=A27 OUTEST=A27 l ; 
1 MODEL Yl=Xl X2 ; 
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( 1 PROC REG DATA=A27 OUTEST=A272 ; WEIGHT W2; 
1 MODEL Y2 =Xl X2 
' 
1 PROC REG DATA=A27 OUTEST=A273 ; 
1 MODEL Y3 =Xl XlSQR ; 
1 PROC REG DATA=A27 OUTEST=A274 ; WEIGHT W4 ; 
1 MODEL Y4 =Xl ; 
1 PROC REG DATA=A27 OUTEST=A275 ;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR ; 
1 TITLE 'END OF SIMULATION t l7' ; 
1 PROC REG DATA=A28 OUTEST=A281; 
1 MODEL Yl=Xl X2 
' ... 
1 PROC REG DATA=A28 OUTEST=A282 ; WEIGHT W2; 
1 -MODEL Y2=Xl X2 
' 
( 1 PROC REG DATA=A28 OUTEST=A283 ; 
1 MODEL Y3=Xl XlSQR ; 
1 PROC REG DATA=A28 OUTEST=A284 ; WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A28 OUTEST=A285 ; WEIGHT W5 ; 
1 MODEL Y5=Xl XlSQR ; 
1 TITLE ' END OF SIMULATION t28' 
' 
1 PROC REG DATA=A29 OUTEST=A291 ; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A29 OUTEST=A292 ;WEIGHT W2 ; 
1 MODEL Y2=Xl X2 ; 
1 PROC REG DATA=A29 OUTEST=A293 ; 
1 MODEL Y3=Xl XlSQR ; 
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1 PROC REG DATA=A29 OUTEST=A294;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A29 OUTEST=A295 ; WEIGHT W5 ; 
1 MODEL Y5 =Xl XlSt;)R; 
1 TITLE ' END OF SIMULATION #29 '; 
1 PROC REG DATA=A30 OUTEST=A301; 
1 MODEL Yl=Xl X2 ; 
1 PROC REG DATA=A30 OUTEST=A302 ; WEIGHT W2; 
1 MODEL Y2 =Xl X2 ; 
1 PROC REG DATA=A30 OUTEST=A303; 
1 MODEL Y3=Xl XlSt;)R ; 
1. 
1 PROC REG DATA=A30 OUTEST=A304;WEIGHT W4; 
1 MODEL Y4=Xl; 
1 PROC REG DATA=A30 OUTEST=A305;WEIGHT W5; 
1 MODEL Y5=Xl XlSQR ; 
1 TITLE 'END OF SIMULATION #30 ' ; 
1 DATA JOINl; 
1 SET AOll A012 A013 A014 A015 A021 A022 A023 A024 A025 
5 A031 A032 A033 A034 A035 A041 A042 A043 A044 A045 
5 A051 A052 A053 A054 A055 A061 A062 A063 A064 A065 
5 A071 A072 A073 A074 A075 A081 A082 A083 A084 A085 
5 A091 A092 A093 A094 A095 AlOl Al02 Al03 Al04 Al05 
5 Alll All2 All3 All4 All5 Al21 Al22 Al23 Al24 Al25 
5 Al31 Al32 Al33 Al34 Al35 Al41 Al42 Al43 Al44 Al45 
5 Al51 Al52 Al53 Al54 Al55 Al61 Al62 Al63 Al64 Al65 
5 Al71 Al72 Al73 Al74 Al75 Al81 Al82 Al83 Al84 Al85 
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( 
r 
l 
5 Al91 Al92 Al93 Al94 Al95 A201 A202 A203 A204 A205; 
1 DATA JOIN2; 
1 SET A211 A212 A213 A214 A215 A221 A222 A223 A224 A225 
5 A231 A232 A233 A234 A235 A241 A242 A243 A244 A245 
5 A251 A252 A253 A254 A255 A261 A262 A263 A264 A265 
5 A271 A272 A273 A274 A275 A281 A282 A283 A284 A285 
5 A291 A292 A293 A294 A295 A301 A302 A303 A304 A305; 
1 DATA JOIN; SET JOINl JOIN2; 
1 PROC PRINT DATA= JOIN 
1 TITLE 'END OF SIMULATION PROGRAM REACHED'; 
1 PROC SORT DATA=JOIN; 
1 BY Yl Y2 Y3 Y4 Y5 INTERCEP Xl X2 XlSQR; 
1 PROC MEANS DATA=JOIN; 
1 BY Yl Y2 Y3 Y4 Y5; 
1 // 
This is the end of the SAS program for simulating 
new compression force values within the standard 
deviations limits and obtaining the response surface 
equations for mean values of tablet in vitro 
properties as orignally obtained for the nine 
formulations of the optimization study. 
This program calculates the mean in vitro dissolution time . 
The parameters for the equation should be entered 
252 
on line 480-500 . The program will request for the last 
dissolution sampling time. The area under the dissolution 
rate time curve and the area under dissolution 
were calculated using trapezoidal rule. 
10 REM CALCULATE ZERO AND FIRST MOMENT 
50 DIM M2 ( 5000 ) 
60 DIM Y(5000) 
70 DIM X(5000) 
80 DIM Dl(5000) 
90 DIM Al(5000) 
110 DIM A(5000) 
130 DIM A4(5000) 
140 DIM A5(5000) 
150 LET Z=O 
160 LET Al(O)=O 
190 LET A4(0)=0 
200 LET Y(O)=O 
220 LET M2(0)=0 
230 LET Dl(O)=O 
240 LET X(O)=O 
260 LET A4=0 
270 LET A5=0 
290 LET S=O 
300 LET M2=0 
320 INPUT "TIME FOR TOTAL %RELEAS";A 
330 IF A=0.00 THEN 860 
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rate curve 
360 LET G=O .l 
365 REM B=450 DIVISIONS , EACH DIVISION IS 0 . 1 MIN LENGTH 
370 LET B=(A IG) 
380 LET I= 1 
390 LET C= 1.0 
400 LET Dl(I)=O.l 
410 LET X(I )=G 
420 LET X(O ) =O 
430 LET H= 0 
431 LET Hl=O 
432 LET H2=0 
433 LET H3=0 
434 LET Sl=O 
435 REM Z=450 DIVISIONS , EACH DIVISION IS 0 . 1 MIN LENGTH 
440 LET Z=A IG 
450 FOR I = 1 TO B STEP C 
460 LET Dl (I) =O . l 
470 LETH= H +0.1 
480 LET BO= 5.2499 
490 LET Bl= 0.1125 
500 LET B2= 95.2424 
510 LET X(I )=H 
515 REM Y(I ) IS PERCENT DISSOLVED AT TIME X(I) 
516 REM Y(I-C) IS PERCENT DISSOLVED AT TIME X(I-C) 
520 LET Y(I)=B2*EXP(-BO*EXP(-Bl*X(I))) 
530 LET Y(I- C)=B2 * EXP (-BO *EXP (-Bl *X(I- C))) 
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( 531 REM OBTAINING TIME FOR 80 % RELEASE 
532 IF Y( I ) > 79.7 AND Y( I ) ' 80 . 3 THEN DO 
534 LET Hl =Hl +H 
535 LET Sl= Sl+ l 
536 LET H2=Hl / Sl 
53 7 REM OBTAINING TI ME FOR 80 % RELEASE IN HOURS 
538 LET H3 =H2 160 
539 DOEND 
540 LET Al(I)= ( Y( I ) - Y( I - C)) / Dl ( I ) 
545 REM Al IS RATE OF DISSOLUTION , 
546 REM BETWEEN TIME POINTS X( I ) AND X( I- C) 
550 LET S =S + 1 
560 REM A4 ( I ) IS AREA OF EACH SUBINTERVAL BY TRAPEZOIDAL 
565 REM DISSOLUTION RATE-TIME CURVE 
566 REM ( Al ( I - C) IS DISSOLUTION RATE AT TIME X(I - C) 
567 REM ( Al ( I ) IS DISSOLUTION RATE AT TIME X(I) 
568 REM X(I - C) - X( I ) =O . l ; ITS MID- POINT=0 . 05 
569 REM ( A/ 2 *Z) 45 / ( 2 *450 )=0.05 
570 LET A4(I)= ( Al(I- C)+Al ( I ) )* ( A- 0 ) / ( 2 *Z) 
580 LET A5=A5 +A4(I) 
590 REM A5 TOTAL AREA UNDER DISSOLUTION RATE CURVE UPTO LAST 
595 REM TRAPEZOIDAL SUBINTERVAL 
600 REM M2 IS AREA UNDER FIRST MOMENTS CURVE BY TRAPEZOIDAL 
610 LET M2(I )= A4(I )* H 
620 LET M2=M2 +M2 ( I ) 
640 NEXT I 
255 
645 REM TO OBTAIN MDT IN VITRO TIME 
646 REM WE DIVIDE BY 60 MINUTES 
65 0 LET R= M2 / ( A5 *60 ) 
660 PRINT 
670 PRINT "BO = "; BO 
680 PRINT "Bl = " ; Bl 
690 PRINT "B2 = "; B2 
700 PRINT 
710 PRINT " S INLOOP "; s 
720 PRINT " I INLOOP " ; I 
730 PRINT 
740 PRINT "TIME AT INFINITY="; A; 
750 PRINT 
IN HOURS ( R) 
760 PRINT "TOTAL AUC DISSOLUTION RATE BY TRAPEZOIDAL= " ; A5 ; 
770 PRINT 
780 PRINT "TOTAL MOMENT AUC FOR DISSOLUTION RATE BY 
TRAPEZOIDAL= " ; M2 ; 
790 PRINT 
800 PRINT "MDT IN VITRO R ; 
801 PRINT 
802 PRINT "TIME FOR 80% RELEASE = " ; H3 ; 
810 LET A5=0 
830 LET M2=0 
840 LET M=O 
850 LET H=O 
860 GOTO 10 
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870 END 
This is the end of the program that calculates the mean 
in vitro dissolution time. 
THIS IS THE SUCCESSIVE QUADRATIC PROGRAMMING ALGORITHM 
FOR NONLINEARLY CONSTRAINED MINIMIZATION PROBLEM . 
SOURCE : P . 899 , IMSL FORTRAN SUBROUTINES. 
INTEGER IBTYPE , IPRINT, M, MAXINT , ME , N 
ME = TOTAL NO . OF EQUALITY CONSTRAINTS 
PARAMETER ( IBTYPE=O, IPRINT=2 , M=6, MAXINT=lOO, ME=O , N=2) 
REAL FVALUE , X(N ), XGUESS(N ), XLB ( N), XSCALE ( N) , XUB(N) 
EXTERNAL FCN , NCONF , WRRRN 
DATA XGUESS / 0 . 50E0 , 0.850EO / , XSCALE / 1.0,1 . 0 / 
DATA XLB ! -l .OE6,-l.OE6 / , XUB / l.OE6 , l.OE6 / 
CALL NCONF (FCN, M, ME, N, XGUESS , IBTYPE, XLB , XUB , 
XSCALE , IPRINT , MAXINT , X, FVALUE) 
CALL WRRRN ('THE SOLUTION IS ' , N,l, X,N , O) 
END 
SUBROUTINE FCN (M,ME,N,X,ACTIVE,F,G) 
INTEGER 
REAL 
LOGICAL 
M, ME , N 
X( *), F , G( *) 
ACTIVE( *) 
HIMMELBLAU PROBLEM 1 
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• 
Bl (12 . 0-12.85) *0 
B2 (0 . 3- 0.3000) *0 
B3 (605-(598)) *0 
B4 ( 7.5 - 6.90) *0 
F= 0.2601 + 0 . 1206 * X(l) - ( 0 . 0492) * X(2) 
IF ( ACTIVE(l)) G( l) = (-1.404 + Bl) + 3.039 * X(l) 
IF ( ACTIVE(2)) G( 2) =(-0.0395 - B2) + .1017 * X(l) -
0.0624 * (X(l) ** 2) 
IF ACTIVE(3)) G(3) (0 . 06721 - B3) - 0 . 1182 * X(l) 
+ .03875 * (X(l) ** 2) 
IF (ACTIVE(4)) G(4) = (1 . 4895 - B4) - 2.7426 * X(l) 
+ 1.3497 * (X(2)) 
IF (ACTIVE(5)) G(5) 1 - (X(l) ** 2) 
IF (ACTIVE(6)) G(6) 0.749956 - (X(2) ** 2) 
RETURN 
END 
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The Effect of Moisture on Powder Flow and on 
Compaction and Physical Stability of Tablets. 
Shabbir Dawoodbhai and Christopher T . Rhodes 
Department of Pharmaceutics 
University of Rhode Island 
Kingston, RI 02881. 
Introduction 
Water vapor pressure in the atmosphere is 
quantified by the percent relative humidity. The moisture 
content at which a solid material produces a water vapour 
pressure equal to that of the surrounding environment is 
defined to be the equilibrium moisture content (EMC). The 
resultant weight gain of the solid is expressed as a 
percentage of its initial dry weight at a specified 
temperature and percent relative humidity . 
The magnitude of the EMC depends on the percent 
relative humidity, temperature, binding site energy, surface 
area and the nature of the material. Certain materials have 
a low EMC such as non-porous talc, and kaolin. Conversely , 
organic sugars , hydrogen bonding polymers and crystal 
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hydrates have high a EMC . The EMC of starch, alginic acid , 
and tragacanth was reported to increase with increased 
percent relative humidity , but remained unaffected by 
increases in temperature ( 1 ). In contrast , increases in 
temperatures allowed the formation and deliquescence of 
hydrates to occur at lower percent relative humidity ( 1). 
However , lactose did not show deliquescence and its EMC 
increased only slightly even at 50 C and 100 % relative 
humidity ( 1). 
The surface area of material also affects its EMC . 
Fine particle sizes of both sucrose and sodium chloride had 
~ 
higher EMC values compared to the coarse particles of these . 
materials (2). Most of the 4 . 8% of the moisture content 
usually present in microcrystalline cellulose is within the 
porous structure of its particles . The internal surface 
area represents 95% of the surf ace area of the 
microcrystalline cellulose particle that interacts with 
water vapor in the atmosphere (3). 
Moisture in solids exists in several states. The 
adsorbed water vapor can become bound in the form of water 
of crystallization, for example, in the crystal hydrates of 
inorganic salts such as dibasic calcium phosphate dihydrate, 
and in organic sugars (lactose monohydrate) . When the 
moisture is present in excess , as in the hygroscopic and 
deliquescent states , the water is said to exist in the 
unbound state . 
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In amorphous solids , and in polymers such as starch 
and acacia , sorption of water proceeds-beyond that required 
to satisfy all external particle surface area. Sorption of 
moisture also occurs within the amorphous solid, with the 
result that the mobility of moisture increases from tightly 
bound state to solvent like state . This is due to the 
lowering of the glass transition temperatur·e by the moisture 
with the consequent increase in the free volume of 
individual molecules . 
Effect Of Moisture On The Flow Of Powders. 
The two fundamental forces that can affect the flow 
of powders are cohesion and friction. Cohesion is the 
mutual attraction, and resistance to seperation of 
contacting powder particles of a indentical material . 
Friction is the resistance exerted by one particle against 
the motion of another particle at the points of contact. 
The frictional forces act at a tangent to the contact point 
surface . The frictional force increases as the true 
( microscopic) contact area and as the average stress 
required to shear cold- welded junctions that form between 
contacting asperities of particles increases . The adsorbed 
moisture film lubricates the particles , and possibly 
prevents to some degree the cold welding of asperities , and 
thereby reduces the frictional force that opposes the 
relative motion of the particles . 
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Cohesion in dry powder is a function of van der 
Waals forces, electrostatic forces and mechanical 
interlocking. The van der Waals forces increase as the 
particle diameter decreases. The electrostatic forces are 
influenced by the particulate nature , shape and the particle 
size distribution. Mechanical interlocking is a macroscopic 
phenomenon. It is more pronounced with particles of smaller 
size, which have a more irregular surface relative to 
diameter. Cohesion in moist powder involves liquid bridges 
and may also involve solid bridges, between particles. The 
liquid bridges connections depends on the percent of water 
and its distribution. The contributing factors are 
interfacial tension and capillary pressure. If the number -
of solid bridges increases it can result in increased 
cohesion and aggregation, and ultimately formation of a hard 
cake. Caking is the state in which the powder cannot be 
moved by vigorously shaking or tapping of the container. 
A parameter known as tensile strength of a powder 
bed , is obtained from measurements of the shear strength of 
a packed powder bed, with a shear cell. The influence of 
moisture content on the flow properties of powders has also 
been quantified by tensile strength values. Factors that 
influence tensile strength of powder bed include the nature 
of the material, percent moisture, particle size and the 
material packing density. Moisture significantly influenced 
the tensile strength of powders by formation of liquid 
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( bridges (4-6). At higher moisture content and at higher 
packing densities liquid bridges may progress from pendular 
to funicular bonds (4-6). Although the packing density of 
fine powder is less than that of coarse powder , the tensile 
strength of dry fine powder is greater than that of dry 
coarse powder. This is because of the greater number of 
contact points of fine powder particles (greater surface 
irregularity relative to diameter). This makes the 
particle- particle interaction forces greater than the 
mobilizing gravitational force . For coarse particles 
gravitational force exceeds interaction forces, leading to 
greater mobility (5,6). 
Increased packing density has been shown to increase 
the tensile strength for porous and non-porous, and also for 
cohesive and non-cohesive, powders (4-6). The nature of 
material and its particle size were important factors that 
influenced the tensile strength of powders. For a porous 
and cohesive powder (calcium phosphate), tensile strength 
was not changed because the moisture entered the 
intraparticulate voids and was therefore unable to 
accumulate on external surface to influence interparticulate 
forces by formation of liquid bridges (4). A non-porous and 
non-cohesive powder, the coarse fraction (32-75 um) of 
sodium chloride (5,6), showed an increase in tensile 
strength with increase in moisture content up to about 4% 
because of the increase in the number of liquid bridges 
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initially at points of actual contact (lower percent 
moisture) and eventually at points of near contact (at 4 
percent moisture) . Beyond a certain moisture content, the 
number of liquid bridges of both types remain constant. The 
forces of attraction of the liquid bridges at actual contact 
points are more powerful than at near contact points. 
However , with further increase in moisture content, the 
tensile strength reached a plateau because of the balance 
between increased net attractive forces at points of near 
contact and decreased attractive forces at points of actual 
contact , as the dimension of liquid bridges at points of 
actual contact increased (4 , 5). Therefore , an increase in 
moisture content can be expected to decrease the powder flow 
of both non-porous and non-cohesive materials. 
With non-porous and cohesive powder such as fine 
sodium chloride particles there are more potential sites of 
contact compared to coarse particles (5,6). A small initial 
increase in moisture content raised its tensile strength 
even further, due to increased particle-particle 
interactions. The combined effects of the number and 
attractive forces of the liquid bridges are similar as with 
coarse sodium chloride particles. However, with further 
increase in moisture content the particle- particle 
interaction decreased and became insignificant. As a 
result , the tensile strength exponentially decreased to a 
low level plateau value ( 5,6). Therefore , increase in 
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( moisture cannot be expected to help improve the flow 
properties of already cohesive powder. Excessive moisture 
will further increase the tensile strength and may lead to 
caking of the powder. Caking has been observed at high 
percent relative humidity with several commonly used powder 
excipients including starch (2 , 7 , 8). The occurrance of 
caking was suppressed by the addition of 0.25 to 0.5% 
magnesium oxide to starch , or by 1.0% of magnesium oxide to 
sugars and salts (2,5) . It was suggested that the fine 
plate shaped magnesium oxide particles adhered to the 
surf aces of caking material by van der Waals and 
electrostatic forces and that their presence reduced 
interparticulate cohesion by decreasing the number liquid 
bridges within caking material (2,8). 
Effect of Moisture on Compaction of Powders. 
Compaction is a process by which powder particles 
are brought sufficiently close together so that the bonding 
forces between them are large enough to produce a strong 
compact. The necessity for the presence of moisture in 
formation of strong tablets was indicated by the fact that 
the crystal hydrates that inherently compressed well did not 
do so when their water of crystallization was removed e . g. 
ferrous sulphate heptahydrate (9). Moisture increases the 
compact strength by increasing the tensile strength of the 
powder bed , by increasing the contact area among the 
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particles for bonding , by decreasing the variation of 
density within the tablet and by the recrystallization 
effect . 
The reduced variation of density within the tablet 
was mainly attributed to the lubrication of the die walls 
( which allows a greater fraction of the applied force to be 
transmitted through the compact onto the lower punch , this 
is also known as the R value) and only slightly attributed 
to the lubrication of powder particle surface (which 
facilitates rearrangement and repacking of particles) (10-
12). The adsorbed water film decreases the particle surfac~ 
energy and thus decreases the adhesion of the tablet to the ~ 
die wall. In addition, the expressed water film on the die 
wall during compaction functioned as a low viscosity 
lubricant (10 - 12). The increase in lubrication was 
indicated by the increase in the R values , decrease in the 
ejection forces and decrease in the forces lost to the die 
wall (10- 12). 
Repacking and rearrangement of anhydrous dextrose 
and dextrose monohydrate increased with increasing percent 
moisture con~ent as indicated by decrease of in situ 
porosity and decrease of yield force and by increased 
compact density (13) . This presumably was due to 
interparticulate and die wall lubrication effects , and due 
to plasticizing effect of water, as the moisture content 
increased (13). With substances like microcrystalline 
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cellulose, the moisture within its pores acts as an internal 
lubricant and facilitates the slippage and flow within 
individual microcrystals during compaction (3 , 14). The 
moisture facilitates plastic deformation of microcrystals to 
allow close contact and hydrogen bonding between particles 
( 3,14) . The moisture acted as a plasticizer , and thereby 
reduced the yield point and the elastic recovery during 
compaction (3,14) . Microcrystalline cellulose (14) and also 
soy protein (15) tablets, when directly compressed, showed 
increase in hardness as the percent moisture content 
increased and as the compression force increased until the 
true density of the material was reached . Either lack of 
moisture or insufficient moisture is one of the factors 
responsible for lamination of tablets since the yield force 
becomes high and the elastic recovery is increased. 
With crystalline , water soluble substances such as 
sodium chloride, the thin adsorbed layers of moisture 
increase the effective surface area for intimate contact 
(10-12). The phenomenon of recrystallization during 
compression will increase compact strength , when water is 
present as vapor in the pores of the particles. For 
anhydrous dextrose, with up to 8 . 9% moisture content the 
percent relative humidity is below the critical value of 
less than 81.3% (RHo), and therefore the moisture is present 
as vapor in the pores. The water vapor condenses on 
application of compression force and promotes the formation 
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of a saturated solution which moves to the flaws within the 
particles or to the particle crystal contact points, 
mobilized in part by surface tension forces (13) . 
Recrystallization upon decompression in these areas of 
weakness results in an increase in tensile strength ( 13) . 
The presence of "excessive " moisture at moderate to 
high compression force decreases the compact strength, by 
·decreasing the tensile strength of the powder bed, 
decreasing the microirregularities of the particles, by 
hydrodynamic resistance and by increased elastic recovery 
after ejection when compressed beyond true density. 
... 
The tensile strength of dextrose monohydrate tablets 
decreased with any increase of moisture content (13 , 16) , and 
the microcrystalline cellulose tablets capped in the 
presence of excessive moisture at high compression force 
(14), because of hydrodynamic resistance , together with 
increased elastic recovery after ejection. The tensile 
strength of anhydrous dextrose tablets decreased when made 
at moderate to high compression force in presence of 
excessive moisture due to hydrodynamic resistance of the 
liquid present in the voids of the compact (13). 
Excessive moisture also produces the cappillary 
state of the powder aggregation and thereby the surface 
tension effect becomes insignificant in maintaining the high 
tensile strength of the powder bed. The moisture has a 
solvent effect of eliminating the surface cracks and 
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irregularities in the crystals . This increases the 
crystals ' resistance to fragmentation, and decreases the 
crystal surface energy , which therefore decreases adhesion 
between particles . The electrostatic charges of attraction 
also become dispersed ( 10- 12 ) . The hardness of lactose 
tablets containing naproxen at low and high compression 
force decreased as the moisture content increased beyond two 
percent (17). 
Effect of Moisture on Physical Stability. 
Physical stability is the study of in vitro changes 
in a dosage .form properties when subjected to physical 
stress and time. These in vitro changes may alter 
bioavailibility and therapeutic efficacy , even though the 
drug potency and purity appear unaltered . 
Major changes in the physical stability of a 
compact can result from moisture gain and / or moisture loss 
at different points in time. The sorption of moisture by 
ingredients of tablets can result in formation of their 
solution for water soluble substances, with consequent 
crystal change and / or growth of crystalline substances or 
can manifest as swelling of polymeric materials. 
Moisture Gain . 
Changes in tablet appearance ( 18 , 19) and increase 
in tablet volume (14 , 18 , 20- 23) as a result of moisture 
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sorption was observed with several direct compression 
excipients . Amorphous or spray dried lactose tablet volume 
increased monotonously due to hygroscopic swelling at 35% 
relative humidity and 30 C ( 21 , 23) . No crystallization of 
lactose was detected because the amount of water sorbed was 
not sufficient for making super saturated solution of 
lactose (21 , 23) . At high percent relative humidity, the 
amorphous lactose tablet volume expansion was more rapid and 
extensive and , corresponded to rapid increase in 
crystallinity as the moisture content stabilized to a 
plateau level (21 , 23) . It was suggested that the water 
liberated from super- saturated amorphous lactose solution -
was due to decrease in surface area. This liberated water 
further promoted the formation of supersaturated amorphous 
lactose solution, and accelerated the autocatalytic 
crystallization into a - monohydrate and b-anhydrous lactose 
(21 , 23). Tablets containing hygroscopic materials such as 
docusate sodium , magnesium chloride, or potassium acetate 
and made up of crystalline water soluble excipients e.g. 
lactose or mannitol, showed crystal growth of these 
excipients when stored at high percent relative humidity at 
37 C for 4 months. The identity of these crystal growths 
was confirmed by DSC and TLC (18) . 
The crushing strength of tablets , made from 
crystalline substances or polymers, which are either water 
soluble or insoluble, will decrease when exposed to high 
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percent relative humidity. Lactose tablets the with highest 
initial crushing strength underwent th~ greatest decrease in 
hardness , and vice versa , in a linear fashion (24 , 26) . With 
dibasic calcium phosphate dihydrate , the tablet hardness 
decrease was greater for tablets with lower initial moisture 
content compared to tablets with higher initial moisture 
content (25). Dibasic calcium phosphate dihydrate tablets 
made at an initial moisture content of 2.8% showed the least 
decrease in tablet hardness (25). The decrease in crushing 
strength of microcrystalline cellulose tablets was directly 
related to the amount of water sorbed ( 22) . 
The effect of moisture sorption on disintegration 
time depends on whether the tablet material is crystalline 
or polymeric. The disintegration time of microcrystalline 
cellulose tablets decreased more rapidly as the amount of 
sorbed moisture increased and as the exposure period to the 
high percent relative humidity increased (22). These 
tablets when evaluated after 202 days had the same hardness , 
thickness , and percent moisture content but shorter 
disintegration times , than those tablets evaluated after the 
9 days. The change in the tablet internal structure was 
indicated by the abscence of fragments which disintegrated 
slowly from the tablets stored for 202 days (22). For 
tablets that contained lactose only and lactose plus 
naproxen there was a tendency for the disintegration time to 
slightly increase (25) . For dibasic calcium phosphate 
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dihydrate tablets prepared with an initial moisture content 
of 1.5 to 3.2% the disintegration time increased as the 
period of exposure to high humidity increased (25) . For 
shorter periods of exposure the tablets with initial 
moisture content of 2 . 5 to 2 . 8% seemed to be least affected. 
However , with a prolonged period of exposure the 
disintegration time increased regardless of the initial 
moisture content (25). 
After exposure to four humidity levels, the physical 
stability of the tablets were ranked using the criteria of 
minimum moisture uptake , minimum increase in volume of 
tablets and the retention of the maximum hardness and the 
minimum disintegration times. The excipients dibasic 
calcium phosphate dihydrate , and both hydrous and anhydrous 
lactose resulted in more physically stable tablets than did 
mannitol or monobasic calcium phosphate monohydrate. 
Sorbitol, dextrose and sucrose gave the least physically 
stable tablets (20). 
The T50% values for dissolution of naproxen from 
dibasic calcium phosphate increased as the period of 
exposure to high humidity increased (25) . The T50% values 
of naproxen from dibasic calcium phosphate dihydrate did not 
increase more significantly in the tablets with higher 
initial moisture content as compared to lower initial 
moisture content tablets for any given period of exposure to 
the high percent humidity (25). However , only a slight 
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trend towards the decrease in dissolution rate of naproxen 
at 5 and 15 minutes from lactose tablets exposed to high 
percent relative humidity occurred ( 24 ) . The dissolution 
rate of sodium naproxen at 5 and 10 minutes, from 
microcrystalline cellulose tablets made with increasing 
initial moisture content from 3 to 7 % did not significantly 
change (17). 
Moisture Loss. 
Moisture loss from tablets containing high initial 
moisture content will cause recrystallization. The effect 
of this phenomenon will be discussed in the section below. 
The crushing strength of microcrystalline cellulose tablets 
showed only a slight decrease or no change, especially in 
the abscence of water soluble components (3,14) . With 
dibasic calcium phosphate dihydrate tablets , moisture loss 
is accompanied by general hardening in the bulk of the 
tablets ( 25). 
Moisture loss also shortened the disintegration 
times of the tablets containing microcrystalline cellulose 
(3 , 14). The disintegration time of dibasic calcium 
phosphate dihydrate tablets remained unchanged for short 
period of exposure to low relative humidity (25). Prolonged 
exposure to low percent relative humidity slightly shortened 
the disintegration time (25) . 
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Moisture Gain Followed by Moisture Loss. 
Partial moisture loss from moisture rich tablets 
resul ts in formation of solid bridges in the form of 
recrystallized and / or material hardening of polymeric 
binding materials. The partial moisture loss generally 
results in an increase in the crushing strength of the 
tablets ( 16 , 24,25 , 27) . As the percent lactose was increased 
the tablet hardness increased because the lactose 
recrystallization effect became more pronounced (17). 
Dibasic calcium phosphate dihydrate tablets softened by 
exposure to high percent relative humidity were able to 
regain some ·of their loss in hardness after storage at low 
percent relative humidity (25). Almost complete restoration 
to original tablet hardness was possible when the initial 
moisture content was 2.8% (25) . The strength of crystalline 
bridges formed is dependent on the recrystallization rate. 
The recrystallization rate affects the tablet hardness by 
modifying the size and the numbers of the crystalline 
bridges formed in the void spaces. The recrystallization 
rate is affected by formulation changes that modifies the 
formulation moisture sorption properties . 
The magnitude of hardness increase in lactose 
containing tablets at a given moisture content depended on 
the concentration and the type of binder used (17). When 
the various binders were compared , the celluloses types gave 
greater increases in hardness compared to either gelatin or 
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povidone. Acacia produced a minimal increase, and starch 
produced the least increase , in tablet hardness (17). As 
the amount of the binder was increased, a higher initial 
moisture concentration in the granulation could be 
incorporated without getting the severe hardness increases 
following partial moisture loss. This suggested that the 
higher binder concentration slowed recrystallization rate of 
water soluble drug and / or excipients which in turn resulted 
in formation of fewer crystalline bonds, and hence, the 
minimal increase in the tablet hardness with partial 
moisture loss (17,24,27). The greater effectiveness of 
higher binder concentration in reducing the 
recrystallization rate is possibly due to increased 
viscosity which would slow down the rate of diffusion of the 
dissolved substances to the growing crystal surfaces. 
It has been shown that the strength of the 
crystalline bridges are not dependent on the tablet hardness 
immediately following compression (24). The lactose based 
tablets that had been softened by exposure to high percent 
relative humidity, when exposed overnight to ambient 
conditions, showed that the hardness increase did not depend 
on the initial post compression hardness (24). With 
polymeric materials such as microcrystalline cellulose, 
recrystallization of water soluble substances may lead to 
increases in the tablet hardness (17) . 
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The disintegration times of the microcrystalline 
cellulose tablets did not increase to their original values 
after partial moisture loss , indicating that the hydrogen 
bonds were not regenerated ( 22 ) . For dibasic calcium 
phosphate dihydrate tablets , previously conditioned at high 
relative humidity , a single overnight room condition 
exposure further prolonged the disintegration times , 
especially if the tablets had very low or very high moisture 
content at the time of compression (25). For pure lactose 
tablets , and also for lactose tablets containing naproxen, 
the recrystallization effect tended to slightly prolong 
disintegration times (24,28). 
The recrystallization effect did not significantly 
change the dissolution rate of naproxen from lactose tablets 
with high initial moisture concentration at the time of 
compression, or which had been exposed to high percent 
relative humidity, followed by an overnight exposure to 
ambient conditions (17 , 24,27) , or by change of percent 
lactose in the formulation (17) . Compared to the lactose 
tablets with an initial moisture content of under 2 . 3%, the 
tablets afte~ partial moisture loss , had somewhat lower 
percent of naproxen dissolved at 5 minutes compared to their 
initial value , indicating a lag time (17) . The dissolution 
rate of sodium naproxen and the sodium benzoate from the 
microcrystalline cellulose tablets remained rapid and 
unchanged (17). Modification of recrystallization rate by 
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the presence of different binders had no effect on salicylic 
acid T50% dissolution from lactose containing tablets (27). 
The dissolution rate of naproxen from dibasic calcium 
phosphate dihydrate tablets after partial moisture loss 
remained close to their elevated T50% values as obtained 
after exposure to high percent relative humidity (24,25). 
In summary, the effect of moisture gain is similar to 
partial moisture loss in slowing the dissolution rate of 
naproxen from dibasic calcium phosphate dihydrate tablets. 
Conclusions. 
Powder flow properties are affected by numerous 
factors. In general, the presence of moisture tends to 
decrease the flow of the powders by increasing their tensile 
strength. The adsorbed moisture film acts as a low viscosity 
lubricant during compaction, thereby promoting uniform 
density within the tablets and decreasing the adhesion of 
the tablets to the die wall. In addition, the plasticizing 
effect of moisture on amorphous and polymeric materials, and 
the recrystallization effect with some crystalline materials 
contributes to formation of a strong tablet. Conversely , 
excessive moisture decreases the tablet strength by 
decreasing the powder tensile strength, increasing both 
elastic recovery and hydrodynamic resistance. Physical 
stability of the tablets is significantly altered by 
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moisture gain, moisture loss and partial moisture loss. The 
effects observed are largely dependent upon the formulation. 
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